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The UNICEF conceptual framework for child undernutrition indicates that 
malnutrition occurs as a result of inadequate dietary intake and disease.  Exclusive 
breastfeeding for six months is the “gold standard” in infant feeding, yet the majority 
of women in sub-Saharan Africa do not practice EBF for the recommended duration.  
Additionally, diarrhea remains one of the leading causes of child death in developing 
countries, with Cryptosporidium as one of the most common diarrhea-causing 
parasites.  Despite the health consequences of Cryptosporidium infection in childhood, 
little is known about the natural history of and risk factors associated with infection.  
The aim of this study was to determine the prevalence of Cryptosporidium in mothers 
and infants up to six months post-partum and the factors associated with infection, 
namely duration of exclusive breastfeeding and immune composition of breast milk. 
In a prospective cohort of 125 mothers and infants we found that maternal 
post-partum prevalence of Cryptosporidium was high, yet prevalence of infant 
infection remained low until six months of age.  Factors associated with an increased 
risk of infant Cryptosporidium infection included maternal Cryptosporidium infection 
and maternal hand washing prior to infant feeding.  We also saw increases in infant 
Cryptosporidium infection that corresponded to changes in infant feeding patterns. 
Using the same cohort of mothers, we collected breast milk and blood samples 
 to determine how concentrations of immunoglobulins and cytokines evolved over the 
six months post-partum period.  We found that there were no differences in breast 
milk immune composition based on maternal HIV-status or maternal nutritional status.  
However, we did find that concentrations of breast milk immunoglobulins increased as 
the duration of exclusive breastfeeding increased and with increased breastfeeding 
frequency.  Breast milk cytokine concentrations were associated with indicators of 
maternal illness, such as mastitis and fever. 
Finally, we explored the relationship between infant feeding patterns and 
breast milk immune concentrations to determine if they were associated with infant 
Cryptosporidium infection.  We found that an increased duration of exclusive 
breastfeeding and higher doses of breast milk immunoglobulins and cytokines were 
associated with a decreased risk of infant Cryptosporidium infection, while the feeding 
of certain complementary foods was associated with an increased risk of infection. 
We conclude that Cryptosporidium is an important gastrointestinal parasite in 
this region of Tanzania.  The research underscored the importance of appropriate 
infant feeding in the first six months as optimal infant feeding behaviors were 
associated with both an increase in breast milk immune molecules as well as a 
decreased risk of infant Cryptosporidium infection. 
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1  
CHAPTER 1 
 
INTRODUCTION 
 
1.1 Introduction 
Despite decades of research and interventions, maternal and child undernutrition 
remains a staggering health challenge in developing countries.  Globally, approximately 
3.5 million deaths each year are attributable to maternal and child undernutrition [1].  
Poor nutrition in the period from birth to 24 months contributes to 50% of deaths in 
children under five, mainly due to increased mortality from infectious disease [2]. The 
UNICEF conceptual framework for child malnutrition depicts a synergistic relationship 
between infection and undernutrition on child malnutrition, death, and disability (Figure 
1.1).  Forty-five percent of all child deaths related to diarrhea occur in sub-Saharan Africa 
[3].  This region also has a high childhood undernutrition burden, with stunting 
prevalence >40% among children under five. This combination of chronic undernutrition 
and frequent diarrheal infection leads to poor growth, more frequent illness, and 
ultimately, increased risk of mortality. 
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Figure 1.1. UNICEF conceptual framework for child undernutrition, adapted from 
[4] 
 
 
One of the immediate causes of child undernutrition is inadequate dietary intake.  
Ideally, for the first six months of life, an infant’s food system is dependent on breast 
milk provided by his or her mother.  Therefore, it is vital to understand the best method to 
optimize this critical period of feeding, growth, and immune development.   
Breastfeeding has a profound role in shaping infant health and is influential in immune 
system development, and nutrition of the developing infant as well as to the development 
of the gut and associated microbiota [5, 6].  When practiced optimally, breastfeeding is 
one of the most effective available methods to promote child health and survival [6]; 50% 
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of child deaths due to infection may be prevented through better breastfeeding practices 
[7].  As a result of these benefits, the WHO recommends that mothers exclusively 
breastfeed for the first six months of an infant’s life.  However, in practice very few 
women in African countries follow this recommendation, despite the numerous benefits 
associated with exclusive breastfeeding.  Barriers to exclusive breastfeeding in 
developing countries include: inconsistent public-health messages, lack of familial 
support, lack of breastfeeding education and support systems, cultural beliefs, and poor 
maternal and/or infant health [8-10]. Suboptimal breastfeeding, especially non-excusive 
breastfeeding in the first 6 months of life, results in 1.4 million deaths and 10% of the 
disease burden in children under 5 [1]. 
In addition to inadequate feeding, disease is the other immediate cause of child 
undernutrition.  Diarrhea is the second leading cause of infant mortality, and 
Cryptosporidium (Figure 1.2) is a major cause of diarrhea globally, particularly in young 
children in the developing world [11]. However, few studies have addressed the risk 
factors for Cryptosporidium infection in young infants in resource-poor areas, likely due 
to a cycle driven by contextual and disease-specific factors (Figure 1.3).  For these 
reasons, the WHO has included Cryptosporidium in its Neglected Diseases Initiative 
[12].  Currently there is no vaccine available for Cryptosporidium and treatment options 
remain suboptimal.  Nitazoxanide is an FDA-approved drug for the treatment of 
cryptosporidiosis, however randomized trials have indicated that this drug is not 
efficacious in the treatment of cryptosporidiosis in HIV-infected individuals or children 
under-12 months of age [13]. 
4  
 Cryptosporidium is a genus of protozoan parasites, with over 15 different species 
capable of causing infection in humans [13].  Worldwide, Cryptosporidium hominis and 
Cryptosporidium parvum are responsible for the majority of human infections. The 
effects of Cryptosporidium infection can range from asymptomatic to severe, chronic 
diarrhea, and symptoms may vary according to the infective species.  Even in the absence 
of symptoms, Cryptosporidium infection can have damaging effects on the growth and 
development of children. Studies in Brazil and Peru contribute evidence of this dangerous 
relationship. Malnutrition and stunting were common in children even after 
asymptomatic Cryptosporidium infection [14].  Moreover, detrimental long-term 
cognitive and functional deficits were observed in a cohort of Brazilian children 4-7 years 
after Cryptosporidium infection when compared with children who did not experience 
Cryptosporidium infection [15].  
5  
Figure 1.2. Modified Ziehl-Neelsen stained fecal sample positive for Cryptosporidium 
 
Photo credit: Sarah H. Pedersen © 2012 
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Figure 1.3. Cycle of the gap in knowledge of Cryptosporidium  
 
 
1.2 The Context 
Tanzania, a country situated in East Africa, is heavily impacted by childhood 
malnutrition. In 2010, it was estimated that over 40% of children under five were stunted, 
an indicator of chronic undernutrition [16].  As indicated in the UNICEF conceptual 
framework for malnutrition, the causes of undernutrition are related to both inadequate 
feeding and infection. Tanzania ranks in the top 15 countries globally in terms of annual 
child deaths attributed to diarrhea [3]. Additionally, over 6% of the adult population is 
living with HIV/AIDS, a number that is significantly greater than both global and 
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regional prevalence rates [17].  Prevention of mother to child transmission (PMTCT) 
efforts have reduced the proportion of infants born to HIV-positive mothers who 
themselves become infected with HIV.  PMTCT interventions in Tanzania include HIV 
testing during antenatal care, provision of anti-retroviral therapy (ART), and infant 
feeding counseling.  These interventions have reduced the risk of HIV transmission from 
15-45% in the absence of treatment to <5% under optimal PMTCT treatment [18]. At the 
time of my study, Tanzania was implementing Option A of the WHO PMTCT 
recommendations. 
 Sub-optimal breastfeeding is common among Tanzanian women - only 59% of 
women initiate breastfeeding within one hour of birth, while only 41% of women 
exclusively breastfeed for six months [19]. As a result of less than adequate breastfeeding 
practices and a high burden of diarrhea in developing countries, more research is needed 
to provide further evidence to better inform intervention programmers, and policymakers 
alike, on strategies to decrease the burden of diarrhea and infectious disease in young 
infants. My research takes a holistic view of the highly interconnected system of mother 
and child, considering maternal health, nutrition, environment, and behaviors that have 
the possibility to impact morbidity and mortality in the infant. 
 
1.3 Background 
Breast milk provides the infant with a variety of soluble factors including 
immunoglobulins, cytokines, lactoferrin, and lysozyme, all of which confer immune 
benefits on the infant and influence the composition of the neonatal microbiota, playing a 
role in the protection of the neonatal intestine [20]. As a result of these benefits, the 
World Health Organization (WHO) includes two breastfeeding practices in its list of core 
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indicators of healthy infant and young child feeding (IYCF): early initiation of 
breastfeeding (within one hour of giving birth) and exclusive breastfeeding for six 
months [21]. 
Exclusive breastfeeding, as defined by WHO, means that the infant receives only 
breast milk (including expressed breast milk or breast milk from a wet nurse) and also 
allows the infant to receive oral rehydration solution (ORS), drops, syrups (vitamins, 
minerals, medicines), but nothing else [22]. Cross-sectional studies indicate that 
exclusive breastfeeding in the first six months is protective against infections, including 
diarrhea and acute respiratory infection, in developed and developing countries [23-29]. 
However, little is understood about how neonatal feeding methods correspond with the 
natural progression of infection due to common environmental exposures, or of pathogen-
specific diarrheal incidence rates. 
In developed countries, it is recommended that HIV-positive mothers use 
replacement feeding, however most HIV-positive mothers in developing countries do not 
have reliable and safe access to replacement feeding for the entire six-month duration and 
therefore an alternate prevention of mother-to-child transmission (PMTCT) strategy is 
recommended.  To reduce the risk of transmitting HIV to their infants, mothers should 
receive antiretroviral therapy (ART) and exclusively breastfeed for six months, 
introducing complementary foods thereafter and continue breastfeeding for the first 12 
months of life [30]. 
Despite the WHO recommendation that all women (including HIV-positive 
mothers) exclusively breastfeed for six months, recent studies in several developing 
countries have found that very few women continue exclusive breastfeeding beyond 3 
9  
months [8, 23].  During this period of partial breastfeeding, water and food are introduced 
thus exposing the infant to various environmental pathogens while depriving the infant of 
nutrient-dense breast milk containing beneficial immunoglobulins, cytokines, and other 
non-specific growth factors [31]. Periods of mixed feeding also disrupt the intestinal 
mucosal barrier leading to increased microbial translocation [32].  The underlying 
hypothesis of my research is that the first six months of a child’s life represent a critical 
period in immune development and that this development is influenced by the way in 
which a mother feeds her child. 
Following in utero immune protection provided by the maternal cocoon, breast 
milk provides an immunological bridge to protect the infant from infectious disease and 
also stimulates the infant’s developing immune system. Breast milk immune protective 
factors, such as cytokines and immunoglobulins, are especially important in the context 
of high-risk environments, such as those encountered by infants born to HIV-infected 
mothers and those in developing countries where environmental contamination with 
pathogens is ubiquitous and access to health care is limited. Numerous studies have 
related exclusive breastfeeding to decreased infection, particularly gastrointestinal illness, 
during infancy and beyond, yet the majority of women in Tanzania fail to exclusively 
breastfeed for six months. 
Since breastfeeding is associated with reduced diarrheal illness in infancy, and 
Cryptosporidium is one of the most common diarrhea-causing parasites in children, I 
designed this study to examine the relationship between infant feeding practices and early 
infancy Cryptosporidium infection.  Research regarding the prevalence of 
Cryptosporidium in infant populations of Tanzania is sparse.  Most estimates of 
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prevalence are based on samples of children with diarrhea presenting at hospitals or 
clinics.  This method for determining prevalence likely underestimates the true 
prevalence of Cryptosporidium in the pediatric population because it excludes children 
with asymptomatic Cryptosporidium and children with diarrhea who fail to present at 
hospitals or clinics.   This is the first study to measure the prevalence and natural history 
of Cryptosporidium infection in infants under-six months in Tanzania.  A recent 
publication by Moyo, et al. [33] emphasized the lack of studies regarding the prevalence 
of enteric pathogens in Tanzania.  Table 1.1 summarizes the currently available research 
regarding Cryptosporidium prevalence in Tanzania.  
Table 1.1 Prevalence of Cryptosporidium in Tanzania-previous research 
Location, Year 
(Ref) 
Study Design Population Sample 
Size 
Detection Method 
(Sample Analyzed) 
Prevalence 
Zanzibar, 2014 
[34] 
Case-Control Children 2 to 59 
months 
330 PCR (diarrhea/non-
diarrhea) 
20.0% 
Dar es Salaam, 
2011 [33] 
Cross-Sectional Children 0 to 60 
months 
270 Immunocard Stat! Rapid 
Assay (diarrhea) 
18.9% 
Kilimanjaro, 
2005 [35] 
Cross-Sectional HIV-positive 
adults 
127 IFA & PCR                   
(active case detection) 
17.0% 
Dar es Salaam, 
1999 [36] 
Case-Control Children 3 to 108 
months 
134 Kinyoun & IFA            
(diarrhea/non-diarrhea) 
9.0% 
Dar es Salaam, 
1999 [36] 
Cross-Sectional HIV-positive 
adults 
86 Kinyoun & IFA            
(diarrhea) 
7.0% 
 
This is one of the first studies to comprehensively study the risk factors for 
Cryptosporidium infection in sub-Saharan Africa infants.  Molloy and colleagues [37] 
stated that there is a paucity of data relating to the risk factors for Cryptosporidium 
infection within developing regions.  Figure 1.4 outlines the risk factors related to 
Cryptosporidium infection in children in the context of the Ecological Model. I 
hypothesized that sub-optimal infant feeding would be a risk factor associated with infant 
Cryptosporidium infection.  I further hypothesized that the immune composition of breast 
milk would have implications for infant Cryptosporidium infection.  Both the content 
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(quality) of breast milk and the duration of exclusive breastfeeding may impact microbial 
colonization of the gut and presence of diarrheal pathogens, such as Cryptosporidium. 
Mechanisms by which exclusive breastfeeding may protect the infant from pathogens are 
multi-modal. Providing crucial immune components present in breast milk may be just as 
important to infant gut health as delaying the introduction of potentially contaminated 
complementary foods and beverages.  However, previous cross-sectional studies have 
shown mixed results in terms of the protective effect of breastfeeding on 
Cryptosporidium infection in infants. 
Figure 1.4 Socio-Ecological Determinants of Cryptosporidium infection in infants 
 
Individual: 
HIV-status/exposure; Age; 
Gender; Nutritional Status; 
Birth Weight; Socio-economic 
Status; Infections; Immune 
Status; Developmental Stage 
Interpersonal: 
Maternal Nutritional Status; Overcrowding; 
Household Diarrhea; Home Environment 
(water, toilet, animals) 
Maternal 
Knowledge 
Food 
Preparation 
Organizational: 
Health Care System  
Limited 
Diagnostics 
No Vaccine No Treatment for 
young children or 
HIV+ 
Community:  
Water source; Seasonal Rainfall; Lack of 
Education; Rural Environment; 
Accessibility to water, sanitation, and 
hygiene 
Society/Policy: 
Cultural Norms regarding water 
treatment, breastfeeding, complementary 
feeding; No Government Policy on 
Cryptosporidium 
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Table 1.2 summarizes the current research on the impact of breastfeeding on 
Cryptosporidium infection.  A study in Zambia found that breastfeeding was associated 
with infant Cryptosporidium infection [38], several studies in developing regions have 
shown that breastfeeding is protective against Cryptosporidium [39-44], while other 
studies, including two from Tanzania, found no effect of breastfeeding on the presence of 
Cryptosporidium [33, 36, 45-49].  Inconsistent results regarding the relationship between 
breastfeeding and Cryptosporidium may be due to inconsistency of study design, 
breastfeeding definition, and method of Cryptosporidium detection.  Many studies 
defined breastfeeding as simply, “ongoing breastfeeding”, indicating that additional foods 
and water may be part of the infant’s diet (36, 38, 41, 42, 44, 45, 47, 48).  Additionally, 
most failed to consider asymptomatic Cryptosporidium infection and analyze only fecal 
samples from children presenting with diarrhea [33, 38, 41, 42-44, 47, 48].  To my 
knowledge, there have been no prospective, longitudinal studies examining exclusive 
breastfeeding duration (defined according to the WHO) and risk of Cryptosporidium 
infection in infants. 
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Table 1.2 Association between breastfeeding and Cryptosporidium-previous research 
Location, Year 
(Ref) 
Study Design Breastfeeding Sample Size 
(age) 
Detection Method 
(Sample Analyzed) 
Outcome 
Bangladesh, 2013  
[49] 
Prospective 
Cohort 
Duration of EBF* 226                     
(0 to 12 months) 
PCR (active case 
detection) 
No 
Association 
Egypt, 2013      
[43] 
Cross-Sectional Partial BF vs.       
No BF 
322                     
(2 to 6 months) 
Modified Ziehl-Neelsen 
(diarrhea) 
Positive 
Association 
Tanzania, 2011 
[33] 
Cross-Sectional EBF* vs.        
non-EBF 
280                     
(0 to 60 months) 
Immunocard Stat! 
Rapid Assay (diarrhea) 
No 
Association 
Malaysia, 2011 
[46] 
Cross-Sectional BF >4 months vs. 
BF ≤4 months 
276                     
(2 to 15 years) 
Modified Ziehl-Neelsen 
(active case detection) 
No 
Association 
Israel, 2008       
[40] 
Prospective 
Cohort 
Predominant BF 
vs. No BF 
238                     
(0 to 18 months) 
ELISA                           
(active case detection) 
Positive 
Association 
Egypt, 2005      
[47] 
Cross-Sectional Currently BF vs. 
Not currently BF 
1018                   
(0 to 60 months) 
ELISA                 
(diarrhea) 
No 
Association 
Iran, 2005         
[48] 
Cross-Sectional BF vs.               
No BF 
44                       
(6 to 18 months) 
Modified Ziehl-Neelsen 
(diarrhea) 
No 
Association 
Uganda, 2003   
[45] 
Case-Control  Currently BF vs. 
Not currently BF 
2446                   
(0 to 60 months) 
Acid fast stain & IFA  
(diarrhea/non-diarrhea) 
No 
Association 
Haiti, 2002        
[39] 
Case-Control EBF* vs.       
Non-EBF 
49                       
(0 to 18 months) 
Modified Ziehl-Neelsen 
(diarrhea/non-diarrhea) 
Positive 
Association 
Tanzania, 1999 
[36] 
Case-Control Currently BF vs. 
Not currently BF 
134                     
(3 to 108 months) 
Kinyoun & IFA            
(diarrhea/non-diarrhea) 
No 
Association 
Zambia, 1998   
[38] 
Cross-Sectional BF vs.               
No BF 
222                     
(0 to 11 years) 
Modified Ziehl-Neelsen 
(diarrhea) 
Negative 
Association 
Bangladesh, 1997 
[41] 
Case-Control BF vs.                   
No BF 
272                     
(0 to 59 months) 
Modified Kinyoun 
(diarrhea) 
Positive 
Association 
Mexico, 1997   
[42] 
Cross-Sectional BF vs.                
No BF 
200                     
(0 to 6 months) 
Modified Kinyoun & 
IFA (diarrhea) 
Positive 
Association 
Guinea-Bissau, 
1994 [44] 
 Case-Control BF vs.               
No BF 
1040                   
(0 to 4 years) 
Modified Ziehl-Neelsen 
(diarrhea) 
Positive 
Association 
*EBF not defined in the publication 
 
Currently, there are no data on breast milk cytokines and immunoglobulins in 
rural Tanzanian women. My research is innovative because it is the first study to consider 
the composition of cytokines and immunoglobulins in breast milk of Tanzanian women.  
Multiple factors affect the ultimate composition of a mother’s breast milk.  A recent 
review by Agarwal, et al. [50] states that little is known about how demographic 
characteristics and human behaviors influence the concentrations of breast milk immune 
markers. 
One class of immune molecules in breast milk are the immunoglobulins, also 
known as antibodies, which are proteins involved in the immune response to pathogens, 
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such as bacteria and viruses.  Immunoglobulins are classified into five major isotypes; 
IgA, IgD, IgE, IgG, and IgM.  Isotypes of classes IgA, IgG, and IgM have been measured 
in human breast milk and serum [50-54].  IgA is found in higher concentrations than all 
other immunoglobulin isotypes in human breast milk and is a critical component of the 
mucosal immune response [50].  IgG has four subclasses, IgG1, IgG2, IgG3, and IgG4, 
and acts by binding to pathogens [50].  IgM is the second most common immunoglobulin 
in breast milk and is generally the first antibody produced in a primary immune response 
[50, 55].  
Some studies show that factors such as maternal nutritional status, maternal health 
status, and infection may impact the concentrations of immunoglobulins present in breast 
milk and serum. Due to the structure of the mucosal immune system, immune responses 
induced in the mother’s gut produce immune cells that migrate to other secretory tissues, 
such as the mammary glands.  Therefore, it is likely that mothers exposed to microbes 
and pathogens present in developing countries may secrete higher concentrations of 
specific immune factors in their milk.  A study in Botswana considered differences in 
immunoglobulin composition of breast milk from HIV-positive/ART-naive women 
versus HIV-negative women.  The authors found significantly higher concentrations of 
total IgM, IgG, and IgA in the breast milk of HIV-positive women [51].  Researchers in 
Colombia showed that malnourished mothers had decreased concentrations of IgG, IgA, 
and IgM in serum and decreased concentrations of IgG and IgA in breast milk compared 
with well-nourished women [53].  Additionally, human subjects in India with 
cryptosporidiosis had higher concentrations of IgA and IgG in serum than subjects 
without Cryptosporidium infection, regardless of HIV status [56].   
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Cytokines, another class of immune molecules found in breast milk, are signaling 
molecules used in cellular communication.  Some cytokines, such as interferon gamma 
(IFN-γ) and interleukin-15 (IL-15), can be measured in human breast milk and serum 
samples [50, 52, 57-59].  Concentrations of cytokines in breast milk vary widely between 
women and may be related to differences in health status, infection, environmental 
microbial load, caloric intake and exercise, and time since giving birth [50, 52, 57, 58]. 
  Interferon gamma (IFN-γ) is a cytokine critical to innate and adaptive immunity 
against viral and intracellular bacterial infection.   Greater exposure to microbes and 
infectious agents is shown to increase concentrations of IFN-γ in both breast milk and 
serum.  A study of Swedish and Estonian women found that Estonian women, who have 
higher environmental exposure to microbes, excreted higher concentrations of IFN-γ in 
their milk [58].  A study of HIV-transmission in Kenyan infants showed a protective 
effect of IFN-γ expression in infants on vertical HIV transmission and increased 
concentrations of IFN-γ in infant serum 2 to 5 months after HIV infection [60, 61].  
Several studies also suggest that IFN-γ is associated with the human T-cell memory 
response to Cryptosporidium [62].  Human subjects with previous Cryptosporidium 
infection produced IFN-γ when challenged with Cryptosporidium, while 
Cryptosporidium-naïve subjects produced no IFN-γ [63].  Overall, IFN-γ in both breast 
milk and serum seems to be associated with greater exposure and enhanced response to 
infectious disease and microbial exposure. 
Interleukin-15 (IL-15) plays an important role in the innate immune response to 
viruses and parasites by activating natural killer cells. Among HIV-positive women in 
Zambia, higher concentrations of IL-15 in breast milk were associated with a decreased 
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risk of maternal-to-child transmission of HIV [57].  IL-15 also appears to be an important 
component of the primary immune response to Cryptosporidium in the intestine.  Dann, 
et al. [64] showed that within hours of Cryptosporidium exposure, intestinal tissues of 
healthy human volunteers increased expression of IL-15 and that this response is crucial 
to the clearance of Cryptosporidium infection in humans.  IL-15 expression is also 
negatively correlated with Cryptosporidium parasite burden [62].  
 
1.4 Objectives 
The objective of this dissertation is to understand how exclusive breastfeeding, in the 
context of HIV/AIDS and a high burden of parasitological contamination, promotes 
healthy development of the infant gut.  This dissertation also seeks to bridge the gap in 
knowledge between maternal breast milk immune components and infant immune 
response to pathogens.  This research had three specific aims: 
1) To determine the prevalence of Cryptosporidium in post-partum mothers and their 
infants in this setting. 
2) To measure concentrations of immunoglobulins and cytokines in breast milk 
longitudinally, from birth to six months post-partum, and to relate these 
concentrations to the health and nutritional status of mothers. 
3) To determine how the duration of exclusive breastfeeding and concentrations of 
cytokines and immunoglobulins in breast milk are related to the presence of 
Cryptosporidium in the infant’s gut. 
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Figure 1.5 Conceptual Framework of the Research Aims 
1.5 Dissertation Outline 
I present the results of the research in chapters 2 through 4.  The first study, which 
is the subject of chapter 2, reports the prevalence of Cryptosporidium in post-partum 
mothers and their infants from birth through six months.  Using a cohort of 108 women 
attending the antenatal unit of a semi-rural public health facility in Northwestern 
Tanzania, I report on the longitudinal prevalence of Cryptosporidium and the risk factors 
that are associated with infection in this setting.  In chapter 3, after describing the novel 
methods used to analyze breast milk immunoglobulins and cytokines, I report the 
concentrations of these immune molecules in all three biological compartments, namely, 
Primary Outcome: 
Cryptosporidium in Infant 
Household Factors: 
Sanitation 
Wealth 
Education 
Contact with Animals 
Food Security 
Water source 
Household Size 
Duration of 
EBF 
Maternal HIV Status 
Maternal Health: 
Mastitis 
Fever  
Cough 
Cryptosporidium 
infection 
BMI 
Secondary 
Outcome: 
Breast Milk 
Immune 
Composition 
Aim #1 Aim #2 Aim #3 
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maternal serum, breast milk, and infant serum.  Chapter 3 also summarizes the 
associations between maternal/infant health/nutritional factors and concentrations of 
immunoglobulins and cytokines in breast milk.  Lastly, chapter 4 incorporates the 
information from the previous 2 chapters to investigate how exclusive breastfeeding and 
concentrations of breast milk cytokines and immunoglobulins are related to 
Cryptosporidium in the infant.  Finally, chapter 5 provides a discussion of the findings 
from all three studies.  In the conclusion, I outline how my research findings could 
impact clinical care and public health messaging for pregnant and lactating women and 
their infants in the developing world. 
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CHAPTER 2 
 
CRYPTOSPORIDIUM PREVALENCE AND RISK FACTORS AMONG MOTHERS 
AND INFANTS 0 TO 6 MONTHS IN RURAL AND SEMI-RURAL NORTHWEST 
TANZANIA: A PROSPECTIVE COHORT STUDY 
 
2.1 Abstract 
Background:  Cryptosporidium epidemiology is poorly understood, but infection 
is suspected of contributing to childhood malnutrition and diarrhea-related mortality 
worldwide. 
Methods/Findings:  A prospective cohort of 108 women and their infants in 
rural/semi-rural Tanzania were followed from delivery through six months. 
Cryptosporidium infection was determined in feces using modified Ziehl-Neelsen 
staining.  Breastfeeding/infant feeding practices were queried and anthropometry 
measured.  Maternal Cryptosporidium infection remained high throughout the study 
(monthly proportion=44 to 63%).  Infection did not differ during lactation or by HIV-
serostatus, except that a greater proportion of HIV-positive mothers were infected at 
Month 1. Infant Cryptosporidium infection remained undetected until Month 2 and 
uncommon through Month 3 however, by Month 6, 33% of infants were infected.  There 
were no differences in infant infection by HIV-exposure.  Overall, exclusive 
breastfeeding (EBF) was limited, but as the proportion of infants exclusively breastfed 
declined from 32% at Month 1 to 4% at Month 6, infant infection increased from 0% at 
Month 1 to 33% at Month 6.  Maternal Cryptosporidium infection was associated with 
increased odds of infant infection (unadjusted OR=3.18, 95% CI 1.01 to 9.99), while 
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maternal hand washing prior to infant feeding was counterintuitively also associated with 
increased odds of infant infection (adjusted OR=5.02, 95% CI=1.11 to 22.78). 
Conclusions: Both mothers and infants living in this setting suffer a high burden 
of Cryptosporidium infection, and the timing of first infant infection coincides with 
changes in breastfeeding practices. It is unknown whether this is due to breastfeeding 
practices reducing pathogen exposure through avoidance of contaminated food/water 
consumption; and/or breast milk providing important protective immune factors.  
Without a Cryptosporidium vaccine, and facing considerable diagnostic challenges and 
ineffective treatment in young infants, minimizing the overall environmental burden (e.g. 
contaminated water) and particularly, maternal Cryptosporidium infection burden as a 
means to protect against early infant infection needs prioritization. 
 
2.2 Author Summary 
Early infancy and childhood Cryptosporidium infection is associated with poor 
nutritional status, stunted growth, and cognitive deficits, yet minimal research is available 
regarding the burden and risk factors worldwide.  Since there is no vaccine available, and 
because diagnostic challenges exist and treatment for children younger than one year is 
ineffective, prevention of early infancy infection through a better understanding of basic 
epidemiology is critical.  This study was designed to investigate symptomatic and 
clinically silent infection amongst HIV-seropositive and HIV-seronegative mothers and 
their infants in a longitudinal cohort, and to indentify potential risk factors.  Findings 
indicate that infants are living in a Cryptosporidium environment as demonstrated by the 
chronically high level of maternal infection throughout the 6-month post-partum period.  
Despite this, infant infection prevalence remains low until six months of age when it 
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dramatically rises.  The increase in infant infection corresponds to a reduction in 
exclusive breastfeeding.  As expected, maternal infection is associated with increased 
infant infection, but unexpectedly, so is maternal hand washing prior to infant feeding.  
Since prevention may indeed be the “best medicine” for infants, investigation of 
beneficial breastfeeding practices, protective correlates in breast milk, and ways to reduce 
the maternal and environmental Cryptosporidium burden are needed. 
 
2.3 Introduction 
The World Health Organization reports that the most common diarrhea-causing 
protozoan parasite worldwide is Cryptosporidium [1], and a recent, large, multi-country 
investigation reported Cryptosporidium as the second most common pathogen indentified 
among care-seeking African and Asian infants 0 to 11 months [2].  The significance of 
this infection was underscored as this study revealed that infection was associated with a 
greater than two-fold increase in mortality of children 12 to 23 months [2].  Despite these 
indications of the potential global scope and impact of Cryptosporidium infection, a full 
understanding of the epidemiology of infant and early childhood infection remains 
limited due to logistical and methodological difficulties in conducting such research in 
impoverished high-burden urban and rural settings [2]. 
Cryptosporidium is a pathogen transmitted via the oral-fecal route from human 
(C. hominis) and animal (predominately C. parvum) reservoirs. Infection risk factors 
include a contaminated environment with elements such as: unsafe water, poor sanitation 
and hygiene, and close proximity to infected livestock, while severe clinical disease risk 
factors include: malnutrition and compromised immunity, particularly HIV-associated 
immunosuppression [1,3]. Symptoms include: nausea, vomiting, voluminous and watery 
27  
diarrhea, dehydration, abdominal discomfort, anorexia, fever, fatigue, and respiratory 
problems [4,5], with chronic and life-threatening symptoms possible amongst 
immunocompromised individuals due to the increased duration and severity of illness [4]. 
However an unknown number of individuals experience asymptomatic Cryptosporidium 
infection [6].  This clinically silent infection may remain undetected and untreated and 
therefore may contribute to malnutrition, growth impairment, and long-term cognitive 
and functional deficits in infants and children [7,8].   
The primary aim of this research was to determine the prevalence of 
Cryptosporidium in young infants living in rural and semi-rural Tanzania by identifying 
the timing of the first and subsequent Cryptosporidium events in both symptomatic and 
asymptomatic infections.  Secondarily, I aimed to evaluate potential infant infection risk 
factors including: infant nutritional status, infant feeding practices, infant HIV-exposure, 
maternal nutritional status, maternal HIV infection, and, uniquely, maternal post-partum 
Cryptosporidium infection. 
 
2.4 Methods 
This study was a prospective birth cohort enrolling newborns and their HIV-
seropositive or –negative mothers living in the rural and semi-rural areas of Kisesa Ward 
(population 30,000) [9] in northwestern Tanzania. Pregnant women receiving antenatal 
care at Kisesa Health Centre (KHC), a Tanzanian government-administered, publically 
accessible primary care facility were recruited from March through December, 2012, a 
period that included both the dry and rainy seasons (Appendix A, Appendix F, Appendix 
G, Appendix H). Women gave birth between April, 2012 and January, 2013 (Appendix 
B, Appendix I); the study follow-up appointments for mothers and infants were 
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conducted between May, 2012 and July, 2013 (Appendix C, Appendix J).  Eligibility 
criteria were gestation < 37 weeks at consent, singleton birth, known maternal HIV 
serostatus (screening with Determine HIV-1/2 [Inverness Medical], confirmation with 
Uni-Gold HIV-1/2 [Trinity Biotech]), maternal ability to speak and understand the local 
language of Kiswahili, and stated intention to reside within the clinic catchment at 
delivery and through six months post-partum. The study was advertised through health 
workers at KHC as well as rural government-run health dispensaries in the region.  All 
HIV-positive women were receiving anti-retroviral treatment (ART) for their own care or 
for prevention of mother-to-child transmission by the time of delivery.  Infants born to 
HIV-positive women were given nevirapine daily for six weeks and tested for HIV-
infection by dried blood spot DNA-PCR at the regional hospital laboratory at the Month 
3 follow-up visit. The study protocol was approved by the ethics review committees of 
the Tanzania National Health Research Ethics Review Committee and Cornell 
University. Written informed consent was obtained from mothers for themselves and on 
behalf of their infants at enrolment with verbal assent re-confirmed at follow-up 
(Appendix G).  
All women were encouraged to deliver at KHC unless otherwise medically 
advised.  As many women in this region do not deliver at health clinics, and preliminary 
research revealed that transportation expenses were the primary barriers to accessing 
healthcare [10], the study provided transportation compensation and other clinical 
expenses typically borne by mothers for delivery and follow-up visits. For women who 
delivered elsewhere, including home births, mothers and infants were requested to attend 
a follow-up clinic visit within three days of delivery. The study flow chart is summarized 
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in Figure 2.1. If a mother-infant pair did not return for a regularly scheduled follow-up 
visit, a field worker traveled to their last known address to invite them to return to the 
clinic for a follow-up appointment.  
Figure 2.1. Study profile of infant cohort participants according to infant HIV-
exposure 
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At each follow-up, the research nurse, under supervision of the study coordinator, 
administered the Infant Feeding and Health Questionnaire to mothers (Appendix C, 
Appendix J). This questionnaire was designed to obtain data on a range of feeding, 
health, and environmental risk factors. Exclusive breastfeeding (EBF-WHO) was defined 
according to the WHO definition where “the infant receives breast milk (including 
expressed breast milk or breast milk from a wet nurse) and allows the infant to receive 
oral rehydration solution (ORS), drops, syrups (vitamins, minerals, medicines), but 
nothing else” [11]. Duration of EBF-WHO was defined as the time from birth until an 
infant first received food or liquids other than breast milk or medicines. Diarrhea was 
defined as loose or watery stools ≥ three times per day that represented a pattern atypical 
for that individual [1]. The questionnaire included: 1) infant nutrition: breastfeeding and 
complementary feeding practices; 2) mother-reported infant morbidity: cough, difficulty 
breathing, fever, convulsions, vomiting, skin rash, anorexia, unscheduled clinic/hospital 
visits, and episodes of diarrhea; and 3) environment: food security, using an index 
composed of questions relating to the mother’s food consumption pattern, and sanitation 
and hygiene practices, such as hand-washing behavior, access to safe water, and toilet 
facilities. Infants exhibiting symptoms of illness were referred to the clinical officer at 
KHC for follow-up.  
Anthropometric assessments were collected at each follow-up visit. Maternal 
height and weight were measured using a standard stadiometer (Health O Meter, Inc., 
Bridgeview, IL) to the nearest 0.2 kg and nearest 0.1 cm, respectively. Maternal mid-
upper arm circumference (MUAC) and triceps skinfold thickness (TSF) were measured 
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to the nearest 0.1 cm and 0.5 mm, respectively. Infant weight and length were measured 
using a calibrated digital infant scale (Seca 334 Digital Baby Scale) to the nearest 0.01 kg 
and a standard infant length board to the nearest 0.1cm, respectively. Infant MUAC, TSF, 
and head circumference were measured to the nearest 0.1 cm, 0.5 mm, and 0.1 cm, 
respectively.   
Active case detection was of interest so maternal and infant fecal samples were 
collected irrespective of self-reported intestinal symptoms at each follow-up visit. 
Cryptosporidium infection was detected using fresh stool samples that were stored in a 
cooler with ice packs for ≤ 5 hours before being transferred and stored at 4°C in the 
parasitology laboratory of the Tanzanian National Institute for Medical Research 
(NIMR), Mwanza Research Centre. Within 24 hours of collection, approximately 5g of 
stool was mixed with 5mL 10% v/v formalin and stored at 4°C until analysis. Presence of 
Cryptosporidium was confirmed using a modified Ziehl-Neelsen staining procedure 
(Appendix P) [12], which is estimated to have a sensitivity ranging from 32 to 79% and a 
specificity ranging from 89 to 100% [13-15]. After staining, slides were examined by a 
single technician, without knowledge of participant clinical status, using a light 
microscope (Olympus model CX41RF) to detect Cryptosporidium oocysts and estimate 
oocyst burden. Cryptosporidium infection was defined as ≥ 1 oocyst detected in stained 
fecal smears. A second technician re-examined a sample (10%) of the slides and inter-
observer agreement was 96%. 
Data were analyzed in STATA10 (STATA Corporation, Texas, USA).  Means of 
normally distributed continuous variables were compared using Student’s t-test and 
proportions of categorical variables were compared using the χ2 test and Fisher’s Exact 
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test. Results were considered statistically significant at α = 0.05, two-sided.  Univariate 
and multivariate logistic regression models were used to estimate the odds ratio (OR) and 
95% confidence interval (95% CI) of a priori considered potential risk factors for infant 
Cryptosporidium infection (HIV-exposure, exclusive breastfeeding, maternal 
Cryptosporidium infection, and household factors, such as animal ownership, sanitation, 
wealth, and maternal education). This study is registered with ClinicalTrials.gov, number 
NCT01699841. 
The sponsors (Cornell University and the National Science Foundation) were not 
involved in the design or oversight of the study. Members of the writing team had full 
access to the study data. The authors had final responsibility for the decision to submit for 
publication. 
 
2.5 Results 
During the study period, 108 infants were born, and of these, six infants exited the 
study because of death, migration, or withdrawal of consent prior to the Month 1 study 
visit (Figure 2.1) and were not included in follow-up analyses. Birth anthropometrics 
were statistically different between HIV-exposed and HIV-unexposed infants (Table 
2.1). A greater proportion of HIV-exposed infants had low birth weight (LBW; defined as 
birth weight < 2500g) compared to HIV-unexposed infants (HIV-exposed vs HIV-
unexposed = 15 vs 3%, respectively; p = 0.026). Likewise, a greater proportion of HIV-
exposed infants were stunted at birth (defined as birth length < 44.7 cm) compared to 
HIV-unexposed infants (HIV-exposed vs HIV-unexposed = 18 vs 2%, respectively; p = 
0.004).  No HIV-exposed infant tested positive for HIV between birth and three months 
of age. Maternal and household characteristics did not differ based on HIV-status of the 
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mother, other than marital status, where HIV-positive women were more likely to be 
divorced than HIV-negative women (HIV-positive vs HIV-negative = 21 vs 0%, 
respectively; p = 0.002). 
 
Table 2.1. Anthropometric characteristics of infants at birth and baseline maternal 
characteristics 
INFANTS 
 All HIV-exposed HIV-unexposed p value 
Sample Size 102 39 63  
Sex    0.240 
Male 52 (51%) 17 (44%) 35 (56%)  
Female 50 (49%) 22 (56%) 28 (44%)  
Birth weight (kg)     
Mean (SD) 3.2 (0.44) 3.1 (0.48) 3.3 (0.39) 0.028 
Low birth weight (< 2500g) 8 (8%) 6 (15%) 2 (3%) 0.026 
Birth length (cm)     
Mean (SD) 46.7 (0.22) 46.0 (0.41) 47.1 (0.22) 0.010 
Stunted (< 44.7cm) 8 (8%) 7 (18%) 1 (2%) 0.003 
Birth MUAC (cm)     
Mean (SD) 10.7 (0.11) 10.6 (0.19) 10.8 (0.13) 0.372 
Birth head circumference (cm)     
Mean (SD) 34.5 (0.17) 34.2 (0.24) 34.7 (0.24) 0.127 
Small head (< 31.5cm) 4 (4%) 1 (3%) 3 (5%) 0.578 
MOTHERS 
 All HIV-positive HIV-negative p value 
Age (years)     
Mean (SD) 28.4 (5.9) 29.4 (6.0) 27.7 (5.8) 0.168 
CD4 cell count (cells/µL)     
Median (IQR)  459 (330, 774)   
Body mass index at Month 1     
Mean (SD) 22.0 (2.6) 22.2 (2.7) 21.8 (2.5) 0.483 
Underweight (< 18.5 kg/m2) 8 (9%) 3 (8%) 5 (9%) 0.790 
Parity (number of children)     
Mean (SD) 2.6 (1.7) 2.7 (1.9) 2.6 (1.6) 0.660 
Water    0.342 
Treats water 77 (76%) 27 (71%) 50 (79%)  
Does not treat water 24 (24%) 11 (29%) 13 (21%)  
SD = standard deviation; Stunting was defined using WHO growth standards where 
length-for-age z-score (LAZ) < -2 (44.7 cm for infants at birth) is considered stunted.  
Likewise, small head was defined as a birth head circumference < 31.5 cm, which 
corresponds to a head circumference-for-age z-score < -2; MUAC = mid-upper arm 
circumference, there are currently no MUAC cut-off values for infants at birth [29]; IQR 
= interquartile range; Treats water = maternal report that the household takes measures 
to make water safe for drinking, i.e. boiling, filtration. 
The proportion of all mothers (HIV+ and HIV- combined) infected with 
Cryptosporidium ranged from a low of 44% (31/70) at Month 1 to a high of 63% (45/71) 
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at Month 6 post-partum, and this proportion was not statistically different across time 
points.  The majority of all mothers experienced Cryptosporidium infection at some point 
during the study follow-up period, with 82% experiencing Cryptosporidium infection at 
least once and 16% infected at every time point.  Self-reported diarrhea was not related to 
Cryptosporidium infection and symptomatic infection ranged from a low of 0% at Month 
3 to a high of 14% at Month 6. While the majority (60%) of mothers experienced self-
recovery from Cryptosporidium infection between visits based on the presence/absence 
of oocysts in their feces, 15% of mothers who recovered later became re-infected on a 
subsequent visit.  Maternal anthropometry (BMI) did not differ based on 
Cryptosporidium infection status. Additionally, statistically significant differences in 
maternal Cryptosporidium prevalence based on HIV-serostatus were not evident, with the 
exception of the Month 1 study visit (p = 0.012) (Figure 2.2). 
All infants remained free from Cryptosporidium infection until Month 2 and 
infection remained uncommon through Month 3. By Month 6, the increase in infection 
was dramatic with 33% (23/69) of infants exhibiting evidence of infection. Infant 
anthropometry (HAZ, WHZ, WAZ) did not differ based on Cryptosporidium infection 
status.  There were no statistically significant differences in infant Cryptosporidium 
infection based on HIV-exposure (p = 0.284).  Prevalence of infant Cryptosporidium 
infection did not significantly differ based on whether a mother was experiencing 
asymptomatic versus symptomatic Cryptosporidium infection.   
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Figure 2.2. Prevalence of Cryptosporidium infection in mothers and infants 
according to HIV-status/exposure. 
 
+ = number of participants with evidence of Cryptosporidium infection; n = number of 
fecal samples analyzed.  Note: the denominator increases across the study period for 
some groups due to missing data resulting from a missed appointment or failure to bring 
a fecal sample to the follow-up appointment. 
 
As overall EBF-WHO declined, the proportion of infant Cryptosporidium 
infection increased (Figure 2.3). Post-partum, there was a higher proportion of HIV-
positive mothers practicing EBF-WHO compared with HIV-negative mothers and this 
difference was statistically significant at both Month 1 (proportion HIV-positive vs HIV-
negative: 44 vs. 23%, p = 0.03) and Month 2 (proportion HIV-positive vs HIV-negative: 
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26 vs. 10%, p = 0.04).  Figure 2.4 depicts the survival curves of EBF by maternal HIV-
status.  Notably, of the four infants who continued EBF-WHO until six months, none had 
evidence of Cryptosporidium infection even though they were living in a 
Cryptosporidium environment as confirmed by evidence of maternal Cryptosporidium 
infection in all four cases. There was a pattern of lower proportion of Cryptosporidium 
infection in infants with a greater proportion of the diet consisting of breast milk (EBF-
WHO vs. partial/no breastfeeding) and this was significant at Month 6 (p = 0.030) 
(Figure 2.5). 
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Figure 2.3. Proportion of infants exclusively breastfed (EBF) and proportion with 
Cryptosporidium infection according to HIV-exposure. 
 
M1 = Month 1; M2 = Month 2; M3 = Month 3; M6 = Month 6; EBF-WHO = WHO 
definition of exclusive breastfeeding. 
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Figure 2.4. Kaplan-Meier survival curve of duration of EBF in weeks, by maternal 
HIV-status 
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Figure 2.5. Proportion of infants infected with Cryptosporidium between 0 and 6 
months according to status of breastfeeding practice 
 
Cryptosporidium negative = Cryptosporidium was not detected in the feces of the infant 
during the study period; Cryptosporidium positive = Cryptosporidium was detected at 
least once during the study period; No BF (breastfeeding) = infant was not receiving any 
breast milk; Mixed BF = infant was receiving breast milk and other liquids and foods; 
Pred. BF = infant was receiving breast milk and locally prepared gripe water; EBF-
WHO = WHO definition of exclusive breastfeeding. 
 
Neither maternal nor infant Cryptosporidium infection was associated with 
reported symptoms of infection that included diarrhea, anorexia, vomiting, and in 
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mothers only, abdominal pain and nausea. Care-seeking behavior, operationalized as an 
unscheduled clinic or hospital visit, was uncommon for both mother (4%) and infant 
(8%) between each scheduled follow-up visit and was not associated with 
Cryptosporidium infection.   
Table 2.2 summarizes the contribution of infant Cryptosporidium infection risk 
factors in this setting. In univariate analyses, only maternal Cryptosporidium infection at 
Month 1 (unadjusted OR = 3.18, 95% CI = 1.01 to 9.99) was associated with infant 
infection. While EBF-WHO was not significantly associated with lower odds of infant 
Cryptosporidium infection, there was a consistent trend between longer duration of EBF-
WHO and lower infant infection. In the multivariate model, maternal hand washing prior 
to infant feeding was significantly associated with an increased likelihood of infant 
Cryptosporidium infection (adjusted OR = 5.02, 95% CI = 1.11 to 22.78).  Maternal 
nutritional status, defined by body mass index (BMI) and MUAC, was not associated 
with maternal Cryptosporidium infection. Likewise, birth weight was not associated with 
infant Cryptosporidium infection nor was infant growth faltering up to six months a 
predictor of infant infection. Maternal food security index was negatively correlated with 
the practice of EBF-WHO at each visit; meaning that the more food secure a household, 
the less likely the infant was EBF-WHO. Similarly, the wealthier a household, the less 
likely the infant was EBF-WHO and the more educated a mother, the less likely the 
infant was EBF-WHO.  Neither maternal nor infant Cryptosporidium infection were 
associated with season or rainfall. 
 
41  
Table 2.2. Risk factors for infant Cryptosporidium infection between birth and six 
months 
 
 
Infants 
(n) 
Unadjusted 
OR (95% CI) 
p 
value 
Multivariate 
adjusted* 
OR (95% CI) 
p value 
HIV 
HIV-exposed 98 0.38 (0.14 – 1.07) 0.067 0.45 (0.10 – 1.98) 0.292 
Breastfeeding 
EBF-WHO at Month 1 89 0.66 (0.23 – 1.90) 0.442   
EBF-WHO at Month 2 93 0.58 (0.15 – 2.22) 0.424   
EBF-WHO at Month 3 97 0.43 (0.09 – 2.09) 0.299   
PBF at Month 6 91 0.23 (0.05 – 1.09) 0.063 0.32 (0.05 – 2.08) 0.233 
Maternal Cryptosporidium 
Crypto Month 1 69 3.18 (1.01 – 9.99) 0.047 3.40 (0.88 – 13.06) 0.075 
Crypto Month 2 69 1.30 (0.47 – 3.63) 0.617   
Crypto Month 3 71 1.93 (0.63 – 5.89) 0.251   
Crypto Month 6 71 1.23 (0.42 – 3.58) 0.710   
Crypto any time 95 2.76 (0.58 – 13.12) 0.201   
Household Factors 
Owns Animals 98 0.80 (0.31 – 2.11) 0.654 0.75 (0.19 – 2.94) 0.676 
Washes hands 98 1.72 (0.68 – 4·33) 0.249 5.02 (1.11 – 22.78) 0.036 
Wealth 98 0.97 (0.31 – 3.00) 0.953 0.48 (0.09 – 2.44) 0.373 
Maternal Literacy 98 1.51 (0.50 – 4.57) 0.466 0.76 (0.16 – 3.70) 0.735 
*Adjusted for maternal HIV status (0 = negative; 1 = positive), PBF at Month 6 (0 = no 
breastfeeding or partial breastfeeding; 1 = predominant breastfeeding or exclusive 
breastfeeding), Maternal Cryptosporidium infection at Month 1 (0 = uninfected; 1 = 
infected), animal ownership (0 = no animals; 1 = owns animals), hand washing (0 = 
mother doesn’t wash hands prior to infant feeding; 1 = mother washes hands prior to 
infant feeding), wealth (0 = lower 2 tertiles; 1 = top tertile), and maternal literacy (0 = 
mother cannot read; 1 = mother can read).  OR = odds ratio; CI = confidence interval; 
EBF-WHO = WHO definition of exclusive breastfeeding; PBF = exclusive or 
predominant breastfeeding; Washes hands = mother’s self report of washing hands prior 
to feeding infant; Wealth = index (0 – 10) calculated by summing a categorical list of 
household possessions and then stratified into wealth (top tertile) vs. not wealthy (lower 2 
tertiles); maternal literacy = mother’s self-report that she can read. 
Multivariate adjusted model: Infant Cryptosporidium infection = β(HIV-exposed) + 
β(PBF at Month 6) + β(maternal Cryptosporidium infection at Month 1) + β(Owns 
Animals) + β(Washes hands) + β(Wealth) + β(Maternal literacy) + µ 
2.6 Discussion 
This is the first report of maternal-infant Cryptosporidium infection in Sub-
Saharan Africa and the prevalence of infection was high.  Post-partum infection was 
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detected at least once in the majority of women and, for many, on multiple occasions. 
The Cryptosporidium burden in infants increased dramatically between three and six 
months of age, a period that corresponds to changes in breast feeding practices. My 
results indicate that young infants living in rural and semi-rural Tanzania are susceptible 
to Cryptosporidium infection in early infancy with approximately 1/3 of infants showing 
evidence of infection by six months of age. 
This study confirms and extends the importance of Cryptosporidium infection in 
young infants reported in the GEMS study [2] that included both rural and urban settings. 
My results are comparative to the findings of a sub-sample of young Tanzanian infants in 
urban, hospital-based studies where 25% of infants 0 to 6 months had evidence of either 
G. lamblia or Cryptosporidium parvum [16], though the burden of Cryptosporidium 
parvum was not individually reported.  In studies conducted in the Tanzanian capital of 
Dar es Salaam, only 9% of children three months to nine years and 18.9% of children 0 to 
60 months had evidence of Cryptosporidium infection [5,16] and this may represent an 
urban-rural difference in young infant burden in Tanzania. 
Previous studies in Tanzania of HIV-positive adults report a Cryptosporidium 
prevalence between 7 and 17% [5,6] and HIV infection has been identified as a risk 
factor for Cryptosporidium and cryptosporidiosis in some studies [6,17-20] but not others 
[2].  Maternal HIV infection did not appear strongly related to Cryptosporidium infection 
in my study and this may be explained in part because the majority of HIV-positive 
women were otherwise healthy and not severely immunocompromised based on their 
CD4 cell counts.  Previous studies that identified HIV infection as a risk factor were 
primarily conducted in the pre-ARV era and greater immunosuppression may explain 
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differences [6,17,20]. Likewise, HIV-exposure was not a significant risk factor for 
Cryptosporidium infection in infants and this might be due in part to more optimal 
feeding methods in the HIV-exposed infants due to infant feeding counseling for HIV-
positive mothers. While HIV infection may not be a significant risk factor for infection in 
this setting, it remains relevant for the clinical management of cryptosporidiosis in 
immunocompromised individuals given the lack of effective Cryptosporidium treatment 
other than ART’s to improve HIV immunocompetency [21]. 
While maternal Cryptosporidium infection was associated with greater infant 
infection, previously (or even currently) infected mothers may also be providing 
protective passive immunity in utero or in breast milk. A recent study of Bangladeshi 
infants reported that protection from Cryptosporidium infection was associated with high 
anti-Cryptosporidium IgA in breast milk [22]. Despite possible passive immunity and/or 
risk elimination (from contaminated food/water), EBF-WHO was uncommon in my study 
population and was not sustained for the universally recommended duration of six 
months.  In this study, using the WHO definition of EBF, only a third of mothers were 
practicing EBF-WHO at Month 1. Previous Tanzanian studies indicated much higher 
levels of “EBF” ranging from 49% within 3 days after birth [23], 90% at Month 1 [24], 
and 80% at Month 2 [25], but these large differences are likely due to the less strict non-
WHO-EBF definitions and/or maternal recall methods used [24,25]. Additionally, two of 
these studies included HIV-positive women only and HIV maternal care includes infant 
feeding counseling that is typically unavailable to HIV-negative mothers in this setting 
[24,25]. Indeed, I found significantly higher rates of EBF-WHO in HIV-positive mothers 
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and this may explain why infant HIV-exposure was associated with lower infant 
Cryptosporidium infections. 
Globally, knowledge of the epidemiology of Cryptosporidium infection in early 
infancy is scarce and, in Tanzania, such data are unavailable.  When the lack of 
prevalence data is combined with barriers to diagnosis, the disease rarely features on the 
clinician’s diagnostic radar.  This leads to a cycle that likely perpetuates the 
underestimation of the Cryptosporidium burden leading to an inappropriately lower 
global health and research priority.  This cycle reinforces ineffective clinical and public 
health management of Cryptosporidium.  In my study, maternal hand washing prior to 
infant feeding was counterintuitively associated with infant infection, although given the 
wide 95% confidence interval, I recommend caution in the interpretation of this finding. 
Previous studies have indicated that household sanitation and hygiene, including hand 
washing, were related to reduced Cryptosporidium infection [17].  Since 
Cryptosporidium has notoriously robust survival and transmissibility [26,27], and 
mothers may wash their hands with contaminated water and then feed their children, my 
result is plausible in this setting. It may also be that the practice of hand washing is a 
proxy indicator for women who lived in more contaminated environments.  Further 
research could include testing water sources and/or analysis of the species of 
Cryptosporidium in order to determine probable transmission routes of infection.  Such 
investigations would help interpret this finding in relation to major public health 
messages related to hand washing in similar settings. 
My study had a number of limitations.  First, at each follow-up visit, only one 
stool sample was collected from each mother and infant.  Due to the intermittent 
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shedding of Cryptosporidium oocysts, collection of a single stool sample may result in an 
underestimate of the true Cryptosporidium prevalence [28].  Additionally, my study used 
modified Ziehl-Neelsen staining, the most common diagnostic technique to detect the 
presence of Cryptosporidium oocysts in stool samples, however, the sensitivity and 
specificity of this method are not 100% leading to possible misclassification [13].  Lastly, 
my results may not be generalizable to other geographical settings due to urban/rural 
differences and geographical variation in Cryptosporidium contamination. 
In conclusion, there is a high prevalence of infant and maternal Cryptosporidium 
infection in this setting. Public health interventions promoting EBF-WHO among all 
women, including HIV-negative mothers should be strengthened. Modeling the message 
of breast milk as an immunologically protective substance to prevent certain infectious 
diseases common in childhood may be effective in regions where there are high rates of 
vaccination coverage.  Additionally, further research is needed to address efforts to 
minimize the maternal and environmental Cryptosporidium burden as a means of 
protecting young infants in the absence of effective vaccines, diagnostics, and treatment 
for early infancy cryptosporidiosis. 
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CHAPTER 3 
THE IMMUNOLOGICAL COMPOSITION OF MATURE BREAST MILK FROM 
MOTHERS OF MIXED HIV-STATUS IN RURAL NORTHWESTERN 
TANZANIA 
3.1 Abstract 
Background:  Breastfeeding is the “gold standard” in infant feeding, yet the 
correlates of immune protection in breast milk (BM) remain unclear.  In the context of 
rural sub-Saharan Africa, it is crucial to understand the immunological protection 
provided through BM to reduce infant morbidity and mortality. 
Methods:  A cohort of 125 women/infants in rural Tanzania was followed from 
birth through six months. BM and maternal/infant blood were collected to determine 
concentrations of immunoglobulins and cytokines and how they were associated with 
maternal/infant health/nutritional status.  
Results: While cytokine and immunoglobulin concentrations did not differ based 
on maternal nutritional status or HIV status, exclusive breastfeeding (EBF) was 
associated with greater concentrations of IgA, IgG, and IL-12p70.  There were 
weak/moderate correlations for immunoglobulins between maternal serum-BM and BM-
infant serum, but cytokines showed a more complex, inconsistent pattern of correlation.  
In regression analyses, total BM immunoglobulin concentrations were positively 
associated with EBF and more frequent feeding, while total BM cytokines were 
associated with maternal and infant infection symptoms. 
Conclusions: Breastfeeding practices in this cohort of rural Tanzanian mothers 
remain sub-optimal, yet EBF and feeding frequency were associated with increased 
49  
concentrations of certain cytokines and immunoglobulins in BM.  Maternal body mass 
index and HIV-infection were not associated with differences in BM immunological 
composition.  Future research should focus on a broader array of modifiable factors that 
may impact BM immune composition, as well as the clinical and public health relevance 
of BM differences on infant infectious diseases. 
 
3.2 Introduction 
The nutritional, immunological, and maternal-infant bonding benefits achieved 
through breastfeeding makes it the universal “gold standard” for infant feeding [1]. 
Breastfeeding has also repeatedly been associated with lower incidences of early 
childhood infectious diseases, such as pneumonia and diarrhea [2].  However, the 
correlates of immune protection in breast milk remain unclear. Diarrhea and pneumonia 
are the two largest contributors to infant morbidity and mortality in resource-limited 
regions [3] so the identification of immunological factors associated with infection in 
early infancy is needed.  Consequently, a better understanding of breast milk 
immunology throughout the lactation period is crucial to reducing infant illness and 
death.  
Early infancy represents a period of immunological vulnerability, as the immune 
system continues to mature after birth [4].  Breast milk provides an important 
immunological bridge between the maternal immune system and the developing infant 
immune system.  Many immune cells and molecules in breast milk are involved in the 
prevention of infection and contribute to the priming and further maturation of the 
neonatal immune system. For example, immunoglobulin A (IgA), the most abundant 
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antibody in human milk, provides adaptive immune protection against certain intestinal 
infections by neutralizing and eliminating enteric pathogens [5].  Human milk also 
contains commensal microbes, cells (e.g. macrophages), molecules (e.g. cytokines, 
lactoferrin), and other immunoglobulins contributing to immune protection.  Cytokines, 
through diverse signaling pathways, are key mediators of both the innate and adaptive 
immune response [6-8].   
The nature of the immunological bridge provided by breast milk likely depends 
upon the specific immunological composition of a mother’s milk.  It has been 
demonstrated that breast milk immune composition is influenced by maternal factors, 
such as her nutritional status and health, as well as biological factors like stage of 
lactation. Since a mother’s nutritional status can alter her own immune status [9,10], by 
extension, maternal nutritional status may impact breast milk immunological 
composition, however the limited evidence lacks consensus [11-14]. More evidence is 
available to support a link between maternal immune status and breast milk immune 
composition. A key example is the maternal entero-mammary system whereby the 
maternal immune response to intestinal pathogens induces the production of circulating 
immune cells that migrate to mucosal secretory immune tissues, including the mammary 
glands [15].  Additional factors, such as infant health status [16], and breastfeeding 
practices [17] may also influence breast milk immunology, but data are limited. 
In rural sub-Saharan Africa, infants are at high risk of infectious diseases and, 
once infected, health consequences may be severe due to limited health care 
infrastructure and resources. Maternal HIV-infection remains common in this context 
(6.8% of pregnant women in Tanzania are infected with HIV [18]), while the success of 
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anti-retroviral treatment (ART) and prevention of mother-to-child transmission (PMTCT) 
have improved the health of both HIV-positive mothers and their infants.  Public health 
policy recommends exclusive breastfeeding (EBF) for all mothers, irrespective of HIV 
status [19].  As a result, the number of infants receiving HIV-exposed breast milk is both 
considerable and increasing.  Despite links between mucosal immunity and circulating 
immune cells in HIV-infection [20], evidence regarding the link between maternal HIV-
infection and breast milk immune composition remains limited and inconsistent [8, 21].  
Therefore, in a prospective cohort of women and infants living in rural northwestern 
Tanzania, this study’s aims were to: 1) characterize breast milk immune composition up 
to six months post-partum among women with and without HIV infection; 2) investigate 
immunoglobulin and cytokine concentrations in different biological compartments 
including maternal serum, breast milk, and infant serum; and 3) compare breast milk 
immunoglobulin and cytokine profiles in relation to maternal and infant health and 
nutritional status indicators. 
 
3.3 Methods 
3.3.1 Study Participants 
This prospective cohort included 50 HIV-positive and 75 HIV-negative pregnant 
women living in rural and semi-rural areas of Kisesa Ward (population 30,000) [22], 
Magu District, northwestern Tanzania (Figure 3.1). Pregnant women seeking antenatal 
care at Kisesa Health Centre or remote health care dispensaries, both of which are 
publically accessible facilities administered by the Tanzanian government, were recruited 
between March 27 and December 19, 2012.  Prospective participants were encouraged to 
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attend Kisesa Health Centre for an enrollment interview (Appendix A, Appendix F, 
Appendix G, Appendix H).  All HIV-positive pregnant women and the first three HIV-
negative pregnant women attending the antenatal clinic each day were invited to 
participate if they met the following eligibility criteria: gestation <37 weeks at consent, 
singleton birth, known maternal HIV serostatus (screening with Determine™ HIV-1/2 
[Inverness Medical], confirmation with Uni-Gold™ HIV-1/2 [Trinity Biotech]), maternal 
ability to speak and understand the local language of Kiswahili, and stated intention to 
reside within the clinic catchment area from delivery through six months post-partum.  
To maintain study retention, if a participant did not return for a scheduled follow-up 
study visit, a field worker traveled to her last known address to invite her to return to the 
clinic for a follow-up appointment.  All HIV-positive women were receiving 
antiretroviral therapy (ART), either for their own HIV management or for PMTCT, by 
the time of delivery in accordance with Tanzanian national guidelines [18].  
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Figure 3.1. Flow of study participants 
 
The study protocol was approved by the ethics review committees of the Tanzania 
National Health Research Ethics Review Committee and Cornell University 
(ClinicalTrials.gov, number NCT01699841). Written informed consent was obtained 
from mothers and on behalf of their infants at enrollment and verbal assent for mothers 
and infants was re-confirmed at each follow-up (Appendix G). 
3.3.2 Data Collection 
At each study visit, participants were administered a questionnaire on 
demographics, self-reported maternal and child morbidity, and infant feeding practices 
42 HIV+ Women 66 HIV- Women 
39 (93%) HIV+ women attended 
32 (82%) milk samples 
37 (95%) maternal blood samples 
5 (13%) infant blood samples 
63 (95%) HIV- women attended 
49 (78%) milk samples 
41 (65%) maternal blood samples 
11 (17%) infant blood samples  
38 (90%) HIV+ women attended 
25 (66%) milk samples 
31 (82%) maternal blood samples 
10 (26%) infant blood samples 
62 (94%) HIV- women attended 
51 (82%) milk samples 
40 (65%) maternal blood samples  
12 (19%) infant blood samples 
36 (86%) HIV+ women attended 
30 (83%) milk samples 
33 (92%) maternal blood samples 
12 (33%) infant blood samples 
61 (92%) HIV- women attended 
53 (87%) milk samples 
40 (66%) maternal blood samples 
10 (16%) infant blood samples 
35 (83%) HIV+ women attended 
20 (57%) milk samples 
31 (89%) maternal blood samples 
7 (20%) infant blood samples 
59 (89%) HIV- women attended 
50 (85%) milk samples 
49 (83%) maternal blood samples 
6 (10%) infant blood samples 
1 (2.3%) withdrew consent 
1 (2.3%) migrated out 
1 (2.3%) infant died 
1 (1.5%) withdrew consent 
1 (1.5%) migrated out 
1 (1.5%) infant died 
1 (1.5%) migrated out 
1 (2.3%) withdrew consent 
1 (2.3%) migrated out 1 (1.5%) migrated out 
1 (2.3%) untraceable 2 (3.0%) untraceable 
Month 1 
Month 2 
Month 3 
Month 6 
1 (2.3%) woman died 
125 Pregnant Women Enrolled 
Delivery 
2 (2.7%) withdrew consent 
3 (4.0%) migrated out 
1 (1.3%) maternal death 
2 (2.7%) twins 
1 (1.3%) stillbirth 
3 (6.0%) migrated out 
3 (6.0%) miscarried 
2 (4.0%) twins 
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(Appendix C, Appendix J).  EBF was defined according to the World Health 
Organization (WHO) definition where “the infant receives breast milk (including 
expressed breast milk or breast milk from a wet nurse) and allows the infant to receive 
oral rehydration solution (ORS), drops, syrups (vitamins, minerals, medicines), but 
nothing else” [23]. EBF duration was defined as the time (in weeks) from birth until an 
infant first received food or liquids other than breast milk or prescribed medicines. 
Breastfeeding intensity was defined as the number of times a mother reported putting her 
infant to the breast in the previous 24 hours. Food Security was assessed using a series of 
five questions modified from the Household Food Insecurity Access Scale (HFIAS), 
previously validated in rural Tanzania [24]. 
3.3.3 Nutritional Status 
Maternal and infant anthropometric data were collected at each study visit. 
Maternal height and weight were measured using a standard stadiometer (Health O 
Meter, Inc., Bridgeview, IL) to the nearest 0.2 kg and nearest 0.1 cm, respectively. Infant 
weight and length were measured using a calibrated digital infant scale (Seca 334 Digital 
Baby Scale) to the nearest 0.01 kg and a standard infant length board to the nearest 
0.1cm, respectively.  Body mass index (BMI) was calculated for mothers and weight-for-
age z-score (WAZ) and height-for-age z-score (HAZ) were calculated for infants using 
WHO growth standards [25]. 
3.3.4 Breast Milk and Blood Collection and Laboratory Analysis of 
Immunoglobulins and Cytokines 
Immunoglobulins selected for analyses were: IgA, IgG1, IgG2, IgG3, IgG4, and 
IgM; cytokines were: interleukin (IL)-1β, IL-2, IL-6, IL-10, IL-12p70, IL-13, IL-15, 
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tumor necrosis factor (TNF)-α, and interferon (IFN)-γ.  Table 3.1 summarizes the a 
priori rationale for analyte selection. 
Table 3.1. Immune molecule rationale for analysis 
Molecule Rationale Breast milk-
specific 
reference 
IgA Critical for mucosal immunity; concentration in milk associated 
with maternal HIV-infection and nutritional status (BMI); 
dominant immunoglobulin in human milk 
4, 7, 11-14, 21, 
26 
IgG1 – 
IgG4 
Binds to pathogens; concentrations in milk associated with 
maternal HIV-infection and nutritional status (BMI) 
4, 11, 13, 21, 
26 
IgM Concentration in milk associated with maternal HIV-infection; 
second most common antibody in human milk 
4, 11, 13, 21, 
26 
IL-1β Bio-activity reported in human milk; important inflammatory 
mediator 
4, 26, 27, 28 
IL-2 Involved in immunoglobulin and T-cell production 4, 27, 29 
IL-6 Associated with mastitic milk; microbial protection against 
Streptococcus pneumoniae; inflammatory mediator 
26, 30 
IL-10 Associated with HIV viral load in breast milk; anti-inflammatory 
mediator; immunomodulation 
26, 31 
IL-12p70 Involved in regulation of inflammation and T-cell differentiation 4, 26, 27, 32 
IL-13 Involved in immune response to enteric parasites, including 
Schistosoma mansoni 
26, 33 
IL-15 Associated with protection against postnatal HIV transmission; T-
cell and natural killer cell proliferation 
8 
TNFα Associated with HIV viral load in breast milk; pro-inflammatory 
cytokine; involved in the induction of acute phase response 
26, 31, 34-36 
IFNγ Associated with modulation of neonatal immune development; 
key cytokine in regulating responses to viral, bacterial, and 
protozoan infections 
4, 26, 33, 37 
 
Maternal blood, infant blood, and hand-expressed breast milk samples were 
collected at each follow-up visit.  Time of breast milk collection was noted, as was 
classification of fore or hind milk.  Breast milk samples were stored in a polypropylene 
container at 4°C for ≤5 hours before transfer to the regional laboratory at the National 
Institute for Medical Research-Mwanza (NIMR).  Breast milk samples were centrifuged 
and the milk fatty layer removed prior to storage at -20°C. Blood samples were collected 
in EDTA tubes, centrifuged, and the plasma was stored at -20°C (Appendix K, Appendix 
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L).  Immunoglobulin and cytokine concentrations were measured using MAGPIX® 
instrumentation with xMAP® technology (Luminex Corporation) and MILLPLEX® 
MAG magnetic bead-based multianalyte panels (Cat. #HGAMMAG-301K and Cat. 
#HCYTOMAG-60K). Plasma assays were performed according to the manufacturer’s 
protocol with standard curves and quality controls performed for each assay (Appendix 
N, Appendix O).  After preliminary testing using a range of breast milk cell-free 
supernatant dilutions, optimal recovery of selected analytes was obtained in undiluted 
samples.  In accordance with Groer, et al. [38], breast milk was assayed by adapting the 
manufacturer’s protocol for plasma samples using a commercial serum matrix provided 
in the Millipore kit.  Samples with concentrations below the limit of detection (LOD) 
were assigned a value corresponding to the LOD/√2 [39]. 
3.3.5 Statistical Analysis 
Data were analyzed in STATA10 (STATA Corporation, Texas, USA).  The 
means of normally distributed continuous variables were compared using Student’s t-test 
and proportions of categorical variables were compared using the χ2 test. Results were 
considered statistically significant at α = 0.05, two-sided.  Longitudinal trends were 
analyzed using multilevel mixed-effects linear regression.  Correlation coefficients were 
calculated using Pearson’s correlation for normally distributed variables and Spearman’s 
correlation for non-normally distributed variables. In order to calculate total breast milk 
immunoglobulins for use in logistic regression, concentrations of IgA and IgM were 
converted from ng/ml to 10-7g/ml, IgG1 and IgG2 were converted from ng/ml to µg/ml, 
and IgG3 and IgG4 were converted from ng/ml to 10-8g/ml.  The converted 
concentrations were summed to create a “unit-less” total immunoglobulin concentration.  
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Il-1β, IL-2, and IL-10 in breast milk and IL-13 in plasma were <LOD in all participants 
for at least one time point and were therefore excluded in the total cytokine concentration 
calculation, which represented the sum of the remaining cytokines (measured in pg/ml).  
Univariate and multivariate multiple linear regression models were used to estimate the 
association between maternal and infant characteristics and total breast milk cytokine and 
immunoglobulin concentrations. 
 
3.4 Results 
3.4.1 Participant Characteristics 
Of the 125 pregnant women enrolled, 23 (18%) exited the study between 
enrollment prior to delivery and the first follow-up visit at Month 1 (Figure 3.1).  
Participants who exited during this period did not significantly differ from the rest of the 
study population based on demographic variables or HIV status at enrollment. 
The majority of mothers were well-nourished: the prevalence of underweight in 
mothers (defined by a BMI < 18.5 kg/m2) ranged from 9 to 15% over the six-month study 
period.  Maternal post-partum nutritional status, based on BMI, did not differ according 
to maternal HIV status, and gestational age at birth was not significantly different 
between HIV-exposed and HIV-unexposed infants.  However, as expected, HIV-exposed 
infants had significantly lower birth weight than HIV-unexposed infants (3.05 kg vs. 3.26 
kg, p = 0.020) and early infancy anthropometric differences continued, as HIV-exposed 
infants experienced significantly lower WAZ than HIV-unexposed infants (Table 3.2). 
Infant malnutrition in the form of stunting (HAZ <-2) was common among all infants (45 
to 56%), regardless of HIV-exposure, with prevalence increasing over the six-month 
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study period. The duration of EBF was short among all women, with the mean being only 
four weeks.  However, on average, HIV-positive women continued EBF for three weeks 
longer than HIV-negative women.  In early infancy, HIV-positive and HIV-negative 
women did not differ significantly in breastfeeding status (Month 1 EBF = 44 vs. 23%; 
predominant breastfeeding = 44 vs. 51%; partial breastfeeding = 13 vs. 26%; no 
breastfeeding = 0%, p = 0.067).  However, from Month 2 through Month 6, HIV-positive 
women significantly differed in infant feeding method, where HIV-exposed infants had a 
greater proportion of breast milk in their diet than HIV-unexposed infants (Month 2, p = 
0.030; Month 3, p = 0.009; Month 6, p = 0.001).  Consistent differences in breastfeeding 
intensity or food security based on HIV-status were not apparent (Table 3.2). 
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Table 3.2. Characteristics of Mothers and Infants from birth through six months 
post-partum in rural Northwest Tanzania. 
 WOMEN 
 All HIV+ HIV- 
Sample Size 102 39 63 
Age (years)    
Mean (SD) 28.4 (5.9) 29.4 (6.0) 27.7 (5.8) 
Parity (number of children)    
Mean (SD) 2.6 (1.7) 2.7 (1.9) 2.5 (1.6) 
% Primiparous (n) 9% (9) 8% (3) 10% (6) 
CD4 cell count (cells/µL)    
Median (IQR)  459 (330, 
774) 
 
Mastitis     
% at Month 1 (n) 4% (4) 5% (2) 4% (2) 
% at Month 2 (n) 4% (4) 3% (1) 5% (3) 
% at Month 3 (n) 5% (5) 3% (1) 7% (4) 
% at Month 6 (n) 8% (7) 9% (3) 7% (4) 
Maternal Fever    
% at Month 1 (n) 24% (22) 21% (8) 26% (14) 
% at Month 2 (n) 29% (26) 24% (8) 32% (18) 
% at Month 3 (n) 29% (28) 30% (11) 29% (17) 
% at Month 6 (n) 43% (40) 46% (16) 42% (24) 
Maternal Cough    
% at Month 1 (n) 20% (19) 23% (9) 19% (10) 
% at Month 2 (n) 17% (15) 15% (5) 18% (10) 
% at Month 3 (n) 19% (18) 14% (5) 22% (13) 
% at Month 6 (n) 30% (28) 40% (14) 25% (14) 
Maternal BMI    
Month 1 Mean (SD) 22.0 (2.6) 22.2 (2.7) 21.8 (2.5) 
Month 2 Mean (SD) 21.9 (2.6) 22.0 (2.6) 21.8 (2.6) 
Month 3 Mean (SD) 21.9 (2.8) 21.9 (2.9) 21.8 (2.7) 
Month 6 Mean (SD) 21.6 (2.7) 21.8 (2.7) 21.6 (2.8) 
Food Security Index (FSI)    
Month 1 Mean (SD) 13.0 (2.1) 12.2 (2.5)* 13.6 (1.6)* 
Month 2 Mean (SD) 12.7 (2.1) 12.3 (2.5) 13.0 (1.9) 
Month 3 Mean (SD) 12.5 (2.1) 12.2 (2.2) 12.7 (2.0) 
Month 6 Mean (SD) 12.1 (2.4) 11.5 (2.5)* 12.5 (2.2)* 
 INFANTS 
 All HIV-
exposed 
HIV-
unexposed 
Gestational Age at Birth 
(weeks) 
   
Mean (SD) 38.2 (3.5) 37.7 (3.0) 38.5 (3.7) 
% Preterm (< 37 weeks) (n) 29% (28) 35% (13) 25% (15) 
Infant Birth Weight (kg)    
Mean (SD) 3.2 (0.44) 3.1 (0.48)* 3.3 (0.39)* 
% Low birth weight (< 2.5kg) 
(n) 
8% (8) 15% (6)* 3% (2)* 
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 INFANTS 
 All HIV-
exposed 
HIV-
unexposed 
Weight-for-Age Z-Score 
(WAZ) 
   
Month 1 Mean (SD) -0.19 (0.95) -0.50 (1.13)* 0.03 (0.73)* 
Month 2 Mean (SD) -0.13 (1.01) -0.55 (1.17)* 0.13 (0.81)* 
Month 3 Mean (SD) -0.27 (1.12) -0.69 (1.12)* 0.01 (1.03)* 
Month 6 Mean (SD) -0.37 (1.04) -0.79 (1.13)* -0.11 (0.88)* 
Height-for-Age Z-Score 
(HAZ) 
   
Month 1 Mean (SD) -1.73 (1.44) -1.95 (1.58) -1.58 (1.32) 
Month 2 Mean (SD) -1.78 (1.36) -2.17 (1.43)* -1.54 (1.26)* 
Month 3 Mean (SD) -1.87 (1.34) -2.03 (1.31) -1.77 (1.36) 
Month 6 Mean (SD) -2.33 (1.44) -2.67 (1.20) -2.12 (1.54) 
Duration of Exclusive 
Breastfeeding (weeks)  
   
Mean (SD) 4.4 (6.5) 6.0 (7.5) 3.4 (5.6) 
Breastfeeding Intensity 
(times/day) 
   
Month 1 Mean (SD) 11.8 (4.7) 11.8 (4.3) 11.9 (5.0) 
Month 2 Mean (SD) 10.9 (4.6) 11.4 (4.7) 10.6 (4.5) 
Month 3 Mean (SD) 10.7 (3.9) 11.8 (3.8)* 10.1 (3.8)* 
Month 6 Mean (SD) 9.2 (4.4) 9.0 (4.5) 9.4 (4.4) 
Infant Fever    
% at Month 1 (n) 26% (24) 33% (13) 20% (11) 
% at Month 2 (n) 29% (26) 31% (11) 27% (15) 
% at Month 3 (n) 42% (41) 45% (17) 41% (24) 
% at Month 6 (n) 66% (61) 56% (20) 72% (41) 
*p < 0.05, comparing HIV-positive/exposed vs. HIV-negative/unexposed.   
Overall, HIV-positive women were not severely immunosuppressed at 
enrollment: 45% of HIV-positive women had CD4 cell counts above the normal lower 
limit (CD4 >500 cells/µL), while only 9% of women had CD4 cell counts <200 cells/µL.  
Results from the questionnaire indicated that self-reported maternal morbidity did not 
differ based on maternal HIV-status (Table 3.2).  The most commonly reported maternal 
symptoms for all women were fever (24 to 43%) and cough (17 to 30%), while other self-
reported symptoms, including diarrhea, skin rash, vomiting, abdominal pain, anorexia, 
nausea, fatigue, and difficulty breathing were rare (data not shown).  Self-reported 
mastitis was also rare (4 to 8%) among HIV-positive and HIV-negative women. Infant 
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fever was a common symptom, with the percentage increasing from 26% at Month 1 to 
66% at Month 6.  Other self-reported infant symptoms, including diarrhea, cough, 
breathing problems, convulsions, vomiting, skin rash, and anorexia did not significantly 
differ between HIV-exposed and HIV-unexposed infants throughout the study period 
(data not shown). 
3.4.2 Mature Breast Milk Immunology 
Breastfeeding exclusivity and intensity were associated with differential 
immunoglobulin concentration: the practice of EBF was associated with significantly 
greater breast milk concentrations of IgA (EBF = 263.4 vs. No EBF = 192.4, p = 0.048), 
IgG1 (EBF = 1638.4 vs. no EBF = 702.4, p = 0.003), IgG2 (EBF = 6918.4 vs. no EBF = 
3299.6, p = 0.033), and IgG3 (EBF = 40.3 vs. no EBF = 17.7, p <0.001) (Appendix D).  
Neither maternal HIV status nor maternal malnutrition were associated with significant 
differences in concentrations of any immunoglobulins measured (Appendix D), although 
IgG1 concentration was consistently higher in breast milk of HIV-positive women at each 
time point (Month 1: HIV-positive = 1033.0 vs. HIV-negative = 667.8, p = 0.365; Month 
2: HIV-positive = 1060.7 vs. HIV-negative = 975.0, p = 0.756; Month 3: HIV-positive = 
1114.4 vs. HIV-negative = 834.2, p = 0.219; Month 6: HIV-positive = 857.9 vs. HIV-
negative = 584.2, p = 0.325).  Since immunoglobulin concentrations did not differ 
according to HIV status, all women were combined for subsequent analyses.  In this 
combined analysis, IgA, IgG3, IgG4, and IgM varied during lactation, with an inverted 
U-shaped pattern apparent over the six-month study period (Figure 3.2). 
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Figure 3.2. Mean breast milk immunoglobulin concentrations from one to six 
months post-partum in mothers from rural northwest Tanzania. 
 
Note: Different letters above bars indicate that concentrations are significantly different, 
two-sided t-test, p < 0.05 
 
Like immunoglobulins, breast milk cytokine concentrations varied according to 
breastfeeding practices, but not according to maternal HIV or nutritional status 
(Appendix E).  Mothers who EBF at the time of breast milk collection had significantly 
higher concentrations of breast milk IL-12p70 at Months 2 and 3 (Month 2: EBF = 2.58 
vs. no EBF <LOD, p = 0.006; Month 3: EBF = 3.31 vs. no EBF = 2.42, p = 0.017). TNFα 
concentration indicated an inverted U-shaped pattern during lactation, IL-6 and IL-15 
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concentrations exhibited a linear decrease, while IFNγ, IL-12p70, and IL-13 were static 
and IL-1β, IL-2, and IL-10 remained undetected (Figure 3.3 and Appendix E).  
Figure 3.3. Longitudinal patterns of mean breast milk cytokine concentrations from 
one to six months post-partum in mothers from rural northwest Tanzania. 
 
Note: Different letters above bars indicate concentrations are significantly different, two-
sided t-test, p < 0.05 
 
Correlations ranged from negligible to strong when examining concentrations 
between biological compartments (e.g. maternal serum and breast milk or breast milk and 
infant serum) (Table 3.3).  The data showed weak to moderate positive correlations 
between maternal serum and breast milk for IgA, IgG2, IgG4, IgM, and total 
immunoglobulins (Table 3.3a, left panel), while only TNFα concentrations at Month 2 
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were moderately correlated among cytokines (Table 3.3b, left panel).  Breast milk and 
infant serum immunoglobulins were consistently correlated in early infancy through 
Month 2, with weak to strong positive correlations apparent for each immunoglobulin, 
and no consistent correlation evident thereafter (Table 3.3a, right panel).  Cytokine 
correlations between breast milk and infant serum revealed a more complex correlation 
matrix with both positive and negative correlations evident (Table 3.3b, right panel). 
Table 3.3. Pair-wise correlation between concentrations of immunoglobulins (a) and 
cytokines (b) in maternal serum vs. breast milk (left panel), and breast milk vs. 
infant serum (right panel). 
 Maternal Serum: Breast Milk  Breast Milk: Infant Serum 
 Month 
1 
Month 
2 
Month 
3 
Month 
6 
 Month 
1 
Month 
2 
Month 
3 
Month 
6 
a   
IgA 0.19 0.24 0.24 0.14  0.49 0.35 -0.19 -0.28 
IgG1 0.13 0.15 0.11 NA  -0.18 0.20 -0.15 0.04 
IgG2 0.03 0.24 NA NA  0.24 -0.08 NA NA 
IgG3 NA 0.09 0.11 -0.03  NA 0.15 -0.12 -0.11 
IgG4 0.20 0.18 0.07 0.01  0.20 0.43 -0.14 -0.01 
IgM 0.09 0.34 0.14 NA  -0.01 0.41 -0.13 0.17 
Total Ig 0.12 0.14 0.20 0.22  0.12 0.17 -0.15 -0.06 
b   
IFNγ  -0.09 -0.12 -0.13 0.16  ND ND -0.08 ND 
TNFα  0.10 0.34 0.16 -0.02  0.00 -0.23 0.25 -0.11 
IL-6 -0.07 0.03 -0.07 -0.05  0.33 ND -0.11 ND 
IL-12p70 -0.09 ND 0.08 -0.06  ND ND -0.14 ND 
IL-15 0.09 -0.06 0.01 0.12  -0.08 ND ND -0.26 
Total Cyt 0.01 0.11 0.05 0.11  0.14 -0.24 0.11 -0.80 
 
Strong 
Negative  
(-1 to -0.4) 
Moderate 
Negative       
(-0.3 to -0.39) 
Weak 
Negative        
(-0.2 to -0.29) 
Negligible     
(-0.19 to 0.19) 
Weak 
Positive  
(0.2 to 0.29) 
Moderate 
Positive  
(0.3 to 0.39) 
Strong 
Positive 
(0.4 to 1) 
Note: NA = not available; ND = not detected 
 
Table 3.4 summarizes maternal and infant health and nutrition associations with 
total breast milk immunoglobulins and cytokines.  Total immunoglobulin concentrations 
were consistently positively associated with breastfeeding practices: EBF or more 
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frequent feeding was associated with higher total breast milk immunoglobulins 
throughout lactation.  Gestational age at birth was inversely associated with total 
immunoglobulins in early infancy only.  Maternal health status, including mastitis, fever, 
and cough, was associated with higher total breast milk cytokine concentrations in 
univariate and multivariate regression analyses.  Interestingly, fever in infants was also 
significantly associated with breast milk cytokines, where the presence of fever was 
associated with lower total cytokine concentration.  Breast milk from mothers with 
infants who had higher birth weight and weight-for-age also had significantly lower total 
cytokine concentration at Month 1 post-partum.  More frequent breastfeeding episodes 
were associated with significantly lower total cytokines in breast milk at Month 6.  
Including classification of fore/hind milk or time of milk collection in the multivariate 
models did not affect any of the estimates (data not shown). 
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Table 3.4. Univariate and multivariate multiple linear regression estimators of total 
breast milk immunoglobulin (left panel) and cytokine (right panel) concentrations 
 
*p < 0.05; ** p < 0.01; *** p < 0.001.   
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Note: HIV-status: 0 = HIV-negative or 1 = HIV-positive; Mastitis: 0 = mother’s self-
report that she was not experiencing mastitis or 1 = mother’s self-report that she was 
experiencing mastitis; Fever: 0 = mother’s self-report that she was not experiencing 
fever or 1 = mother’s self-report of fever; Cough: 0 = mother’s self-report of that she 
was not experiencing cough or 1 = mother’s self-report of cough; Infant Fever: 0 = 
mother’s self-report that her infant was not experiencing fever or 1 = mother’s self-
report of infant fever. 
aMultivariate immunoglobulin model: total breast milk immunoglobulins = β(HIV-status) 
+ β(maternal BMI) + β(food security) + β(weeks EBF) + β(gestational age at birth) + µ 
bMultivariate cytokine model: total breast milk cytokines = β(HIV-status) + β(mastitis) + 
β(maternal fever) + β(maternal cough) + β(maternal BMI) + β(food security) + β(infant 
fever) + β(breastfeeding intensity) + β(infant birth weight) + β(WAZ) + β(HAZ) + µ 
 
3.5 Discussion 
In this prospective cohort of rural HIV-positive and HIV-negative Tanzanian 
mothers and their infants, neither maternal HIV status nor the broad nutritional indicator 
of maternal BMI were associated with breast milk immunoglobulin or cytokine 
concentrations.  However, considering breast milk immunology over time, significant 
differences in immunoglobulin and certain cytokine concentrations in mature milk were 
evident, and indicators of maternal and infant health and breastfeeding practices were 
associated with total concentrations in this setting.  In addition, correlations between 
different biological compartments were evident for immunoglobulins and cytokines in 
both maternal serum-breast milk and breast milk-infant serum comparisons, with a more 
consistent association evident for immunoglobulin compartmental correlations.   
Previous studies of colostrum (birth to ~1 week post-partum) and transitional milk 
(<4 weeks post-partum) measuring IgA, IgG, IL-6, IL-10, and TNFα have demonstrated 
a dramatic decrease in breast milk concentrations between birth and four weeks, leveling 
off thereafter [11, 12, 34].  While significant reductions in mature breast milk immune 
factors were not expected, the ongoing variation in mature milk, which comprises the 
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longer-term immunological bridge between mother and infant, may be clinically relevant.  
In many regions of the developing world, infant exposure to diarrheal and respiratory 
pathogens is chronic and, for enteric pathogens, likely to increase as EBF is replaced with 
mixed feeding and infants begin to explore their environment.  Given the dynamic nature 
of pathogen exposure, the differences in breast milk immunology demonstrated by this 
study, alongside changes in immunocompetence as the infant immune system matures, 
justify further longitudinal investigation of breast milk immunology beyond the early 
post-partum period.   
Most breastfeeding research in the context of maternal infection has focused on 
determinants of HIV transmission without characterizing specific breast milk 
immunology. In a Zambian study that included HIV-positive and HIV-negative women, 
Walter, et al. [8] reported that breast milk IL-15 was lower among HIV-positive mothers 
whose infants became infected with HIV compared to HIV-positive/non-transmitting 
mothers and HIV-negative mothers. In the current study, none of the infants tested 
positive for HIV, and breast milk from otherwise healthy HIV-positive women on ART 
was not significantly different from HIV-negative women living in the same African 
setting.  Shapiro, et al. [21] reported that total combined immunoglobulin and individual 
IgA, IgG, and IgM breast milk concentrations were higher in HIV-positive/ART-naïve 
mothers compared to HIV-negative mothers in Botswana.  Together, this suggests that 
generalizations regarding breast milk immunology based on maternal HIV-serostatus 
alone are not sufficient.  While maternal HIV infection was not a key determinant of 
breast milk immunology in this study, localized infection (maternal mastitis) at Month 1 
and generalized infection symptoms (maternal cough/fever and infant fever) at Month 6 
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were associated with breast milk cytokine concentrations.  It is unlikely that the peak in 
symptom reporting at six months post-partum was due to seasonal infections as the 
Month 6 study visit occurred throughout the year for different pairs of mothers and 
infants. 
The relationship between maternal nutritional status and specific breast milk 
immunology throughout lactation remains unclear.  In this study, a statistically non-
significant trend towards higher total breast milk immunoglobulins and cytokines was 
associated with improved nutritional status (e.g. higher maternal BMI), while greater 
food security was associated with lower total breast milk cytokine and higher total 
immunoglobulin concentrations.  Among Taiwanese mothers, colostrum IgA 
concentration in well-nourished women was twice that of malnourished women in the 
first two weeks post-partum [12], while well-nourished Colombian mothers had higher 
transitional breast milk IgA and IgG concentrations at four weeks post-partum than 
malnourished mothers [11].  Differences were also observed in Congolese women, but 
only after four weeks post-partum when IgA was lower in the breast milk of underweight 
mothers [13].  Similar to the current study, Bachour, et al. reported no significant 
differences in IgA concentration from transitional or mature milk from healthy and obese 
Lebanese women [14]. 
  This is the first study to describe immune factors in all three biological 
compartments of the post-partum mother-infant dyad, represented by maternal serum, 
breast milk, and infant serum.  While the correlation matrix is complex, a number of 
positive correlations between maternal serum and breast milk immunoglobulin 
concentrations throughout lactation and between breast milk and infant serum in early 
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infancy are apparent.  Both positive and negative cytokine correlations were observed 
among the compartments.  Investigating associations between maternal serum during 
pregnancy and breast milk at three weeks post-partum, Soto-Ramirez, et al. [40] observed 
strong inverse correlations for IgA and strong positive correlations for IL-6, IL-13, and 
IFNγ in healthy American women.  In another American study, maternal serum and 
breast milk concentrations of IgA, IL-6, and TNFα appeared uncorrelated in healthy 
women [35].  While correlations between biological compartments are apparent in the 
current study, additional research is needed to confirm the complex patterns observed and 
the utility of using a single compartment as a proxy for concentrations in another 
compartment.  Further investigation is required to determine the biological relevance of 
immune concentrations across the mother-infant dyad to infectious disease protection 
throughout the breastfeeding period.  
Preliminary evidence from this study indicates that unraveling the determinants of 
breast milk immunology requires a broader consideration of potentially modifiable 
factors. For instance, breastfeeding practices (e.g. EBF, feeding intensity) that have rarely 
been considered in prior studies, had the most significantly positive association with 
breast milk immunoglobulin concentrations.  In some of the only data available regarding 
breastfeeding practices and concentration of breast milk immunoglobulins, a European 
study of healthy, rural women reported an inverse relationship between duration of 
breastfeeding and breast milk IgA [17].  However, comparisons with the current study are 
limited because the collection of milk samples did not correspond in time with the 
reporting of breastfeeding practices.  Furthermore, that study reports only the duration of 
breastfeeding rather than EBF, specifically.  While Orivuori, et al. [17] speculate that 
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their findings may be attributed to subclinical breast tissue inflammation as a result of a 
short duration of breastfeeding, the current study found no association between self-
reported mastitis and duration of EBF or breast milk IgA concentration. 
In summary, findings from this study shed light on the complex and dynamic 
immunological bridge breast milk provides to HIV-exposed and HIV-unexposed infants 
in a rural Tanzanian setting during early infancy.  While mature breast milk 
immunoglobulin and cytokine profiles do not appear considerably different based on 
maternal HIV status or maternal nutritional status, other relevant factors were identified.  
Generalized symptoms of maternal and infant infection, such as fever, cough, and 
mastitis, as well as breastfeeding practices were also associated with differential breast 
milk immune composition.  Given the suboptimal breastfeeding practices that are 
common in sub-Saharan Africa, alongside high infant morbidity and mortality due to 
diarrheal and respiratory infections, further exploration of the public health and clinical 
implications of breast milk immunology in resource-poor settings is crucial. 
72  
REFERENCES 
 
1. Newton ER. (2004). Breastmilk: the gold standard. Clinical Obstetrics and 
Gynecology, 47: 632-642. 
2. Horta BL, Victora CG. (2013). Short-term effects of breastfeeding: A systematic 
review on the benefits of breastfeeding on diarrhoea and pneumonia mortality. 
WHO, 2013. 
3. WHO/UNICEF (2009) Diarrhea: why children are still dying and what can be 
done. Geneva/New York: World Health Organization/United Nations 
International Children’s Emergency Fund. 
4. Chirico G, Marzollo R, Cortinovis S, et al. (2008). Antiinfective properties of 
human milk. The Journal of Nutrition, 138: 1801S-1806S. 
5. Newburgh DS. (2005). Innate immunity and human milk. Journal of Nutrition, 
135: 1308-1312. 
6. Hanson LA. (2000). The mother-offspring dyad and the immune system. Acta 
Paediatrica, 89: 252-258. 
7. Goldman AS. (2007). The immune system in human milk and the developing 
infant. Breastfeeding Medicine, 2: 195-204. 
8. Walter J, Ghosh MK, Kuhn L, et al. (2009). High concentrations of interleukin 15 
in breast milk are associated with protection against postnatal HIV transmission. 
The Journal of Infectious Diseases, 200: 1498-1502. 
9. Calder PC, Jackson AA. (2000). Undernutrition, infection, and immune function. 
Nutrition Research Reviews, 13: 3-29. 
10. Krawinkel MB. (2012). Interaction of nutrition and infections globally: an 
overview. Annals of Nutrition and Metabolism, 61: 39S-45S. 
11. Miranda R, Saravia NG, Ackerman R, et al. (1983). Effect of maternal nutritional 
status on immunological substances in human colostrum and milk. The American 
Journal of Clinical Nutrition, 37: 632-640. 
12. Chang SJ. (1990). Antimicrobial proteins of maternal and cord sera and human 
milk in relation to maternal nutritional status. American Journal of Clinical 
Nutrition, 51: 183-187. 
13. Brussow H, Barclay D, Sidoti J, et al. (1996). Effect of malnutrition on serum and 
milk antibodies in Zairian women. Clinical and Diagnostic Laboratory 
Immunology, 3: 37-41. 
14. Bachour P, Yafawi R, Jaber F, et al. (2012). Effects of smoking, mother’s age, 
body mass index, and parity number on lipid, protein, and secretory 
immunoglobulin A concentrations of human milk. Breastfeeding Medicine, 3: 
179-188. 
15. Kleinman RE, Walker WA. (1979). The enteromammary immune system: an 
important new concept in breast milk host defense. Digestive Diseases and 
Sciences, 24: 876-882. 
16. Riskin A, Almog M, Peri R, et al. (2012). Changes in immunomodulatory 
constituents of human milk in response to active infection in the nursing infant. 
Pediatric Research, 71: 220-225. 
73  
17. Orivuori L, Loss G, Roduit C, et al. (2014). Soluble immunoglobulin A in breast 
milk is inversely associated with atopic dermatitis at early age: the PASTURE 
cohort study. Clinical and Experimental Allergy, 44: 102-112. 
18. Tanzania Ministry of Health and Social Welfare. (2012). National Guidelines for 
the Management of HIV and AIDS, 4th edition. Dar es Salaam: National AIDS 
Control Programme. 
19. WHO. (2010). Guidelines on HIV and infant feeding: principles and 
recommendations for infant feeding in the context of HIV and a summary of the 
evidence.  Geneva: WHO. 
20. Douek D. (2007). HIV disease progression: immune activation, microbes, and a 
leaky gut. Topics in HIV Medicine, 15: 114-117. 
21. Shapiro RL, Lockman S, Kim S, et al. (2007). Infant morbidity, mortality, and 
breast milk immunologic profiles among breast-feeding HIV-infected and HIV-
uninfected women in Botswana. The Journal of Infectious Diseases, 196: 562-
569. 
22. Mwaluko G, Urassa M, Isingo R, et al. (2003). Trends in HIV and sexual 
behavior in a longitudinal study in a rural population in Tanzania, 1994-2000. 
AIDS, 17: 2645-2651. 
23. WHO. (2008). Indicators for assessing infant and young child feeding practices, 
part 1: definitions. Geneva: WHO. 
24. Knueppel D, Demment M, Kaiser L. (2009). Validation of the Household Food 
Insecurity Access Scale in rural Tanzania. Public Health Nutrition, 13: 360-367. 
25. WHO Multicentre Growth Reference Study Group. (2006). WHO Child Growth 
Standards: Length/height-for-age, weight-for-length, weight-for-height, and body 
mass index-for-age: Methods and development. Geneva: World Health 
Organization. 
26. Agarwal S, Karmaus W, Davis S, Gangur V. (2011). Review: Immune markers in 
breast milk and fetal and maternal body fluids: a systematic review of perinatal 
concentrations. Journal of Human Lactation, 27: 171-186. 
27. Groer MW, Shelton MM. (2009). Exercise is associated with elevated 
proinflammatory cytokines in human milk.  Journal of Obstetric, Gynecologic, 
and Neonatal Nursing, 38: 35-41. 
28. Goldman AS, Chheda S, Garofalo R, Schmalstieg FC. (1996). Cytokines in 
human milk: properties and potential effects upon the mammary gland and the 
neonate. Journal of Mammary Gland Biology and Neoplasia, 1: 251-258. 
29. Bryan DL, Forsyth KD, Gibson RA, Hawkes JS. (2006). Interleukin-2 in human 
milk: a potential modulator of lymphocyte development in the breastfed infant. 
Cytokine, 33: 289-293. 
30. Mizuno K, Hatsuno M, Aikawa K, et al. (2012). Mastitis is associated with IL-6 
levels and milk fat globule size in breast milk. Journal of Human Lactation, 28: 
529-534. 
31. Baroncelli S, Andreotti M, Guidotti G, et al. (2008). Tumor necrosis factor-alpha, 
interleukin-10, and alpha-defensins in plasma and breast milk of HIV-infected 
highly active antiretroviral therapy-treated and untreated pregnant women in 
Mozambique. Journal of Acquired Immune Deficiency Syndrome, 15: 647-649. 
74  
32. Yilmaz HL, Saygili-Yilmaz ES, Gunesacar R. (2007). Interleukin-10 and -12 in 
human milk at 3 stages of lactation: a longitudinal study. Advances in Therapy, 
24: 603-610. 
33. Tomicic S, Johansson G, Voor T, et al. (2010). Breast milk cytokine and IgA 
composition differ in Estonian and Swedish mothers – relationship to microbial 
pressure and infant allergy. Pediatric Research, 68: 330-334. 
34. Castellote C, Casillas R, Ramirez-Santana C, et al. (2011). Premature delivery 
influences the immunological composition of colostrum and transitional and 
mature human milk. The Journal of Nutrition, 141: 1181-1187. 
35. Hines EP, Rayner JL, Barbee R, et al. (2007). Assays for endogenous components 
of human milk: comparison of fresh and frozen samples and corresponding 
analytes in serum. Journal of Human Lactation, 23: 144-156. 
36. Ustundag B, Yilmaz E, Dogan Y, et al. (2005). Levels of cytokines (IL-1b, IL-2, 
IL-6, IL-8, TNFα) and trace elements (Zn, Cu) in breast milk from mothers of 
preterm and term infants. Mediators of Inflammation, 6: 331-336. 
37. Burch J, Karmaus W, Gangur V, et al. (2013). Pre- and perinatal characteristics 
and breast milk immune markers. Pediatric Research, 74: 615-621. 
38. Groer MW, Beckstead JW. (2011). Multidimensional scaling of multiplex data: 
human milk cytokines. Biological Research for Nursing, 13: 289-296. 
39. Croghan C, Egeghy PP. (2003). Methods of dealing with values below the limit of 
detection using SAS. Presented at the Southern SAS User Group, St. Petersburg, 
FL, September 22-24, 2003. 
40. Soto-Ramirez N, Karmaus W, Yousefi M, et al. (2012). Maternal immune 
markers in serum during gestation and in breast milk and the risk of asthma-like 
symptoms at ages 6 and 12 months: a longitudinal study. Allergy, Asthma, and 
Clinical Immunology, 8: 11. 
75  
CHAPTER 4 
BREAST MILK IMMUNE COMPOSITION AND INFANT FEEDING 
PRACTICES ARE ASSOCIATED WITH EARLY INFANCY 
CRYPTOSPORIDIUM INFECTION 
4.1 Abstract 
Background: Cryptosporidium is an important cause of infant morbidity and 
mortality, yet little is known about how infant feeding, including exclusive breastfeeding 
(EBF) and complementary foods, and breast milk immunoglobulins and cytokines are 
related to infection. 
Methods: This prospective cohort enrolled 125 mothers/infants of mixed HIV-
status/exposure and followed them from birth through six months.  At each follow-up 
(Month 1, Month 2, Month 3, Month 6), questionnaires were administered to determine 
infant feeding practices, and breast milk, blood, and feces were collected.  Breast milk 
and blood were analyzed for immunoglobulins and cytokines while feces were analyzed 
for Cryptosporidium. 
Results: Cryptosporidium was prevalent among mothers at all time points and in 
infants at Month 6, though the majority of infections were of low intensity.  Duration of 
EBF was negatively associated with infant Cryptosporidium (OR=0.95, 95% CI=0.88, 
1.03), while many complementary foods were positively associated with infection.  
Consumption of either grains or water increased odds of infant Cryptosporidium 
(OR=7.78, 95% CI=2.15, 28.18; OR=4.62, 95% CI=1.27, 16.85, respectively).  Higher 
breast milk concentrations of immunoglobulins and cytokines were associated with lower 
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odds of infant Cryptosporidium (OR=0.92, 95% CI=0.77, 1.09; OR=0.73, 95% CI=0.17, 
3.22, respectively). 
Conclusions: Appropriate infant feeding, ie. EBF and avoidance of complementary 
foods until six months, is strongly associated decreased risk of early infancy 
Cryptosporidium.  Future research and public health strategies need to address the 
association between infant feeding practices and Cryptosporidium infection in order to 
reduce the burden of diarrhea in infancy. 
 
4.2 Introduction 
Diarrhea continues to be a leading cause of morbidity and mortality among infants 
in the developing world [1]. Almost half of child deaths attributable to diarrhea occur in 
sub-Saharan Africa, and the most common diarrhea-causing protozoan parasite found in 
children at health facilities is Cryptosporidium [1]. The effects of Cryptosporidium 
infection can range from asymptomatic to severe, chronic diarrhea and an increased risk 
of infant mortality [2].  Even in the absence of acute symptoms, Cryptosporidium 
infection can have damaging effects on the growth and development of children [3].  
The detrimental health and nutritional consequences of early Cryptosporidium 
infection coupled with the lack of effective Cryptosporidium-treatment options for young 
infants and those with HIV/AIDS make it crucial to understand how to protect young 
infants from infection.  Both the immunological content of breast milk (BM) and the 
duration of exclusive breastfeeding (EBF) may impact an infant’s exposure and 
susceptibility to diarrheal pathogens, such as Cryptosporidium. Breastfeeding may 
provide protection from intestinal pathogens through the transfer of immune molecules 
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and avoidance of contaminated food/water.  Previous cross-sectional studies investigating 
the effect of breastfeeding on infant Cryptosporidium have found conflicting results. 
Studies in Mexico, Egypt, Botswana, Israel, and Haiti reported that breastfeeding infants 
were less likely to experience Cryptosporidium [4-8], yet a study in Zambia found that 
breastfeeding was associated with an increased risk of infection [9]. To our knowledge, 
there have been no prospective longitudinal studies examining the duration of EBF (as 
defined by the World Health Organization [WHO]) on Cryptosporidium among infants in 
sub-Saharan Africa.  
Several studies also suggest an association between cytokines and immunoglobulins 
and both the primary immune response to Cryptosporidium as well as the development of 
partial immunity to subsequent infection [10-14].  This may result from the wide array of 
immune molecules - passively transferred to the infant via BM during the lactation period 
- conferring partial protection from enteric pathogens.  Immunoglobulins are the most 
commonly studied BM immune molecules, yet the relationship between concentrations of 
BM immunoglobulins and the risk of infant Cryptosporidium has rarely been studied. In 
the only available study, BM with high concentrations of anti-Cryptosporidium 
Immunoglobulin A (IgA) was associated with a 38% reduced risk of Cryptosporidium 
infection and a 64% reduced risk of cryptosporidiosis in Bangladeshi infants [15].  
Protection may occur because BM IgA coats the infective stages of Cryptosporidium and 
may prevent excystation, attachment, or invasion of host epithelial cells [15]. Cytokines 
are also immune molecules found in BM and they enhance and initiate immune functions 
that are poorly expressed in the infant [16].  To date there have been no studies 
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investigating the association between BM cytokine concentrations and risk of 
Cryptosporidium in infancy.  
The aim of this research was to determine how early infant feeding practices and 
breast milk immune composition are related to early infant Cryptosporidium infection.  I 
hypothesized that a longer duration of EBF and higher concentrations of BM cytokines 
and immunoglobulins would be associated with a decreased prevalence of 
Cryptosporidium in infants from birth through six months post-partum. 
 
4.3 Methods 
This prospective birth cohort enrolled 50 HIV-positive and 75 HIV-negative 
pregnant mothers living in rural/semi-rural areas of Kisesa (population 30,000) [17] in 
northwestern Tanzania. The study was based at Kisesa Health Centre (KHC), which 
houses an antenatal clinic (ANC), under-5 clinic, voluntary counseling and testing clinic 
(VCT), and an HIV/AIDS care and treatment center (CTC). Figure 4.1 outlines the flow 
of study participants and sample collection. Recruitment and retention procedures have 
been reported in detail elsewhere [18].  The study protocol was approved by the Tanzania 
National Health Research Ethics Review Committee and Cornell University 
(ClinicalTrials.gov, number NCT01699841).  
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Figure 4.1. Flow of study participants 
 
At each follow-up (Month 1 [M1], Month 2 [M2], Month 3 [M3], Month 6 [M6]), 
the research nurse administered a questionnaire that was designed to obtain data on a 
range of feeding, health, and environmental risk factors (Appendix C, Appendix J). To 
accurately determine infant feeding patterns at each visit, mothers were presented with a 
list of complementary foods and liquids and asked whether they had fed each to their 
infant in the previous month.  EBF was defined according to the WHO definition where 
“the infant receives BM and allows the infant to receive oral rehydration solution, drops, 
vitamins, minerals, medicines, but nothing else” [19]. Duration of EBF was defined as 
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time from birth until an infant first received food or liquids other than BM or medicines.  
In order to construct a ‘breastfeeding (BF) score’, at each visit infants were assigned a 
score that corresponded to their current feeding pattern (EBF = 3; predominant BF [BM 
plus locally-prepared gripe water] = 2; partial BF [BM plus other foods/liquids] = 1; not 
breastfeeding = 0) and these scores were summed across the four visits to create a BF 
score that ranged from 0 to 12. Diarrhea was defined as loose or watery stools ≥3 
times/day that represented a pattern atypical for that individual [1]. A food security index 
was constructed using a series of five questions modified from the Household Food 
Insecurity Access Scale that has been validated in rural Tanzania [20].   
At each visit, maternal height and weight were measured using a standard 
stadiometer (Health O Meter, Inc., Bridgeview, IL) to the nearest 0.2kg and nearest 
0.1cm, respectively. Infant weight and length were measured using a calibrated digital 
infant scale (Seca 334 Digital Baby Scale) to the nearest 0.01kg and a standard infant 
length board to the nearest 0.1cm.  Weight-for-height z-scores (WHZ) and body mass 
index (BMI) were calculated based on WHO growth standards [21]. 
Maternal blood, infant blood, and hand-expressed BM samples were collected at 
each follow-up visit. BM samples were stored in a polypropylene container at 4°C for ≤5 
hours before removal of the milk fatty layer and storage at -20°C. Blood samples were 
collected in EDTA tubes, centrifuged, and plasma stored at -20°C (Appendix K, 
Appendix L).  Immunoglobulin and cytokine concentrations were measured using 
MAGPIX® instrumentation with xMAP® technology (Luminex Corporation) and 
MILLPLEX® MAG magnetic bead-based multianalyte panels (Cat. #HGAMMAG-301K 
and Cat. #HCYTOMAG-60K). Plasma assays were performed according to the 
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manufacturer’s protocol with standard curves and quality controls for each assay 
(Appendix N, Appendix O). Undiluted BM was assayed by adapting the manufacturer’s 
protocol for plasma samples, using a commercial serum matrix provided in the Millipore 
kit [22].   
Active Cryptosporidium case detection was of interest, so maternal and infant fecal 
samples were collected, irrespective of symptoms, at each visit. Within 24 hours of 
collection, approximately 5g of fresh stool was mixed with 5mL 10% v/v formalin. 
Presence of Cryptosporidium was confirmed using a modified Ziehl-Neelsen staining 
procedure (Appendix P) [23].  A single technician, without knowledge of participant 
clinical status, examined slides; Cryptosporidium oocyst count was recorded, and 
infection was defined as ≥1 oocyst. A second technician, blinded to participant 
Cryptosporidium status, re-examined a sample (10%) of the slides and inter-observer 
agreement was 96%.  There is currently no treatment available for Cryptosporidium in 
HIV-positive adults or children under 12 months nor are there Tanzanian National 
Guidelines for the treatment of Cryptosporidium, so infected individuals were referred to 
a clinical officer if they were symptomatic. 
Data were analyzed in STATA10 (STATA Corporation, Texas, USA).  Means of 
normally distributed continuous variables were compared using Student’s t-test and 
proportions of categorical variables were compared using the χ2 test. Results were 
considered statistically significant at α = 0.05, using two-sided significance tests. To 
calculate total BM immunoglobulins, concentrations of IgA and IgM were converted 
from ng/ml to 10-7g/ml, IgG1 and IgG2 were converted from ng/ml to µg/ml, and IgG3 
and IgG4 were converted from ng/ml to 10-8g/ml.  The converted concentrations were 
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summed to create a “unit-less” total immunoglobulin concentration.  Cytokine 
concentrations were not normally distributed, therefore concentrations were log-
transformed prior to statistical analysis and results are presented as log10[cytokine 
concentration].  I constructed a breast milk cytokine and immunoglobulin index by 
multiplying the concentration of each analyte by the BF score at that visit; a high index of 
immunoglobulins/cytokines was defined as a value greater than the median, while a low 
index was a value less than the median. Univariate and multivariate logistic regression 
models were used to estimate the effect of infant feeding practices and BM immune 
profiles, identified a priori, on odds of infant Cryptosporidium in the first six months. 
 
4.4 Results 
Over the six-month study period, 282 infant fecal samples (39% from HIV-
exposed infants) and 283 maternal fecal samples (40% from HIV-positive mothers) were 
analyzed for Cryptosporidium (Figure 4.1).  The prevalence of Cryptosporidium in 
mothers increased from 44% at M1 to 63% at M6, with no significant differences based 
on maternal HIV-status.  The majority of maternal infections were of low intensity 
throughout the study (Figure 4.2).  Infants remained free of Cryptosporidium until M2, 
when the prevalence of infection was 4% (3/69).  The first high intensity infant infection 
did not occur until M3, although overall prevalence of infection remained low until M6 
when 33% (23/69) of infants were infected (Figure 4.2).  The intensity of 
Cryptosporidium infection was not associated with any demographic, clinical, or 
anthropometric characteristics of the participants (data not shown). 
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Figure 4.2. Prevalence of Cryptosporidium infection in mothers and infants in rural 
northwest Tanzania from Month 1 through Month 6 post-partum. 
 
High intensity >40 oocysts; medium intensity 20 to 40 oocysts; low intensity 1 to 19 
oocysts. 
 
Table 4.1 describes the demographic, clinical, and nutritional characteristics of 
the infants by Cryptosporidium status, with 27 (28%) infants having at least one 
Cryptosporidium-positive stool sample between M1 and M6. Infant cough (76%) and 
fever (79%) were the most commonly reported clinical symptoms, while the prevalence 
of stunting was high (55%).  Participants did not differ in any characteristics based on 
infant Cryptosporidium, except for maternal underweight, where infection was more 
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common in infants of underweight mothers (Table 4.1). Although not significantly 
different, households with infant Cryptosporidium in the first six months tended to get 
water from public taps (44%), while households with uninfected infants tended to get 
water from covered wells/boreholes (45%).   
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Table 4.1. Socio-demographic, clinical, and nutritional characteristics of 98 mothers 
and infants in rural northwest Tanzania, by infant Cryptosporidium infection in the 
first six months. 
Characteristic, % (n) Infant stool sample ever positive 
for Cryptosporidium (n = 27) 
Infant stool sample always 
negative for Cryptosporidium (n 
= 71) 
p 
Socio-demographic    
Sex   0.726 
Male 48% (13) 52% (37)  
Female 52% (14) 48% (34)  
Maternal Literacy   0.645 
Literate 78% (21) 73% (52)  
Non-literate 22% (6) 27% (19)  
Family Size    0.667 
≤ 5 67% (18) 62% (44)  
> 5 33% (9) 38% (27)  
Water Supply   0.255 
Public Tap 44% (12) 28% (20)  
Open Well 26% (7) 27% (19)  
Covered Well/Borehole 30% (8) 45% (32)  
Food Security Index (FSI)   0.123 
High FSI 67% (18) 49% (35)  
Low FSI 33% (9) 51% (36)  
Animals in the Household   0.368 
Yes 30% (8) 39% (28)  
No 70% (19) 61% (43)  
Clinical    
Infant Diarrhea   0.526 
Yes 59% (16) 52% (37)  
No 41% (11) 48% (34)  
Infant Vomiting   0.668 
Yes 30% (8) 25% (18)  
No 70% (19) 75% (53)  
Infant Cough   0.565 
Yes 81% (22) 76% (54)  
No 19% (5) 24% (17)  
Infant Fever   0.775 
Yes 81% (22) 79% (56)  
No 19% (5) 21% (15)  
HIV-exposure   0.165 
HIV-exposed 30% (8) 45% (32)  
HIV-unexposed 70% (19) 55% (39)  
Nutritional    
Low Birth Weight (< 
2.5kg) 
  0.439 
Yes 4% (1) 10% (7)  
No 96% (26) 90% (64)  
Stunted at Birth (HAZ < -
2) 
  0.439 
Yes 4% (1) 10% (7)  
No 96% (26) 90% (64)  
Maternal Underweight at 
Month 6 (BMI < 18.5) 
  0.033 
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Yes 22% (6) 7% (5)  
No 78% (21) 93% (66)  
Stunted at Month 6 (HAZ 
< -2) 
  0.785 
Yes 52% (14) 55% (39)  
No 48% (13) 45% (32)  
Underweight at Month 6 
(WAZ < -1) 
  0.665 
Yes 19% (5) 23% (16)  
No 81% (22) 77% (55)  
Cryptosporidium-positive = infants who had at least one Cryptosporidium-positive stool 
sample between M1 and M6; Maternal literacy = maternal self-report that she can read; 
HAZ = height-for-age z-score; BMI = body mass index; WAZ = weight-for-age z-score 
 
Infant feeding patterns differed based on maternal HIV-status, where HIV-
infected mothers engaged in more optimal feeding practices than their HIV-negative 
counterparts.  Only 28% (HIV-positive=40% vs. HIV-negative=21%, p=0.085) of 
mothers were still EBF at the M1 visit and this percentage decreased to just 5% (HIV-
positive=10% vs. HIV-negative=2%, p <0.001) by M6.  In univariate logistic regression, 
the odds of infant Cryptosporidium between M1 and M6 decreased by 21% as BM 
increased as a proportion of the diet based on the BF score (OR=0.79, CI=0.64, 0.99).  
Likewise, for every additional week of EBF, the odds of infant Cryptosporidium between 
M1 and M6 decreased by 5% (OR=0.95, CI=0.88, 1.03) (Figure 4.3). 
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Figure 4.3. Logistic regression curve of the relationship between weeks of exclusive 
breastfeeding and risk of infant Cryptosporidium infection from birth through six 
months. 
 
Since the majority of infants began receiving complementary foods/liquids from 
an early age, the impact of specific foods on Cryptosporidium risk was assessed.  Table 
4.2 details the proportion of infants receiving specific complementary foods at any time 
between birth and M6 and the association between these complementary foods and risk 
of Cryptosporidium infection.  Water and grains were the most commonly fed 
complementary foods, and infants who received these foods had an increased risk of 
Cryptosporidium infection compared with infants who did not (Water: OR=4.62, 95% 
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CI=1.27, 16.85; Grains: OR=7.78, 95% CI=2.15, 28.18).  Other foods associated with an 
increased risk of infant Cryptosporidium infection included: fish, legumes, roots, eggs, 
and honey.  Notably, all infants who received formula experienced Cryptosporidium 
infection. Increased consumption of complementary foods was positively correlated with 
increasing food security, such that mothers with high food security were more likely to 
feed complementary foods associated with Cryptosporidium, except for eggs.  The timing 
of the introduction of specific complementary foods did not significantly differ based on 
maternal HIV-status. 
Table 4.2. Percentage of infants receiving specific complementary foods and the 
association between complementary foods and experience of Cryptosporidium 
infection in the first six months of life. 
 Crypto+ Crypto- p value OR 95% CI p value 
Water 89% 63% 0.014 4.62 1.27, 16.85 0.020 
Grains 89% 51% <0.001 7.78 2.15, 28.18 0.002 
Gripe Water 78% 75% 0.748 1.19 0.41, 3.41 0.748 
Orange Fruit 52% 31% 0.056 2.40 0.97, 5.94 0.059 
Tea 48% 46% 0.882 1.07 0.44, 2.60 0.882 
Orange Vegetables 48% 32% 0.148 1.94 0.78, 4.78 0.151 
Fish 41% 10% <0.001 6.29 2.10, 18.78 0.001 
Legumes 37% 15% 0.020 3.21 1.17, 8.82 0.024 
Fruit Juice 26% 13% 0.113 2.41 0.80, 7.31 0.120 
Roots 26% 7% 0.011 4.62 1.32, 16.16 0.017 
Milk 22% 15% 0.432 1.56 0.51, 4.74 0.434 
Eggs 22% 4% 0.012 6.48 1.49, 28.16 0.013 
Soda 19% 15% 0.717 1.24 0.39, 3.97 0.718 
Soup 19% 17% 0.850 1.12 0.35, 3.54 0.850 
Leafy Greens 19% 11% 0.344 1.79 0.53, 6.05 0.349 
Other Fruit 19% 7% 0.094 3.00 0.79, 11.35 0.106 
Honey 15% 3% 0.027 6.00 1.03, 34.94 0.046 
Sweet Water 7% 13% 0.722 0.55 0.11, 2.73 0.466 
Formula 7% 0% 0.074 --- ---- ---- 
Salt/Sugar Water 4% 8% 0.670 0.42 0.05, 3.63 0.428 
Meat 4% 1% 0.477 2.69 0.16, 44.64 0.489 
Other Vegetables 0% 1% 1.000 --- ---- ---- 
Cryptosporidium-positive = infants who had at least one Cryptosporidium-positive stool 
sample between M1 and M6. 
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In infants who remained free from Cryptosporidium through six months, the 
immunoglobulin index at all four visits was higher compared with infants who 
experienced infection at least once in the six-month post-partum period (Figure 4.4).  
The same relationship was found between BM cytokine index and infant 
Cryptosporidium, where the indices of IFNγ, IL-6, IL-12p70, IL-13, IL-15, and TNFα 
were higher in infants who remained Cryptosporidium-free throughout the study (Figure 
4.5).  Infants who were exposed to a high immunoglobulin index in BM had a lower 
prevalence of Cryptosporidium between birth and six months, and this difference was 
statistically significant for IgA (High=21%; Low=58%, p=0.002).  Likewise, a similar 
trend was seen for BM cytokine index, where infants who were exposed to high indices 
of each cytokine in BM had a lower prevalence of Cryptosporidium. 
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Figure 4.4. Mean breast milk immunoglobulin index based on infant 
Cryptosporidium infection from birth through six months. 
Cryptosporidium-positive = infants who had at least one Cryptosporidium-positive stool 
sample between M1 and M6. 
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Figure 4.5. Mean breast milk cytokine index based on infant Cryptosporidium 
infection from birth through six months. 
Cryptosporidium-positive = infants who had at least one Cryptosporidium-positive stool 
sample between M1 and M6. 
 
In univariate logistic regression, as BF score increased, odds of infant 
Cryptosporidium infection decreased (OR=0.79 per unit increase in BF score, 95% 
CI=0.64, 0.99), while maternal underweight and feeding of Cryptosporidium-associated 
foods were associated with 3.77 and 2.11 higher odds of infection, respectively (Table 
4.3).  In multivariate logistic regression, only Cryptosporidium-associated foods 
remained significantly associated with higher odds of Cryptosporidium infection. 
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Table 4.3. Univariate and multivariate logistic regression odds of infant 
Cryptosporidium infection between birth and six months in rural northwest 
Tanzania. 
 
OR = odds ratio, aOdds Ratio per unit increase of the independent variable; CI = 
confidence interval; BM = breast milk; bAdjusted for total BM immunoglobulins, total 
BM cytokines, breastfeeding score, Cryptosporidium-risk foods, maternal underweight, 
and water source; cCryptosporidium-risk foods = number of Cryptosporidium-associated 
foods consumed between M1 and M6; maternal underweight = body mass index ≤18.5, 
dMaternal underweight coded as: 0 = maternal BMI > 18.5 at every visit, 1 = maternal 
BMI ≤18.5 at any visit between M1 and M6; water source coded as 1 = public tap, 2 = 
open well, 3 = covered well/borehole 
*p<0.05; ***p<0.001 
 
Multivariate logistic regression model: Infant Cryptosporidium infection = β(Total BM 
Immunoglobulins) + β(Total BM Cytokines) + β(Breastfeeding Score) + 
β(Cryptosporidium-risk Foods) + β(Maternal Underweight) + β(Water Source) + µ 
 
4.5 Discussion 
Infants in this Tanzanian cohort showed high rates of stunting alongside a high 
burden of infectious disease, as evidenced by the prevalence of Cryptosporidium in the 
post-partum period.  In the context of undernutrition and infection, infant feeding plays 
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an important role.  This study demonstrates that breast milk, both through passive transfer 
of immune molecules and avoidance of contaminated food/water through the practice of 
EBF, is a key factor in protecting infants from gastrointestinal illness. 
Cryptosporidium remains under-recognized and under-diagnosed due to 
difficulties in diagnosis, limited epidemiological data, and a paucity of treatment options 
even if Cryptosporidium is diagnosed.  To date, there have been few prospective 
longitudinal studies focused on Cryptosporidium infection and risk factors in young 
infants, despite the profound implications of early infection on growth, cognitive 
development, morbidity, and mortality. This study found that one of every three infants 
became infected with Cryptosporidium by six months, which is higher than previously 
reported Tanzanian estimates in infants and children [24, 25].  Active case detection in 
the current study may have contributed to higher estimates of Cryptosporidium infection.  
Previous studies were also conducted in urban environments and included older children, 
likely contributing to differences in prevalence estimates.  Surprisingly, the current study 
did not find differences in Cryptosporidium infection in either mothers or infants based 
on HIV-status of the mother.  This finding is likely due to the fact that HIV-positive 
mothers in the study were relatively immunocompetent and all were on ART.  
Additionally, HIV-positive mothers practiced EBF longer than their HIV-negative 
counterparts, which likely protected their infants. 
This study identified infant feeding practice as an important factor associated with 
protection from Cryptosporidium in early infancy.  According to the UNICEF conceptual 
framework for child undernutrition [26], inappropriate infant feeding and infectious 
disease lead to infant undernutrition, and in this study over half the infants were stunted 
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by six months.  The study indicated that few mothers practiced optimal infant feeding, i.e. 
EBF for six months - only 5% of mothers were still EBF at six months.  Notably, 
however, none of these infants became infected with Cryptosporidium.  According to a 
Ugandan study, children are exposed to Cryptosporidium within a few weeks of birth, but 
maternal protection through breastfeeding delays symptomatic infection until at least six 
months [27].  Few studies have considered the impact of EBF on Cryptosporidium in 
infants, but several have identified breastfeeding as protective.  An urban, Mexican study 
of diarrheal infants under six months found that infants who were not breastfed had a 
greater risk of Cryptosporidium infection [6].  Similarly, Israeli Bedouin infants followed 
from birth through 18 months had a lower risk of Cryptosporidium if they were fully 
breastfed (defined as BM, water, and tea) or partially breastfed (defined as BM and other 
foods) compared with non-breastfed infants [5].  Conversely, an urban Zambian study of 
diarrheal children up to 11 years found that breastfeeding was associated with a higher 
risk of Cryptosporidium infection [9]; however, the authors conceded that their finding 
was surprising and difficult to explain.  Importantly, in comparison to my study, the 
Zambian study did not analyze EBF separately.  Thus, children who were in the breastfed 
group were likely also receiving complementary foods and liquids. 
Complementary foods and liquids are an important part of appropriate infant 
feeding after the first six months, yet most mothers in this study began supplementing 
their infants’ diets far too early based on the WHO recommendation of EBF for six 
months.  During the six month study period, most infants were consuming water and 
grains in addition to BM.  No previous studies have linked the consumption of specific 
complementary foods/liquids with infant Cryptosporidium infection, but Mor, et al. noted 
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that infection with Cryptosporidium is often delayed until six months when 
complementary foods are introduced [28].  In this study, infants who became infected 
with Cryptosporidium during the first six months were more likely to have consumed 
both water and grains than infants who remained uninfected.  Interestingly, infants who 
consumed tea (prepared with boiled water) were not at higher risk of Cryptosporidium 
infection, highlighting the fact that untreated water may play a role in transmission. The 
study also identified water source as a possible risk factor in infant Cryptosporidium 
infection, with a greater proportion of infected infants consuming water from public wells 
as opposed to covered wells/boreholes.  As a result, health care workers should increase 
counseling regarding EBF to all mothers, and public health messages targeting mothers 
with young children should stress the importance of water treatment in the prevention of 
diarrhea and infection.  Children who are EBF are not exposed to contaminated 
complementary foods; additional research is needed to determine the risks of specific 
complementary foods for children over six months.  
In addition to EBF, the current study also found that higher BM immunoglobulin 
and cytokine indices were associated with a lower risk of early infant Cryptosporidium 
infection.  In this study, BM immunoglobulin index was calculated using the method of 
infant feeding (BF score) as well as immunoglobulin concentration of the milk.  Through 
my analyses of the BM immunoglobulin index, it became clear that both breastfeeding 
practices and the immunoglobulin concentration of breast milk benefitted the infant.  The 
strongest protective association found was IgA - infants exposed to a high BM IgA index 
were less than half as likely to become infected with Cryptosporidium than infants who 
were exposed to a low index.  Korpe, et al. [15] had similar findings in a cohort of 
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Bangladeshi infants. There, infants exposed to high concentrations of BM IgA had a 38% 
reduced risk of Cryptosporidium infection.  In the current study, a higher BM IgG index 
was also associated with a decreased risk of Cryptosporidium infection.  Though there are 
no studies on BM IgG and Cryptosporidium in infants, research shows that parasite-
specific IgG is produced in response to Cryptosporidium infection [10], and repeat 
exposure to Cryptosporidium may promote an IgG response that imparts partial 
protection [28].  IgG responses to Cryptosporidium can last several months [29], and 
these circulating antibodies may be secreted in breast milk providing passive immunity to 
the infant.   
As with immunoglobulins, a higher BM cytokine index was associated with a 
decreased risk of Cryptosporidium infection.  There are no studies on BM cytokines and 
risk of infant Cryptosporidium infection, but previous research has found that IFN-γ is 
associated with the human T-cell memory response to Cryptosporidium [10-13].  Human 
subjects with previous Cryptosporidium infection produced IFN-γ when challenged with 
Cryptosporidium, while Cryptosporidium-naïve subjects produced no IFN-γ [30]. IL-15 
also appears to be an important component of the primary immune response to 
Cryptosporidium.  Dann, et al. [14] showed that within hours of Cryptosporidium 
exposure, intestinal tissues of healthy human volunteers increased expression of IL-15, 
and that this response was crucial to the clearance of Cryptosporidium. Studies also show 
that IL-12 is expressed during a primary immune response to Cryptosporidium and is 
associated with the development of immunity [10, 13].  Thus, BM may prime the 
immature infant’s immune system with cytokines that are associated with protection and 
clearance of Cryptosporidium. 
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In conclusion, Cryptosporidium is a significant diarrheal pathogen in mothers and 
infants in this rural Tanzanian setting.  Currently, there are no effective vaccines or 
treatments available for Cryptosporidium in HIV-positive individuals or young infants, 
and diagnosis of Cryptosporidium in low-resource settings is a challenge, therefore 
effective preventive measures are urgently needed.  This study indentified BM index, 
which combines breastfeeding practices with concentrations of breast milk immune 
molecules, as protective against early Cryptosporidium infection.  The results of this 
study suggest that breastfeeding protects the infant in two ways: by avoiding 
contaminated complementary foods and by providing passive immunity through BM.  
Public health efforts, similar to PMTCT counseling in Tanzania, should therefore focus 
on increasing the rates of EBF amongst all women while also counseling mothers 
regarding appropriate complementary feeding and safe water practices. 
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CHAPTER 5 
CONCLUSION 
5.1 Conclusion 
In Tanzania, diarrhea remains a major cause of infant morbidity and mortality [1].  
There are a multitude of infectious agents that may cause diarrhea, including viruses (i.e. 
rotavirus), bacteria (i.e. Campylobacter spp.), and other parasites (i.e. Giardia); 
additionally, within populations in sub-Saharan Africa, multiple co-infections are 
common.  Cryptosporidium, a diarrhea-causing protozoan parasite, is ubiquitous in rural 
northwest Tanzania; in the current study, over half of mothers in the post-partum period 
were infected with Cryptosporidium and one-third of infants were infected by six months 
of age.  Within my study population, women and infants were also frequently diagnosed 
with malaria, hookworm, Giardia, and syphilis.  Cryptosporidium is transmitted through 
contaminated water and complementary foods, therefore the practice of exclusive 
breastfeeding (EBF) may protect infants through avoidance of water and foods as well as 
through the passive transmission of immune molecules in breast milk.  Few women in 
Tanzania practice EBF for the recommended six months, although it appears that 
prevention-of-mother-to-child-transmission (PMTCT) counseling has resulted in a 
greater proportion of HIV-positive mothers engaging in EBF.   
Few prospective studies have examined the risk factors associated with infant 
Cryptosporidium infection in sub-Saharan Africa despite the fact that numerous 
researchers over the past 20 years have called for more prospective, longitudinal studies 
of Cryptosporidium infection in young children [2-7].  There is evidence, albeit 
conflicting, that breastfeeding is associated with protection from Cryptosporidium 
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infection in infancy [2, 8, 9] however most studies have not used standardized 
breastfeeding definitions.  Moreover, only one previous study has looked at the 
association between breast milk immune components and the risk of Cryptosporidium 
infection in infancy [10].  As a result, the goal of this research was to investigate the 
magnitude of the Cryptosporidium burden in rural, northwest Tanzania as well as to 
examine risk factors associated with early infant Cryptosporidium infection.  Specifically, 
my prospective cohort study had three aims: 1) to determine the prevalence of 
Cryptosporidium infection in mothers and infants during the first six-months post-
partum; 2) to examine the correlates of immune molecules in breast milk; and 3) to 
understand the associations between exclusive breastfeeding, breast milk immune 
molecules, and risk of early infant Cryptosporidium infection. 
 
5.2 The Burden of Cryptosporidium in Mothers and Infants in Rural, Northwest 
Tanzania 
My first aim was to determine the magnitude of the Cryptosporidium burden in 
post-partum mothers and infants in rural, northwest Tanzania.  My study revealed that a 
majority of mothers experienced Cryptosporidium infection at least once in the six month 
post-partum period and that prevalence did not differ over the study period.  Infants, 
however, appeared to be protected until Month 2 and infection was rare until Month 6.  
By the age of six months, one-third of infants had experienced Cryptosporidium 
infection.  Surprisingly, my study did not observe differences in Cryptosporidium 
prevalence based on HIV-infection in mothers or HIV-exposure in infants.  I also noted 
that exclusive breastfeeding was associated with a decreased risk of infant 
Cryptosporidium infection, while maternal hand-washing prior to infant feeding was 
associated with an increased risk of infection.   
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My estimates of Cryptosporidium prevalence are much higher than previously 
reported, but my study design and research setting likely contributed to these differences.   
Previous estimates of Cryptosporidium in Tanzanian children have ranged from 9 to 20% 
[11-13], while my study found that 33% of children were infected at Month 6.  None of 
the previous Tanzanian studies were prospective or longitudinal in nature and the studies 
included both children and infants.  The neonatal period, particularly the first six months, 
represents a time of immunological immaturity and vulnerability for the infant.  As a 
result, young infants are at greater risk of Cryptosporidium infection.  Furthermore, 
researchers have found that Cryptosporidium prevalence peaks at an earlier age in rural 
settings [14].  Consequently, the inclusion of older infants and children from urban areas 
in previous studies likely resulted in lower prevalence estimates than those found in my 
study.   
In addition to age differences, previous studies were also focused on children 
presenting with diarrhea in hospitals and health clinics.  My study, in contrast, used 
active case detection and analyzed fecal samples from all study participants regardless of 
symptoms.  Maternal report of diarrhea in themselves and their infants was common, yet 
most cases of Cryptosporidium in my study were asymptomatic.  According to one 
Tanzanian study, the most common causes of diarrhea in children under-five years were 
diarrheagenic Escherichia coli (DEC), Cryptosporidium parvum, rotavirus, and 
norovirus; additionally, one of five children in the study were infected with multiple 
pathogens [13].  Other factors contributing to diarrhea in this population may include 
Vibrio cholerae, Shigella spp., Salmonella spp., Giardia lamblia, and hookworm.   
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The clinical presentation of Cryptosporidium infection may differ by the infecting 
species, however I was unable to analyze Cryptosporidium at the species-level in this 
study.  Some research suggests that C. hominis is mainly associated with diarrhea, 
nausea, vomiting, and general malaise, while C. parvum is associated with diarrhea only 
[15].  Firm conclusions regarding the clinical implications of Cryptosporidium at the 
species level are difficult given the limited research at the molecular level.  One study 
demonstrated that C. hominis may be associated with an increased risk of morbidity post-
infection [16], while another study showed that C. hominis was more virulent that C. 
parvum in the developing country context [17].  
Asymptomatic Cryptosporidium infection was common in my study population, 
yet may still have damaging consequences for the infant.  Previous research found that 
after Cryptosporidium infection, children gained weight and height more slowly than 
uninfected children, regardless of symptoms or the infective species, and the largest 
magnitude of growth impairment was seen in children infected between 0 and 5 months 
[18]. 
Contrary to my hypothesis, the prevalence of Cryptosporidium in HIV-positive 
mothers and HIV-exposed infants did not significantly differ from HIV-negative/HIV-
unexposed participants.  Early Cryptosporidium research indicated that HIV-positive 
individuals were at greater risk of infection and were more likely to experience symptoms 
than HIV-negative individuals [19, 20].  Antiretroviral treatment (ART) for HIV-positive 
individuals reduces the incidence and severity of Cryptosporidium [20] and, in recent 
years, ART has become more widely available.  As a result, mother-to-child transmission 
of HIV has decreased.  Among my study population, women with HIV-infection were not 
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severely immunocompromised based on CD4 cell counts and all HIV-positive mothers 
and HIV-exposed infants were receiving treatment.  Thus, increased availability and use 
of ART seems to have evened the playing field of susceptibility to and severity of 
Cryptosporidium in HIV-positive/HIV-exposed individuals. 
My study was the first to examine the relationship between maternal 
Cryptosporidium infection and infant Cryptosporidium infection in the post-partum 
period.  I found that maternal Cryptosporidium infection was a risk factor for infant 
infection.  My study also showed that the majority of Cryptosporidium cases in this 
region were asymptomatic, suggesting that Cryptosporidium is a much larger public 
health problem in rural Tanzania than previous studies suggested.  Lastly, I found that 
one of the strongest risk factors for infant Cryptosporidium infection was maternal hand 
washing prior to infant feeding.  As a result, further research should focus on the impact 
of water source, water treatment, and hygiene as they relate to Cryptosporidium risk in 
mothers and infants.  Additionally, this study provides evidence that EBF for six months 
is associated with protection from early infancy Cryptosporidium infection.  Health 
workers should include breastfeeding education as part of antenatal counseling since 
PMTCT counseling for HIV-positive mothers appears to have successfully increased 
EBF rates among this group. 
 
5.3 Correlates of Breast Milk Immune Protection 
The second aim of the study was to characterize breast milk immune composition 
from Month 1 through Month 6 post-partum and to examine the factors that influence 
concentrations of immunoglobulins and cytokines in breast milk.   My findings suggest 
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that neither maternal HIV-status nor maternal nutritional status influence breast milk 
immune composition in this setting.  However, I did find that breastfeeding practices 
were associated with concentrations of certain immune molecules in breast milk (IgA, 
IgG1, IgG2, IgG3, IL-12p70).  I also found weak to moderate positive correlations 
between maternal serum immunoglobulin concentrations and breast milk 
immunoglobulin concentrations.  Additionally, there were positive correlations between 
breast milk immunoglobulin concentrations and infant serum immunoglobulin 
concentrations in the first two months post-partum.  Lastly, there were significant 
associations between maternal symptoms of illness and concentrations of breast milk 
cytokines. 
The results of this study underscore the complex and dynamic nature of breast 
milk immune composition over time.  I observed an inverted U-shaped pattern of 
immunoglobulin concentrations in breast milk with concentrations rising from Month 1 
to Month 2 and then falling from Month 3 to Month 6.  Previous studies describe a 
significant decrease in breast milk immunoglobulins from birth through three months 
post-partum, but I did not find such patterns in our study.  A recent Japanese study found 
that breast milk IgA concentrations peaked at Day 3 after birth and decreased through 
Month 3 post-partum, with the largest magnitude of decrease between birth and Month 1 
[21].  Since I began milk collection at Month 1 in my study, I was not able to observe 
changes in breast milk as it evolved from colostrum to transitional to mature milk.  Thus, 
the design of my study limited my conclusions to mature milk only.  My analysis of 
breast milk cytokines indicated that concentrations of some (IL-6, IL-15) decreased over 
time, one (TNFα) showed an inverted U-shaped relationship, while others (IFNγ, IL-
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12p70, IL-13) had no significant change over time; IL-1b, IL-2, and IL-10 were not 
detected in breast milk in this study. 
I used a novel method of analyzing immunoglobulins and cytokines in breast 
milk.  In preliminary testing of my breast milk protocol, I used a range of diluted breast 
milk supernatants in order to determine the optimal dilution for detection of 
immunoglobulins and cytokines in breast milk.  The conclusions of preliminary testing 
showed that optimal recovery occurred in undiluted breast milk supernatant, thus in my 
laboratory analysis, I first centrifuged the breast milk, removed the fatty layer and 
analyzed the undiluted cell-free milk supernatant according to the manufacturer’s 
instructions.  In accordance with Groer, et al. [22], I utilized the serum matrix provided in 
the Millipore kit.  The success of my protocol was confirmed by comparing my results to 
those of previous studies.  Previous research has found that breast milk concentrations of 
IFNγ and IL-12p70 remain stable over time [23, 24] and I observed the same in my study.  
IL-10 is reported to have undetectable to low concentrations in breast milk [23] and this 
was consistent in my study where it was not detected in breast milk. 
Another unique aspect of my study was the collection of samples from three 
biological compartments of the mother-infant dyad.  Using these samples, I was able to 
examine correlations between the biological compartments.  These analyses are useful in 
helping to determine whether concentrations in one biological compartment can be used 
as a proxy for concentrations in another compartment.  Based on my results, which 
showed a complex correlation matrix, it is not advisable to make conclusions regarding 
immunoglobulin/cytokine concentrations in one compartment based on the 
concentrations in another compartment.  Previous research indicates that extrapolating 
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breast milk IFNγ concentrations from maternal serum concentrations is not possible given 
the wide variation in concentrations as well as the lack of consistent correlations [23].  
My study confirms the absence of a relationship between maternal serum IFNγ 
concentration and breast milk IFNγ concentration and also indicates the negligible 
correlation between TNFα, IL-6, IL-12p70, and IL-15 between maternal serum and 
breast milk. 
My study was also unique in that I considered breastfeeding practices in my 
analysis of the factors affecting breast milk immune composition.  I was surprised to find 
that the strongest predictors of breast milk immunoglobulin concentrations were duration 
of exclusive breastfeeding and frequency of breastfeeding.  Previous research has often 
failed to consider infant feeding as a variable associated with breast milk immune 
composition, and instead, has focused on factors such as HIV-infection and maternal 
nutritional status.  The results of my study indicate that there may be modifiable factors, 
such as infant feeding practices, that could impact immunoglobulin concentrations in 
breast milk.  The biological relevance of such changes is unclear based on previous 
research, but this issue was further explored in Chapter 4. 
 
5.4 Risk Factors Associated with Infant Cryptosporidium 
Based on the results from Chapters 2 and 3, the aim of Chapter 4 was to examine 
how infant feeding practices and breast milk concentrations of immunoglobulins and 
cytokines were related to infant Cryptosporidium infection.  I found that both infant 
feeding practices, namely exclusive breastfeeding, and higher concentrations of breast 
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milk immunoglobulins and cytokines were associated with a decreased risk of infant 
Cryptosporidium infection through six months of age.   
Consumption of complementary foods was assessed and several complementary 
foods (water, grains, fish, legumes, roots, eggs, honey) were found to be associated with a 
greater risk of infant Cryptosporidium infection.  Many of these complementary foods are 
commonly prepared using water (e.g. grains, fish, legumes, roots), therefore the risk 
associated with complementary foods may be due to contamination through unsafe water.  
For example, infants generally consume grains as porridge, which is commonly prepared 
using boiled water, but mothers often cool down the porridge with unboiled water that 
may result in Cryptosporidium exposure.  Additionally, certain complementary foods 
may be frequently fed together (e.g. grains and honey), therefore the observed risk 
associated with one food (e.g. honey) may actually be due to exposure to the 
accompanying food (e.g. grains). 
I used several novel methods to inspect the relationship between infant feeding 
and Cryptosporidium risk.  First, I constructed a breastfeeding score that summarized 
infant feeding patterns over the six-month post-partum period.  The score was calculated 
by assigning a value corresponding to the current infant feeding pattern (exclusive 
breastfeeding vs. predominant breastfeeding vs. partial breastfeeding vs. no 
breastfeeding) for each visit and then summing the scores over the four visits.  A score of 
12 indicated that the infant was exclusively breastfed for six months, while a score of 0 
indicated that the infant was never breastfed. The breastfeeding score was significantly 
associated with a decreased risk of Cryptosporidium infection, demonstrating that infants 
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who received a greater proportion of breast milk in the diet were less likely to experience 
Cryptosporidium infection. 
Using the breastfeeding score and the breast milk concentrations of 
immunoglobulins and cytokines, I then calculated the index of immune molecules 
received from breast milk.  This is the first report of the effect of a broad range of breast 
milk immune molecules on infant Cryptosporidium risk.  I found that higher breast milk 
immunoglobulin and cytokine indices were associated with a decreased odds of 
Cryptosporidium infection.  This analysis allows us to make inferences regarding the 
biological implications of breast milk immune composition on infant infectious disease 
risk.  In Chapter 3, I showed that breast milk concentrations of immunoglobulins and 
cytokines did not differ by HIV-status or maternal BMI, but that infant feeding practices 
and frequency were associated with higher concentrations.  Chapter 4 then demonstrated 
that infants who are exposed to higher breast milk immunoglobulin and cytokine indices 
are less likely to experience Cryptosporidium infection.  Therefore, I hypothesize that 
there is biological importance to increased breast milk concentrations of immune 
molecules. 
Based on the results from both Chapter 3 and Chapter 4 there is further evidence 
of the benefits of exclusive breastfeeding on infant health.  In Chapter 3, I reported that 
an increased duration of exclusive breastfeeding was associated with increased breast 
milk concentrations of immunoglobulins and in Chapters 2 and 4, I reported that 
exclusive breastfeeding was associated with a decreased risk of infant Cryptosporidium 
infection.  Therefore, the act of exclusive breastfeeding synergistically improves the 
immunological quality of the breast milk as well as protecting infants from exposure to 
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contaminated liquids and foods.  Based on the analyses of Chapter 4, if a mother were to 
increase the duration of exclusive breastfeeding from one month to just three months, the 
odds of infant Cryptosporidium infection would decrease by 40%.   
Despite the numerous benefits of exclusive breastfeeding and the WHO 
recommendation that all women practice EBF for six months, the duration of EBF in this 
population was short.  Previous studies have identified the following barriers to EBF in 
sub-Saharan Africa women: cultural beliefs and traditions, maternal work conditions, 
maternal anemia, lack of maternal education, poor maternal health, infant illness, HIV-
infection, inadequate support from health workers, and perception that milk supply is 
inadequate, among others. [25-28].  Qualitative findings from the current study indicate 
that women enrolled in my study experienced similar barriers to maintaining EBF for six 
months.  Barriers to EBF mentioned by study participants included: pain around the 
nipple, time constraints due to income-generating activities, lack of knowledge about the 
risks of early introduction of complementary foods, concerns about transmitting HIV to 
the infant, and concerns that the infant was not receiving enough milk.  Many of these 
barriers could be overcome with increased infant feeding counseling at the clinic as well 
as additional community and family support for breastfeeding mothers. 
 
5.5 Future Research Priorities 
Although this research has filled some of the gaps in knowledge relating to breast 
milk immunology and Cryptosporidium-risk factors in young infants, there were some 
limitations.  My sample size was relatively small and may not have been powerful 
enough to detect differences in some of my outcome variables.  This study was a pilot 
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study intended to generate data for future, larger studies and the sample size was 
calculated to detect differences in TNFα in maternal serum of HIV-positive and HIV-
negative women.  Indeed, I was able to detect significant differences in maternal serum 
TNFα based on maternal HIV-status.  Future studies should aim to recruit a larger sample 
size, especially given the difficulty in collecting infant serum samples, which was a 
limiting factor in my study.  Based on the results of my study, I have calculated the 
sample size required to detect differences in breast milk immune molecules by maternal 
HIV-status; results are presented in Table 5.1.  According to these sample size 
calculations, the current study was underpowered to find significant differences in breast 
milk immune molecules between HIV-positive and HIV-negative women, especially with 
regards to the immunoglobulins. 
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Table 5.1 Sample size requirements for future studies 
Immune Molecule HIV+ Mean HIV+ SD HIV- Mean HIV- SD n/group* 
IgA 220.3 186.5 223.7 224.6 57867 
IgG1 1016.5 1628.0 765.3 987.6 451 
IgG2 3857.4 7217.2 3683.6 5963.3 22775 
IgG3 23.7 32.6 21.4 23.6 2404 
IgG4 13.6 27.3 12.9 20.4 18605 
IgM 332.0 250.5 372.9 371.6 943 
IFNγ  2.29 0.18 7.95 39.02 374 
IL-6 5.09 6.54 5.83 16.83 4673 
IL-12 2.32 0.30 2.50 1.02 274 
IL-13 2.45 0.64 2.34 0.42 381 
IL-15 24.62 26.16 19.57 15.6 286 
TNFα  7.13 8.33 6.38 8.42 1958 
* α = 0.05; power = 0.8 
In both Chapter 2 and Chapter 4, I noted that water-related exposures were a risk 
for infant Cryptosporidium infection; in Chapter 2, maternal hand washing was 
associated with an increased risk of infant Cryptosporidium infection, while in Chapter 4, 
both water source and the consumption of unboiled water were associated with infant 
Cryptosporidium.  It is important for future studies to not only analyze fecal samples, but 
also water samples from the source and from the home in order to help determine 
transmission pathways.  My study identified Cryptosporidium infection using 
microscopy, which is unable to differentiate between different species of the pathogen.  
Studies show that 90% of human Cryptosporidium infections are due to just two species, 
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namely C. parvum and C. hominis [15].  Previous research has indicated that there may 
be difference in the epidemiology and clinical implications based on the infective species 
of Cryptosporidium.  It appears that the main reservoir for C. parvum infection is 
zoonotic, while C. hominis appears to infect humans exclusively [15].  In addition to 
water testing, genotyping of the Cryptosporidium species would help shed light on the 
mode of transmission thus allowing better planning and implementation of interventions 
to prevent Cryptosporidium infection. 
Many studies have linked low CD4 cell counts of HIV-positive individuals with a 
higher incidence and severity of Cryptosporidium [20], yet none of these studies have 
considered CD4 cell counts of HIV-negative individuals.  In order to get a more complete 
picture of the way in which CD4 cell counts are related to Cryptosporidium risk, future 
studies should collect CD4 cell counts for all participants, not just HIV-positive 
individuals. 
The intrauterine environment is the first exposure the infant has to the maternal 
environment and to the maternal immune system.  Many immune molecules are 
transferred to the infant transplacentally and via cord blood [29-31], thus maternal 
Cryptosporidium infection during pregnancy may impact an infant’s risk of future 
infection.  Collecting and analyzing maternal fecal samples during pregnancy may help 
determine if intrauterine exposure to maternal Cryptosporidium infection is associated 
with Cryptosporidium infection during infancy.  Additionally, since infant 
Cryptosporidium prevalence rose dramatically between Month 3 and Month 6, the 
collection of fecal samples at monthly intervals (Month 4 and Month 5) between these 
visits would help our understanding of the natural history of infection in infants.  During 
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the period between Month 3 and Month 6, infants often undergo dramatic changes in 
feeding and therefore this period is especially crucial in understanding the causal 
relationship between infant feeding practices and Cryptosporidium infection. 
Another limitation of my study was that we only analyzed total concentrations of 
breast milk immunoglobulins rather than antigen-specific immunoglobulins.  Breast milk 
IgA in the infant intestine acts to exclude antigen from circulation by preventing 
penetration through the gut epithelium [32].  Based on the immunology of the entero-
mammary system, antigen encountered in the maternal intestine stimulates the production 
of antigen-specific IgA, which is then secreted in breast milk.  A previous study 
determined that anti-Cryptosporidium IgA targeted the surface of C. parvum oocysts 
leading to the conclusion that Cryptosporidium-specific IgA in breast milk is capable of 
protecting the breastfeeding infant from infection [10].  Indeed, the same study showed 
that infants consuming higher concentrations of Cryptosporidium-specific IgA in breast 
milk were at decreased risk of becoming infected [10].  Future research should focus on 
Cryptosporidium-specific IgA in breast milk rather than simply total breast milk IgA in 
order to better determine how breast milk immunoglobulins are related to protection from 
Cryptosporidium infection. 
Overall, the results of this prospective cohort study demonstrate that 
Cryptosporidium is an under-recognized public health problem for lactating mothers and 
young infants in rural Tanzania.  These results indicate that infant and young child 
feeding practices are associated with early Cryptosporidium infection, and that feeding 
practices remain sub-optimal.  Public health programs should focus on education and 
support for exclusive breastfeeding and appropriate complementary feeding during the 
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antenatal and post-partum periods.  Findings of this study also inform future research 
priorities, namely the testing of household water samples, analysis of Cryptosporidium-
specific breast milk antibodies, and genotyping of infective Cryptosporidium species in 
order to further refine our understanding of the epidemiology of Cryptosporidium 
infection and transmission. 
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APPENDIX A 
 
ENROLLMENT QUESTIONNAIRE 
 
1 Mother Study ID    
2 Date of Interview DD MM YYYY 
3 Interview Conducted by  
 
Identification & Contact Information 
 
4 ANC identification number (write the number 
down from the ANC card).  Place a study sticker 
on the ANC Card with the participant’s ID number.  
 
5 Date of Birth DD MM YYYY 
6 Age or approximate age YY 
7 Marital Status  
1=Single 
2=Monogamously married or cohabiting 
3=Polygamously married or cohabitating 
4=Divorced or separated 
5=Widow 
 
8 What is the name of the head of your household?   
9 What is a phone number where you can be 
contacted?  (leave blank if none given) 
# # # # # # # # # # 
10 Village  
11 Subvillage  
12 Balozi (if known)  
 
Education & Occupation  
 
13 Can you read? 0 = 
No; 1 = Yes 
  
14 Can you write? 0 = 
No; 1 = Yes 
  
15 Have you had a 
formal education? 0 
= No; 1 = Yes If Yes, 
answer 15a 
 15a If yes, what is your highest education 
completed? 
     1 = Some Primary;  
     2 = Completed Primary;  
     3 = Some Secondary;  
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     4 = Completed Secondary;  
     5 = Some University;  
     6 = Completed University;  
     7 = Still in School 
16 Has your partner had 
a formal education?  
0 = No; 1 = Yes If 
Yes, answer 16a 
 16a If yes, what is the highest level of 
education that he completed? 
     1 = Some Primary;  
     2 = Completed Primary;  
     3 = Some Secondary;  
     4 = Completed Secondary;  
     5 = Some University;  
     6 = Completed University;  
     7 = Still in School 
 
17 Do you perform any 
work that helps your 
household earn 
money? 0 = No; 1 = 
Yes  If Yes, answer 
17a 
 17a What is the main way in which you earn 
money?  
     1 = Farming/Cultivating 
     2 = Tending livestock 
     3 = Small business (or cleaning    
            houses) 
     4 = Large business 
     5 = Professional 
     6 = Other (write) 
………………………………………….. 
 
18 Does your partner 
perform work that 
helps your household 
earn money? 0 = No; 
1 = Yes If Yes, 
answer 18a 
 18a What is the main way in which he earns 
money? 
     1 = Farming/Cultivating 
     2 = Tending livestock 
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     3 = Small business (or cleaning    
            houses) 
     4 = Large business 
     5 = Professional 
     6 = Other (write) 
………………………………………….. 
 
Household 
 
19 How many people slept in 
your home last night? 
  
20 How many children under the 
age of 18 slept in your home 
last night? 
  
21 How many children under the 
age of 5 slept in your home 
last night? 
  
22 What is the main source of 
drinking water for your 
household during the dry 
season? 
  
23 What is the main source of 
drinking water for your 
household during the rainy 
season? 
  
24 Do you do anything to the 
water to make it safer to 
drink? No = 0; Yes = 1 If Yes, 
answer 24a 
 24a If yes, what do you do to 
make the water safer to 
drink? 
 
25 What kind of toilet facility 
does your household use? 
  
26 Is your toilet facility shared 
with any other households? 
No = 0; Yes = 1 If Yes, 
answer 26a 
 26a If yes, how many other 
households share your 
toilet facility? 
 
27 Does your household have 
any of the following items: 
No = 0; Yes = 1 
  
 27a Electricity   
 27b Paraffin lamp   
 27c Radio   
 27d Television   
 27e Mobile phone   
 27f Iron   
 27g Refrigerator   
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 27h Watch   
 27i Bicycle   
 27j Motorcycle   
 27k Car   
 27l Bank account   
28 What is the main material of 
the floor of your house? 
  
29 What is the main material of 
the walls of your house? 
  
30 What is the main material of 
the roof of your house? 
  
Animal # 
Animal # 
Animal # 
Animal # 
31 Does your household own any 
animals? No = 0; Yes = 1 If 
Yes, answer 31a  If No, skip to 
question 37 
 31a If yes, please list 
what type and how 
many of each. 
Animal # 
32 Who is responsible for 
feeding the animals? 
  
33 Who is responsible for other 
aspects of animal care? 
  
34 Where are the animals kept 
during the day? 
  
35 Where are the animals kept 
during the night? 
  
36 What is the main source of 
drinking water for the 
animals? 
  
 
Pregnancy and Childbirth History 
 
37 What was the date of 
your last normal 
menstrual period?  
DD MM YYYY (write XX if day or month not known, 
XXXX if year not known) 
38 Is this your first visit 
to Kisesa Health 
Centre for antenatal 
care during this 
pregnancy? 0 = No; 
1 = Yes If No, 
answer 38a 
 38a If no, how many visits to Kisesa 
Health Centre for antenatal care 
during this pregnancy did you make 
before today?  
 
39 Are you planning on 
delivering your baby 
at Kisesa Health 
Centre? 0 = No; 1 = 
Yes If No, answer 
39a 
Encourage the 
mother to deliver her 
 39a If no, where do you plan on 
delivering your baby? 
0=At my home 
1=At a dispensary 
2=At someone else’s home (for 
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baby at Kisesa 
Health Centre and 
say that we will pay 
for her 
transportation.   
example, the home of a midwife) 
3=At a hospital  
4=Other (write) 
………………………………………….. 
40a If yes, how many children have you 
given birth to that were alive?  
 
40b Have you ever had a miscarriage? 0 
= No; 1 = Yes 
 
40 Have you been 
pregnant before this 
pregnancy (include 
miscarriages and 
stillbirths)? 0 = No; 
1 = Yes If Yes 
answer 40a-c 
 
40c Have you ever delivered a stillborn 
baby? 0 = No; 1 = Yes 
 
 
Appetite & General Health 
 
41 During the past 7 days, my appetite (how hungry I am 
usually) has been: 
1 = Very poor (I do not want to eat much food) 
2 = Poor  
3= Average (the same as usual) 
4 = Good 
5= Very good (I am hungry more often) 
 
Answer Questions 42-60 about how you have felt during the past 7 days, using these answers:  
0=Not at all 
1=A little 
2=Quite a bit 
42 Did you have any trouble doing strenuous activities, 
like carrying a full basket from the market?  
 
43 Did you have trouble taking a long walk?  
44 Did you have trouble taking a short walk outside the 
house?  
 
45 Did you need to stay in bed or in a chair during the 
day? 
 
46 Did you need help with eating, dressing, washing 
yourself or using the toilet? 
 
47 Were you limited in doing your work (either your job 
or housework?) 
 
48 Have you had pain?  
49 Did you need to rest during the day?  
50 Have you had trouble sleeping at night?  
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51 Have you felt weak?  
52 Have you felt nauseated (sick to your stomach)?  
53 Have you vomited?   
54 Have you been constipated (have you had trouble 
defecating)? 
 
55 Have you had diarrhea (3 or 4 loose, watery stools 
during one day)? 
 
56 Were you tired during the day?  
57 Did your pain interfere with your work?  
58 Did you worry about your health?  
59 Have you felt burdened by your health?   
60 How would you rate your overall health during the past 
week?  
1=Very poor 
2=Poor 
3=A little poor 
4=Average 
5=Good 
6=Very good 
7=Excellent 
 
 
Karnofsky Performance Status Scale 
 
61  **Study Nurse: Based on these questions, assign the participant 
a “Karnofsky Performance Status” number from the chart below.     
100 Normal no complaints; no evidence of disease. 
90 Able to carry on normal activity; minor signs or symptoms of disease.  
Able to carry on normal 
activity and to work; no 
special care needed. 80 Normal activity with effort; some signs or symptoms of disease. 
70 Cares for self; unable to carry on normal activity or to do active work. 
60 Requires occasional assistance, but is able to care for most of his personal needs.  
Unable to work; able to 
live at home and care for 
most personal needs; 
varying amount of 
assistance needed 50 Requires considerable assistance and frequent medical care. 
40 Disabled; requires special care and assistance. 
30 Severely disabled; hospital admission is indicated although death not imminent. 
20 Very sick; hospital admission necessary; active supportive treatment necessary. 
 
Unable to care for self; 
requires equivalent of 
institutional or hospital 
care; disease may be 
progressing rapidly. 
10 Moribund; fatal processes progressing rapidly. 
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HIV 
 
62 Have you ever tested positive for HIV? 0 = No; 1 = 
Yes If Yes, answer 63-67 If No, take the 
measurements and end the interview  
 
 
63 What date did you first test 
positive for HIV? (write 
XX if day or month not 
known, XXXX if year not 
known) 
DD MM YYYY 
64 Are you currently enrolled 
in PMTCT (Prevention of 
Mother to Child 
Transmission of HIV) at 
Kisesa Health Centre? 0 = 
No; 1 = Yes  
 
65a If yes, what is your CTC 
number?    
 65 Are you currently enrolled 
in CTC at Kisesa Health 
Centre? 0 = No; 1 = Yes If 
Yes, answer 65a-b 
 
65b If you have just been 
referred to CTC, what is 
your CTC Referral 
number?   
 
66 Are you currently taking 
ARV (antiretroviral) 
drugs? 0 = No; 1 = Yes 
  
67 Were you taking ARV 
drugs before you became 
pregnant with this baby? 0 
= No; 1 = Yes 
  
 
Measurements and Sample Collection 
 
68 Maternal Height cm  Comments: 
69 Maternal Weight Kg  Comments: 
70 Maternal MUAC mm  Comments: 
71 Maternal Tricep 
Skinfold Thickness 
mm  Comments: 
72 Fundal Height cm  Comments: 
73 Maternal Blood 
Sample No = 0; Yes 
= 1 
  Comments: 
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APPENDIX B 
 
DELIVERY & BIRTH QUESTIONNAIRE 
 
1 Mother Study ID    
2 Infant Study ID    
3 Date of Measurements D M Y 
4 Place of Measurements  
5 Measurements taken by:  
 
Study Nurse, Please answer the questions below based on your observations and/or 
the participant interview. 
 
6 Was the baby 
delivered at 
Kisesa Health 
Centre? 0 = 
No; 1 = Yes If 
No, answer 6a 
 6a If no, where was the baby delivered? 
0=At the participant’s home 
1=At a dispensary 
2=At someone else’s home (for example, the 
home of a midwife) 
3=At a hospital  
4=Other (write) 
………………………………………….. 
7 What date was 
the baby 
delivered?  
DD MM YYYY  
8 What time was 
the baby 
delivered?  
##:##  
9 Was the baby 
born alive 
(answer ‘No’ 
if it was a 
stillbirth)? 0 = 
No; 1 = Yes 
  
10 Did the baby 
die shortly 
after birth 
(within the 
first 3 days)? 0 
= No; 1 = Yes 
  
 
Measurements and Sample Collection 
 
11 Infant Birth Weight g  Comments: 
12 Infant Birth Length cm  Comments: 
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13 Infant Head 
Circumference 
cm  Comments 
14 Infant MUAC mm  Comments: 
15 Cord Blood Sample 
No = 0; Yes = 1 
  Comments: 
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APPENDIX C 
 
FEEDING AND HEALTH QUESTIONNAIRE 
 
1 Mother Study ID    
2 Date of Interview D M Y 
3 Place of Interview  
4 Visit #  
5 Interview Conducted by  
 
General Questions 
 
6 Have your living arrangements changed since your last visit? 0 = 
No; 1 = Yes If yes, complete enrollment questionnaire again. 
 
7 Infant Date of Birth D M Y 
8 Infant Sex 0 = Male; 1 = Female  
 
Feeding Questions 
 
9 Have you ever breastfed your 
infant? 0 = No; 1 = Yes If no, 
answer 9a 
 9a If no, why did you 
choose not to 
breastfeed? Skip to 
question 18 
 
10 How long after birth did you first 
put your infant to your breast? 
Hours  
11 In the first 3 days after delivery, 
did you give your infant anything 
to drink other than breast milk? 0 
= No; 1 = Yes If Yes, answer 11a 
 11a If yes, what did you 
give to your infant? 
 
12 Since this time yesterday, did 
your infant consume breast milk? 
0 = No; 1 = Yes If No, answer 
12a 
 12a What are the 
reasons you no 
longer breastfeed? 
Skip to question 18 
 
13 How many times did you 
breastfeed last night between 
sunset and sunrise? 
  
14 How many times did you 
breastfeed yesterday during the 
daylight hours? 
  
15 Have you ever felt that you could 
not produce enough milk for your 
infant? 0 = No; 1 = Yes 
  
16 Did your infant consume anything 
other than breast milk yesterday? 
0 = No; 1 = Yes If Yes, answer 
16a 
 16a If yes, how many 
times did your 
infant consume 
anything other than 
breast milk 
yesterday? 
 
17 Since this time yesterday, did  17a At what age did Weeks 
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your infant consume any of the 
following liquids: 0 = No; 1 = 
Yes If Yes to any, answer 17a 
you first introduce 
liquids, other than 
breast milk, to your 
infant? 
 17b Water   
 17c Tea   
 17d Fruit Juice   
 17e Sweetened Water   
 17f Sugar/Salt Water Solution   
 17g Infant Formula   
 17h Tinned/Powdered/Fresh 
Milk 
  
 17i ORS   
 17j Coffee   
 17k Soda   
 17l Broth   
 17m Soup   
 17n Honey   
 17o Gripe Water for Colic   
 17p Any Other Liquids   
18 Since this time yesterday, did 
your infant consume any of the 
following foods: No = 0; Yes = 1 
If Yes to any, answer 18a 
 18a At what age did 
you first introduce 
solid/semi-solid 
foods to your 
infant? 
Weeks 
 18b Cereals/grains (porridge)   
 18c Orange Vegetables 
(pumpkin, carrots, orange 
sweet potato) 
  
 18d Roots/Tubers (potato, 
yam) 
  
 18e Green Leafy Vegetables   
 18f Other Vegetables (tomato)   
 18g Orange fruits (mango, 
papaya, oranges) 
  
 18h Other fruits (banana, 
apple) 
  
 18i Meat (cow, lamb, goat, 
pig) 
  
 18j Fish or Shellfish   
 18k Eggs   
 18l Dairy products (cheese)   
 18m Legumes (lentils, beans)   
 18n Oils, fats, butter   
 18o Any other solid/semi-solid 
foods 
  
19 In the last 7 days, did your infant 
consume any vitamins or mineral 
supplements? No = 0; Yes = 1 If 
 19a If yes, which 
vitamins or mineral 
supplements did 
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Yes, answer 19a your infant 
consume? 
20 In the last 7 days, did your infant 
consume any medicines? No = 0; 
Yes = 1 If Yes, answer 20a 
 20a If yes, what 
medicines did your 
infant consume? 
 
 
Infant Health Questions 
 
21 Since your last visit, has your 
infant experienced any of the 
following: No = 0; Yes = 1 
  
 21a Diarrhea If Yes, 
answer 21b 
 21b If yes, can you describe 
the appearance of the 
diarrhea? 1 = 
voluminous, watery; 2 = 
bloody; 3 = mucus; 0 = 
none of these 
 
 21c Cough   
 21d Difficulty breathing, 
short/quick breaths 
  
 21e Convulsions   
 21f Fever   
 21g Vomiting   
 21h Skin rash   
 21i Refusal to eat, drink, 
or consume breast 
milk 
  
22 On how days in the past 
month has your child had 
diarrhea? 
  
23 When your infant has 
diarrhea, do you offer less, 
more, or the same amount of 
breast milk or other liquids? 
1 = Less; 2 = Same; 3 = 
More 
  
24 When your infant has 
diarrhea, do you offer ORS 
or other treatment? 0 = No; 1 
= Yes 
  
25 Since your last visit, has your 
infant had any unscheduled 
clinic or hospital visits? No = 
0; Yes = 1 If Yes, answer 25a 
 25a If yes, what was the 
reason for the 
clinic/hospital visit? 
 
26 Since your last visit, has your 
infant been diagnosed with 
any illnesses (including 
malaria) by a doctor or a 
nurse? No = 0; Yes = 1 If 
Yes, answer 26a 
 26a If yes, what was the 
diagnosis? 
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27 Since your last visit, has your 
infant taken any medicines? 
No = 0; Yes = 1 If Yes, 
answer 27a 
 27a If yes, what medicine 
and for what purpose? 
 
 
Maternal Health Questions 
 
28 Have you experienced any of 
the following symptoms in 
the past month? No = 0; Yes 
= 1 
  
 28a Diarrhea If Yes, 
answer 28b 
 28b If yes, can you describe 
the appearance of the 
diarrhea? 1 = 
voluminous, watery; 2 
= bloody; 3 = mucus; 0 
= none of these 
 
 28c Mastitis   
 28d Fever   
 28e Skin rash   
 28f Vomiting   
 28g Cough   
 28h Abdominal discomfort   
 28i Loss of appetite   
 28j Nausea   
 28k Fatigue   
 28l Difficulty breathing   
29 Have you been hospitalized 
or had any unscheduled 
clinic visits in the past 
month? No = 0; Yes = 1 If 
Yes, answer 29a 
 29a If yes, for what reasons 
were you hospitalized 
or had unscheduled 
clinic visits? 
 
30 On how many days in the 
past month did you have 
diarrhea? 
  
31 Have any other members of 
your household had diarrhea 
in the past month? No = 0; 
Yes = 1 
  
32 How many meals did you 
consume yesterday? 
  
33 In the past month, how many 
times did you go to sleep 
hungry? 
  
34 In the past month, on how 
many days did you consume 
zero meals? 
  
35 In the past week, on how 
many days did you eat meat 
or fish? 
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36 How many times in the past 
month did your household 
have difficulty in satisfying 
its food needs? 
  
 
Behavior Questions 
 
37 Do you wash your hands 
before eating? No = 0; 
Yes = 1 
  
38 Do you wash your hands 
after going to the toilet? 
No = 0; Yes = 1 
  
39 Do you wash your hands 
before feeding your 
infant? No = 0; Yes = 1 
  
40 Do you use soap or soda 
to wash your hands? No = 
0; Yes = 1 
  
Animal # 
Animal # 
Animal # 
Animal # 
41a If yes, please list the 
type of animal and 
how many of each 
that you own: 
Animal # 
41b Do you care for the 
adult animals? No = 
0; Yes = 1 
 
41 Do you have any adult 
animals in your 
household? No = 0; Yes = 
1 If Yes, answer 41a-c 
 
41c Has your infant had 
contact with any 
adult animals in the 
past month? No = 0; 
Yes = 1 
 
Animal # 
Animal # 
Animal # 
Animal # 
42a If yes, please list the 
type of animal and 
how many of each 
that you own: 
Animal # 
42b Do you care for the 
young animals? No = 
0; Yes = 1 
 
42 Do you have any young 
animals in your 
household? No = 0; Yes = 
1 If Yes, answer 42a-c 
 
42c Has your infant had 
contact with any 
young animals in the 
past month? No = 0; 
Yes = 1 
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Measurements and Sample Collection 
 
43 Maternal Height cm  Comments: 
44 Maternal Weight Kg  Comments: 
45 Maternal MUAC mm  Comments: 
46 Maternal Tricep 
Skinfold Thickness 
mm  Comments: 
47 Maternal Blood 
Sample No = 0; Yes 
= 1 
  Comments: 
48 Breast Milk Sample 
No = 0; Yes = 1 If 
Yes, answer 48a 
 48a Time of Breast Milk 
Collection Record 
time using 24-hour 
clock 
Hour Minute 
49 Maternal Fecal 
Sample No = 0; Yes 
= 1 If Yes, answer 
49a 
 49a Record Appearance 
of Maternal Fecal 
Sample: 
 
50 Infant Length cm  Comments: 
51 Infant Weight g  Comments: 
52 Infant MUAC mm  Comments: 
53 Infant Head 
Circumference 
cm  Comments: 
54 Infant Tricep 
Skinfold Thickness 
mm  Comments: 
55 Infant Blood Sample 
No = 0; Yes = 1 
  Comments: 
56 Infant Fecal Sample 
No = 0; Yes = 1 If 
Yes, answer 56a 
 56a Record Appearance 
of Infant Fecal 
Sample: 
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APPENDIX F 
 
CONSENT & RECRUITMENT PROTOCOL  
PURPOSE 
To ensure that study nurses obtain consent from participants according to ethical 
guidelines. 
INSTRUCTIONS 
1.1. Ask pregnant woman at the Kisesa Health Centre if she would like to be in a 
study on mother and child health during pregnancy. 
1.2. Bring woman to the study room and ask if she meets study requirements: 
1.2.1. Is she already in the study?  (check for sticker on ANC card) 
1.2.1.1. If YES, obtain her folder and use the appropriate Protocol for her 
visit.   
1.2.1.2. If NO, continue.  
1.2.2. Has she had an HIV test during this pregnancy?  
1.2.2.1.  If YES, or if she already knows herself to be HIV-positive, 
continue. 
1.2.2.2. If NO, ask “will you agree to be tested for HIV?”  If she does not 
agree to be tested for HIV, stop the interview.   
1.3. Ask woman if she can read Kiswahili: 
1.3.1.  If YES, check the “Yes” box on the Consent Form and ask her to read it. 
1.3.2. If NO, check the “No” box.  Find a person at KHC (other than yourself) to 
sit in the room while you read the Consent Form to the woman.  This will 
be the “Impartial Witness”. 
1.4. If she agrees to be in the study, have her write her name on the Consent Form 
and sign in ALL 3 PLACES.  If she does not agree, end the interview.   
1.4.1. If there is an “Impartial Witness” (because the woman being consented is 
illiterate), this person must write and sign her own name.   
1.4.2.  If the woman being consented cannot write her name and signature, write 
on her Thumb finger with a Sharpie marker and have her press it down 
firmly in the signature lines on the Consent Form.  Write her name on the 
form.   
1.5. Write your name on the Consent Form and sign where it says “Signature of 
person witnessing consent”. 
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1.6. Write down the woman’s study number and the date in the Log Book. 
**Important** if a woman begins the consent process, but does not wish to 
participate, ask her the reason and write this in the Log Book.   
1.7. Obtain the “Enrollment Interview Protocol”. 
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APPENDIX G 
Maternal and Child Health Study 
Consent Form 
 
You are being invited to take part in a research study to help us understand pregnancy, 
nutrition, infant feeding, and childhood infections. We are asking you to take part 
because you have attended the ANC clinic at Kisesa Health Centre. Please read this form 
carefully and ask any questions before agreeing to take part in the study.  You may also 
request that this information be read to you. 
 
The interview will take approximately 45 minutes to complete.  If any of our tests 
show unusual results, we will notify Kisesa Health Centre so that they may see you 
to make a diagnosis and offer appropriate treatment if needed. 
 
What the study is about: The purpose of this study is to learn how nutrition and 
infections may affect infant growth during pregnancy, and how infant feeding affects 
early childhood growth and chance of getting childhood infections.  
 
What we will ask you to do: If you agree to be in the study, we will ask you some 
questions about your health and look at your medical records to gather information about 
your past health. We will also take 5mL of your blood and take measurements including 
your height, weight, mid-upper arm circumference, fundal height, and skinfold thickness 
two times during your antenatal care visits and four times after you deliver your baby. 
These appointments will last approximately 45 minutes. We will encourage you to 
deliver your baby at the Kisesa Health Centre as is offered to all women, and if you do, 
we will collect 5mL of blood from your umbilical cord and collect a small portion of your 
placenta after delivery. If you miss a study visit, a field worker and the Study Coordinator 
will visit your home address to ascertain the health status of you and your infant and 
whether you wish to remain enrolled in the study.  After you give birth, we will ask you 
to provide a small sample of your breast milk at four times.  We will also ask questions 
about how you and caregivers (i.e. family members) feed your infant. 
 
What we will ask you to provide parental permission for: After you give birth, we 
will take a very small amount of blood from your child using a heel prick and measure 
the length, weight, arm circumference, skinfold thickness, and head circumference of 
your child at four times.  Follow-up visits will be scheduled during your regular 
vaccination appointments for your child when your child is 1, 2, and 3 months old. We 
will also ask you to come for another appointment at the Kisesa Health Centre when your 
child is 6 months of age.  At each of these follow-up visits we will request that you bring 
a small sample of fresh stool from your infant.  We will also take another very small 
amount of blood using a heel prick from your child at these visits.  These appointments 
will last approximately 30 minutes.  If you miss an appointment, a study team member 
will contact you to reschedule the appointment or if you agree, we will visit your home to 
collect a stool sample from your infant, and ask a few questions about the general health 
of your baby.   
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Risks and benefits: We anticipate limited risks to you and your child from participating 
in this study. There is minimal risk of brief temporary discomfort from taking blood.  We 
will minimize this discomfort by using special blood collection tools designed for 
newborns and young infants.  The umbilical cord and placenta are usually discarded after 
delivery, and the collection of cord blood and placenta will not affect the delivery or care 
of you or your child.  Placentas and leftover blood that is not used in this study will be 
stored at NIMR (National Institute of Medical Research), Mwanza. All stored samples 
will be marked with a number code that will not contain your name. By signing this 
document, you are giving us, or other researchers, permission to conduct future research 
using these stored samples.   
 
This study will help us understand how a mother’s health during pregnancy may change 
her child’s health and growth.  This study will also help us understand how infant feeding 
methods affect early infant growth and chance of childhood infections.  There are no 
direct benefits to you or your child, but the study will pay for your transportation to 
Kisesa Health Centre and provide you with a small amount of food while at the clinic 
during your visits. 
 
Your answers will be confidential. This paper containing your name will be kept private 
in a locked file at NIMR, and only authorized researchers will have access to this paper. 
It will be destroyed by shredding after seven years.  Public reports of our findings will 
not include any information that will make it possible to identify you or your child.  
 
Taking part is voluntary: Taking part in this study is completely voluntary and you will 
not be compensated for your participation. You may decline to answer any question or 
take any test as part of this study, or completely end your participation in this study 
without prejudice to your current or future care at Kisesa Health Centre. You may also 
stop your or your child’s involvement at any time during any interview or examination. If 
you decide not to take part, it will not affect you or your family’s current or future 
medical care. 
 
If you have questions in the future: The researchers conducting this research study are 
Mr. Mark Urassa, NIMR and Professor Joann McDermid, Cornell University. Your 
healthcare will continue to be provided by Kisesa Health Centre. If you have questions 
later, you may contact Mr. Mark Urassa at: National Institute for Medical Research 
(NIMR), P.O. Box 1462, Mwanza. Tel: +255-282500399 /2503012, Email: 
malloomark@yahoo.com. If you have any questions or concerns regarding you rights as a 
subject in this study, you may contact the National Health Research Review Sub-
committee (NatRec) at: P.O. Box 9653, Dar es Salaam, Tanzania. Tel: 255-22-2121 400, 
Email: ethics@nimr.or.tz. You will be given a copy of this form to keep for your records. 
 
Statement of Consent: I have read the above information, and have received answers to 
any questions I asked. I consent to take part in the study.  
 
Participant is Literate:  Yes  [ ]    No  [ ] 
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Your Signature ___________________________________ Date 
________________________ 
 
Your Name (printed) 
___________________________________________________________ 
 
Parental Permission 
 
In addition to agreeing to my participation, I also consent to have my infant participate in 
the study and have blood taken up to six times. 
 
Your signature ___________________________________ Date 
_________________________ 
 
Signature of person witnessing consent ________________Date 
_________________________ 
 
In addition, I give permission for my placenta and any blood that is collected from me or 
my child that is not used in this study to be used in future research. 
 
Your signature ___________________________________ Date 
_________________________ 
 
Printed name of person witnessing consent _____________Date 
_________________________ 
 
Signature of Impartial Witness (for illiterate participants) 
 
_______________________________________________ Date 
_________________________ 
 
 
This consent form will be kept by the researcher for at least seven years beyond the end 
of the study and has been approved by the National Health Research Ethics 
Subcommitttee, the Cornell Institutional Review Board and the London School of 
Hygiene and Tropical Medicine Ethics Committee.  
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APPENDIX H 
 
 
ENROLLMENT INTERVIEW PROTOCOL 
PURPOSE 
To ensure that study nurses complete questionnaires, and collect body measurements 
and blood appropriately during the Enrollment (first) Interview with a participant.  
This interview is to be completed immediately after obtaining consent from a 
participant (see “Consent & Recruitment Protocol”). 
INSTRUCTIONS 
1.1. Obtain the Enrollment Questionnaire Form from the participant’s folder.   
Ensure that the “Study ID” number on this form matches the number on the 
Consent Form.   
1.2. Ask the participant all of the questions on the Enrollment Questionnaire Form 
and write down her answers.   
1.3. Take all of the participant’s measurements and write them on the Enrollment 
Questionnaire Form (see attached pages for instructions and measurement 
diagrams).  
1.4. Put STUDY STICKERS on the large tube, and on each of the 3 small tubes.   
1.4.1. Take blood from the woman and put it into the large plastic tube. 
1.4.2. Give the large plastic tube and the 3 small tubes to the Study Lab 
Technician.   
1.5. Obtain the Participant Information Card from her folder. 
1.5.1. Explain which day she should come for her next study visit and write this 
date and the day of the week it will be on the Participant Information 
Card.  Explain that if she comes to the ANC between now and her next 
appointment, she does not need to see us.   
1.5.2. **Important**  We need to see the participant again before she gives 
birth, and we want this to be during the Third Trimester and as close to the 
32nd week as possible.   
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1.5.3. Staple the Participant Information Card to the participant’s ANC Card.   
1.6. Give woman her money and food and thank her for being in the study.   
1.7. Write down the woman’s study number on the Participant List and write 
today’s date under the “Enrollment” Box.   
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APPENDIX I 
 
DELIVERY & BIRTH PROTOCOL 
PURPOSE 
To ensure that study nurses collect body measurements and blood appropriately 
during the Delivery & Birth Follow-up with a participant.   
INSTRUCTIONS 
1.1. Verify mother’s name and study ID number on Participant List and the 
Participant Information Card (if she has it).  Obtain the Delivery & Birth 
Questionnaire Form from the participant’s folder.   Ensure that the “Study ID” 
number on this form matches the number on the Participant Information Card.   
1.2. Put a STUDY ID STICKER on a large (8.5 mL) tube, and on 3 small 
(eppendorf) tubes.   
1.3. After the participant has delivered her baby, obtain the woman’s umbilical cord. 
1.3.1. Use a syringe to take blood from the umbilical cord (just as you would if 
you were taking blood from a patient). 
1.3.2. Give the large plastic tube and the 3 small tubes to AW or SP and they 
will deliver them to the Study Lab Technician.   
1.4. Take all of the infant’s measurements and write them on the Delivery & Birth 
Questionnaire Form (refer to Measurement Diagrams for instructions 
regarding measurements and biological sample collection).  
1.5. Before the participant is discharged from Kisesa Health Centre, give her money 
and food and thank her for coming to the appointment.   
1.6. Find the woman’s Study ID number Participant List and write today’s date 
under the “Birth” Box.   
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APPENDIX J 
 
MATERNAL AND INFANT FOLLOW-UP PROTOCOL  
PURPOSE 
To ensure that study nurses complete questionnaires, and collect body measurements 
and biological samples correctly during the maternal and infant follow-up visits 
(completed at month 1, month 2, month 3, and month 6 post-partum) with a 
participant.   
INSTRUCTIONS 
1.1. Verify mother’s name and study ID number on Participant List. (check for 
sticker on ANC card and/or infant under-5 card)  
1.2. Bring woman to the study room and ask if she would still like to participate in 
the study: 
1.2.1. If YES, obtain her folder and use the appropriate Feeding and Health 
Questionnaire for her visit.   
1.2.2. If NO, record that the mother terminated consent on the Study Exit Form.  
1.3. Give the woman a plastic container labeled with her study ID number and ask her 
to try to produce a fecal sample at any time during the visit.  Record the 
appearance of the fecal sample on the Feeding and Health Questionnaire. 
1.4. Instruct the woman to alert you at any time during the visit if her infant has a 
bowel movement. 
1.5. When the infant has a bowel movement, collect the feces and place in a universal 
container labeled with the infant’s study ID number.  Record the appearance of 
the fecal sample on the Feeding and Health Questionnaire. 
1.6. Ask the woman all of the questions on the Feeding and Health Questionnaire 
and write down her answers.  Explain questions to the woman if she does not 
understand them.   
1.7. Take all of the measurements from the woman and her infant and write the 
numbers on the Feeding and Health Questionnaire 
1.7.1. Refer to Measurement Diagrams for instructions regarding 
measurements and biological sample collection. 
1.8. Put a sticker with the woman’s study ID number on a universal container. 
1.9. Ask the woman to feed her infant and then manually express her breast milk into 
the universal container at the end of the feed.  Record the time of collection on 
the Feeding and Health Questionnaire. 
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1.10. Put a sticker with the woman’s Study Identification Number on the blood 
collection tube. 
1.11. Take blood from the woman and put it into the plastic tube. 
1.12. Put a sticker with the infant’s study ID number on the microtainer 
1.13. Take blood from the infant and put it in the microtainer 
1.14. Check to ensure that there is a study sticker on both the woman’s ANC 
card and the infant’s under-5 card.  If not, put a sticker on the woman’s ANC 
(Antenatal Clinic) Card and/or the infant’s under-5 card.   
1.15. Place the containers of breast milk, blood, and feces in the refrigerator.   
1.16. Give woman her money and food and thank her for being in the study.   
1.17. Write down the woman’s study number and the date in the Log Book.  
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APPENDIX K 
 
KISESA LAB SAMPLES PROTOCOL  
PURPOSE 
To ensure that blood, fecal, and breast milk samples are stabilized correctly. 
INSTRUCTIONS 
2. Maternal Blood Samples will be collected by the Study Nurse into pre-sticker-
labeled 8.5mL tubes.  All tubes will have been labeled with Study ID stickers prior to 
blood being drawn in accordance with “Interview” Protocols. 
2.1. After blood collection, AW or SP will immediately transport tubes to a plastic 
rack in the Kisesa Health Centre Laboratory refrigerator.  Three pre-sticker-
labeled Eppendorf tubes will also be transported to the refrigerator and placed in 
a plastic container adjacent to the tube rack.   
2.2. Blood will be processed, and serum extracted by AW or SP within 1 hour of 
blood collection, according to the instructions below:  
2.2.1. Obtain the 3 
Eppendorf tubes that correspond to each 8.5 mL blood tube to be processed.  
Ensure that the Study ID numbers on the Eppendorf tubes match those on 
the blood tube.   
2.2.2. Ensure that the 8.5 
mL blood tube cap is secure, place it in the centrifuge, and spin for 15 
minutes at 2500 rpm.  **Important**  Be sure to balance the tubes before 
spinning.  If blood is not separated after 15 minutes, centrifuge for an 
additional 10 minutes.   
2.2.3. Use a 100mL 
pippete to collect supernatant and aliquot equally into the three Eppendorf 
tubes.   
2.2.4. Store the 
Eppendorf tubes containing serum in a tube rack in the refrigerator.    
2.2.5. Dispose of 8.5mL 
tube (now containing only red blood matter), in the red Biohazard bag.   
2.2.6. Write the “Study 
ID” number of the lab sample on the Lab Sample Transport & Submission 
Form, fill in the appropriate circles under “Type of Sample”, and write your 
initials under “Processed”.   If you have any comments about the sample (for 
example, if a tube breaks), write them under “Comments” and write your 
initials.   
3. Infant Blood Samples will be collected by the Study Nurse into pre-sticker-labeled 
microtainers.  All microtainers will have been labeled with Study ID stickers prior to 
blood being drawn in accordance with “Interview” Protocols.   
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3.1. After blood collection, AW or SP will immediately transport tubes to a plastic 
container in the Kisesa Health Centre Laboratory refrigerator.  Microtainers will 
be processed at NIMR, Mwanza.   AW or SP will follow the instruction below:  
3.2. Write the “Study ID” number of the lab sample on the Lab Sample Transport & 
Submission Form, fill in the appropriate circles under “Type of Sample”, and 
write your initials under “Processed”.   If you have any comments about the 
sample (for example, if a tube breaks), write them under “Comments” and write 
your initials.   
 
4. Maternal Breast milk Samples will be collected by the participant into into pre-
sticker-labeled universal tubes. 
4.1. After blood collection, AW or SP will immediately transport tubes to a plastic 
container in the Kisesa Health Centre Laboratory refrigerator.   
4.2. Breastmilk will be processed, and serum extracted by AW or SP within 1 hour 
of collection, according to the instructions below:  
4.2.1. Obtain the 3 
Eppendorf tubes that correspond to each universal breast milk tube to be 
processed.  Ensure that the Study ID numbers on the Eppendorf tubes match 
those on the universal tube.   
4.2.2. Transfer 
breastmilk into a 10 mL tube.   
4.2.3. Ensure that the 10 
mL tube cap is secure, place it in the centrifuge, and spin for 15 minutes at 
2500 rpm.  **Important**  Be sure to balance the tubes before spinning.  If 
supernatant is not separated after 15 minutes, centrifuge for an additional 10 
minutes.   
4.2.4. Use a 100mL 
pippete to collect supernatant and aliquot equally into the three Eppendorf 
tubes.   
4.2.5. Store the 
Eppendorf tubes containing breast milk supernatant in a tube rack in the 
refrigerator.    
4.2.6. Dispose of 10 mL 
tube and universal tube in the red Biohazard bag.   
4.2.7. Write the “Study 
ID” number of the lab sample on the Lab Sample Transport & Submission 
Form, fill in the appropriate circles under “Type of Sample”, and write your 
initials under “Processed”.   If you have any comments about the sample (for 
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example, if a tube breaks), write them under “Comments” and write your 
initials.   
5. Maternal and Infant Fecal Samples will be collected by the participant into pre-
sticker-labeled universal tubes.   
5.1. After fecal sample collection, AW or SP will transfer approximately 5 g (5 mL) 
of feces into a 30 mL universal container. 
5.2. Add 5 mL 10% v/v formalin with a Pasteur pipet. 
5.3. Invert tube to mix thoroughly. 
5.4. Store the universal container with the fecal sample in the refrigerator until 
transport to NIMR 
5.5. Write the “Study ID” number of the lab sample on the Lab Sample Transport & 
Submission Form, fill in the appropriate circles under “Type of Sample”, and 
write your initials under “Processed”.   If you have any comments about the 
sample (for example, if a tube breaks), write them under “Comments” and write 
your initials.   
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APPENDIX L 
 
TRANSPORT OF LAB SAMPLES PROTOCOL  
PURPOSE 
To ensure that blood, fecal, and breast milk samples are transported under appropriate 
conditions from Kisesa Health Centre to NIMR, Mwanza.   
INSTRUCTIONS 
1.1. AW or SP will be responsible for the transport of all laboratory samples from 
Kisesa Health Centre to NIMR, Mwanza and will follow the instructions below. 
1.2. At the end of the day, cross-reference the Lab Sample Transport & 
Submission Form with the blood, fecal, and breastmilk samples in the Kisesa 
Health Centre Laboratory refrigerator.   
1.2.1. Ensure that all samples are present. 
1.2.2. Any problems or irregularities with a sample should be noted under 
“Comments” on the Lab Sample Transport & Submission Form.   
1.2.3. Ensure that the Lab Sample Transport & Submission Form is dated, 
and that all necessary fields are filled out.   
1.3. Ensure that all tube caps are securely fashioned and load samples into the 
transportable refrigerator. 
1.4. Initial under “Transported to NIMR” on the Lab Sample Transport & 
Submission Form. 
1.5. Upon arrival at NIMR, Mwanza, place all samples into the McDermid 
refrigerator.   
1.6. Initial under “McDermid fridge” on the Lab Sample Transport & Submission 
Form. 
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APPENDIX M 
DATA MANAGEMENT PROTOCOL  
PURPOSE 
To ensure that questionnaire and sample data are entered consistently and accurately.   
INSTRUCTIONS FOR QUESTIONNAIRE DATA ENTRY 
5.6. At the end of each day, bring all completed questionnaire forms back to NIMR 
and store in a locked file cabinet.  
5.7. Every Friday, double enter data into prepared Excel spreadsheet and write the 
date of entry and data enterer’s initials on the questionnaire.  Return the 
questionnaire to the locked file cabinet. 
5.7.1. Following double entry compare documents to ensure data entry accuracy. 
5.7.2. After checking for accuracy, save the data sheet on AW and SP’s personal 
computers, SP’s personal external hard drive, and AW’s Research-Specific 
Online Drop-Box. 
 
INSTRUCTIONS FOR SAMPLE DATA ENTRY 
1.1. Enter results of sample analysis within one week of completion of analysis. 
1.2. Double enter results of sample analysis into prepared Excel spreadsheet and write 
the date of entry and data enterer’s initials on the printed sample results sheet.  
Return the printed sample results sheet to the locked file cabinet. 
1.2.1. Following double entry compare documents to ensure data entry accuracy. 
1.2.2. After checking for accuracy, save the data sheet on AW and SP’s personal 
computers, SP’s personal external hard drive, and AW’s Research-Specific 
Online Drop-Box. 
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APPENDIX N 
MAGPIX Human Cytokine/Chemokine Magnetic Bead Panel 
Standard Operating Procedure 
1. Sample Preparation: begin only after VERS has passed.  All instruments should 
be available in Serology room. 
a. Remove from freezer box and defrost 
b. Vortex each sample for 3 seconds 
c. Centrifuge samples for 5 minutes at 3,000rpm 
d. Remove kit reagents from fridge and allow to come to room temperature 
2. Preparation of Reagent for Immunoassay 
a. Diluted wash buffer = 30mL wash buffer + 270mL DI (deionized water, 
located in clear water bladder) 
i. Store for up to 1 month at 2-8°C 
ii. Label and date unused vials.  Place in secure location in Serology 
fridge 2.  Add to all similar sequences. 
b. Antibody-Immobilized Beads 
i. Sonicate each bead vial for 30 seconds; vortex 1 minute 
ii. Add 60µL from each vial into Mixing Bottle 
iii. Bring final volume to 3mL with Bead Diluent (for 9 beads, add 
2.46mL) 
iv. Vortex mixed beads for 1 minute 
v. Store for up to 1 month at 2-8°C 
c. Prepared Quality Controls (each) = Quality Control vial + 250µL DI 
i. Invert vial 5 times 
ii. Vortex for 30 seconds 
iii. Allow to sit 5-10 minutes 
iv. Store for up to 1 month at ≤-20°C 
d. Prepared Serum Matrix = Serum Matrix bottle + 1mL Assay Buffer 
i. Invert vial 5 times 
ii. Vortex for 30 seconds 
iii. Allow to sit for 10 minutes 
iv. Store for up to 1 month at ≤-20°C 
e. Preparation of Human Cytokine Standard 6 
i. Reconstitute standard with 250µL DI 
ii. Invert vial 5 times to mix 
iii. Vortex for 10 seconds 
iv. Allow to sit for 5-10 minutes 
f. Preparation of Standards 1-5 
i. Label eppendorf tubes 1-5 and arrange in descending order 
ii. Add 200µL Assay Buffer to each of the 5 tubes 
iii. Perform serial dilution, centrifuging each tube for 20 seconds 
between steps 
3. Immunoassay Procedure 
a. Allow all reagents to come to room temperature 
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b. Using the multi-channel pipet, add 200µL Assay Buffer to each well of 
plate 
i. Seal and mix on plate shaker for 10 minutes at room temperature 
(300rpm) 
ii. Gently decant assay buffer into sink 
iii. Remove residual buffer by inverting plate several times and 
tapping smartly onto absorbent towels 
c. Add Reagents to Wells 
i. Add 25µL Assay Buffer to the Background wells 
ii. Add 25µL of each Standard or Control into the appropriate wells 
iii. Add 25µL Assay Buffer to the sample wells 
d. Add 25µL samples to sample wells 
e. Add 25µL Matrix Solution in the Background, Standards, and Quality 
Controls wells 
f. Add beads to each well 
i. Vortex bead bottle for 30 seconds 
ii. Add 25µL of prepared beads to each well 
iii. Shake beads intermittently to avoid settling, suck beads in and out 
of pipet/resevoir to shake 
g. Seal plate with plate sealer 
i. Incubate for 2 hours at room temperature with shaking 
ii. Ensure that the plate shaker is connected to a reliable power source 
4. Allow Detection Antibody and Step.-Phy. Reagents to come to room temperature 
5. Wash plate 2 times 
a. Rest plate on magnet for 60 seconds 
b. While still attached to magnet, gently decant into sink 
i. Lightly tap on absorbent towel several times 
ii. Remove plate from magnet 
c. Wash plate by adding 200µL Wash Buffer to each well 
i. Shake on plate shaker for 30 seconds 
d. Repeat steps a-c for 2 cycles 
6. Add 25µL Detection Antibodies to each well 
a. Seal plate and incubate with agitation on plate shaker for 1 hour at room 
temperature 
b. Do not aspirate after incubation 
7. Add 25µL Streptavidin-Phycoerythrin per well 
a. Seal the plate and incubate with agitation on plate shaker for 30 minutes at 
room temperature 
8. Wash plate 2 times  
9. Add 150µL Drive Fluid per well 
a. Seal plate and resuspend beads on plate shaker for 5 minutes at room 
temperature 
10. Run on Luminex (100µL, 50 beads per Bead set) 
Reagents 
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1. Luminex Drive Fluid; located in NIMR Storage 
2. MAGPIX Human Cytokine/Chemokine Panel (HYCTOMAG-60K) with analytes 
IFNγ, IL-10, IL-12p70, IL-13, IL-15, IL-1β, IL-2, TNFα; located in NIMR Lab 
#4 fridge 
a. Human Cytokine/Chemokine Standard (catalog #MXH8060-2) 
b. Human Cytokine Quality Controls 1 and 2 (catalog #MXH6060-2) 
c. Set of one 96-well plate with 2 sealers 
d. Assay Buffer (catalog #L-AB) 
e. Serum Matrix (catalog #MXHSM) 
f. Bead Diluent (catalog #LBD) 
g. 10X Wash Buffer, 2 bottles (catalog #L-WB) 
h. Human Cytokine Detection Antibodies (catalog #MXH1060-3) 
i. Steptavidin-Phycoerythrin (catalog #L-SAPE10) 
j. Mixing Bottle 
k. Anti-Human IFNγ Bead (catalog #HCYIFNG-MAG) 
l. Anti-Human IL-10 Bead (catalog #HCYIL10-MAG) 
m. Anti-Human IL-12p70 Bead (catalog #HIL12P70-MAG) 
n. Anti-Human IL-13 Bead (catalog #HIL13-MAG) 
o. Anti-Human IL-15 Bead (catalog #HIL15-MAG) 
p. Anti-Human IL-1β Bead (catalog #HCYIL1B-MAG) 
q. Anti-Human IL-2 Bead (catalog #HIL2-MAG) 
r. Anti-Human IL-6 Bead (catalog #HCYIL6-MAG) 
s. Anti-Human TNFα Bead (catalog #HCYTNFA-MAG) 
3. MAGPIX CALS/VERS/Fluidics reagents; located in Parthenon fridge #2 (extra 
reagents available once reagents below expire) 
a. Calibrator: Lot #B21718, Exp: 2/23/2013 
b. Verifier: Lot #B22330, Exp. 2/22/2013 
c. Fluidics 1: Lot #B22323, Exp. 2/18/2012 
d. Fluidics 2: Lot #B22326, Exp. 2/18/1012 
 
Instruments/Materials 
1. MAGPIX (Luminex) 
2. Adjustable pipettes with tips capable of delivering 25-1000µL (Gilson) 
3. Multichannel pipettes capable of delivering 25-200µL (Gilson) 
4. Reagent reservoirs 
5. 50µL Falcon tubes (BD) 
6. Biohazard containers 
7. Polypropylene microfuge tubes 
8. Paper towels 
9. Vortex mixer (Scientific Industries Model #G-560E) 
10. Sonicator (Branson Ultrasonic Cleaner Model #B200) 
11. Microcentrifuge (VWR International catalog #521-2841) 
12. Thermomixer Comfort (Eppendorf #5355 000.011) 
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13. Exchangeable Thermoblock for MTPs and deepwell plates with lid (Eppendorf 
#022670565) 
14. Hand held Magnetic Separation Block (EMD Millipore catalog #40-285) 
15. Gloves 
16. Extra plate sealers 
17. Kimwipes 
156  
APPENDIX O 
 
MAGPIX Human Immunoglobulin Magnetic Bead Panel 
Standard Operating Procedure 
1. Thaw samples completely.  Mix well by vortexing and centrifuge prior to use in 
the assay to remove particles 
2. Preparation of Antibody-Immobilized Beads 
a. Sonicate each antibody-bead vial for 30 seconds, vortex for 1 minute.  
Add 150µL from each antibody bead vial to the Mixing Bottle and bring 
final volume to 3.0mL with Assay Buffer (when using 6 antibody-
immobilized beads, add 150µL from each of the 6 bead sets to the Mixing 
Bottle.  Then add 2.1mL Assay Buffer).  Vortex the mixed beads well.  
Unused portion may be stored at 2-8°C  for up to 1 month 
3. Preparation of Standards 
a. Resuspend MILLIPLEX MAP Human Multi-Immunoglobulin Standard in 
0.4mL DI water.  Vortex at high speed for 15 seconds.  Place on ice for 15 
minutes.  This is Standard 7. 
4. Preparation of Working Standards 
a. Label six polypropylene microfuge tubes Std 6, Std 5, Std 4, Std 3, Std 2, 
Std 1.  Add 200µL of Assay Buffer to each of the six tubes.  Prepare 3-
fold serial dilutions by adding 100µL of the reconstituted Standard 7 to the 
Std 6 tube, mix well and transfer 100µL of the Std 6 to the Std 5 tube, mix 
well and transfer 100µL of the Std 5 to the Std 4 tube, mix well and 
transfer 100µL  of the Std 4 to the Std 3 tube, mix well and transfer 100µL  
of the Std 3 to the Std 2 tube and mix well and transfer 100µL  of the Std 2 
to the Std 1 tube and mix well.  The Standard 0 (Background) will be 
Assay Buffer. 
5. Preparation of Positive Control 
a. Resuspend MILLIPLEX MAP Human Multi-Ig Positive Control (Catalog 
#PC-301) in 0.25mL DI water. Vortex at high speed for 15 seconds.  Place 
on ice for 15 minutes. 
6. Preparation of Human κ and λ Light Chain, PE 
a. To prepare 1X detection reagent, dilute anti-Human Kappa and Lambda-
PE to working solution (1:100) with Assay Buffer (for full plate, use 25µL 
of the 100X anti-Human kappa-PE in 2.475 mL Assay Buffer). 
7. Preparation of Wash Buffer 
a. Bring the 10X Wash Buffer to room temperature and mix to bring all salts 
into solution.  Dilute 30mL of 10X Wash Buffer with 270mL DI water.  
Store unused portion at 2-8°C for up to 1 month. 
8. Immunoassay Procedure 
a. Add 50µL of control, standard, or sample to each well.   
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b. Vortex the MILLIPLEX MAP Anti-Human Multi-Immunoglobulin Beads 
at medium speed for 15 seconds and then sonicate for 15 seconds using a 
sonication bath.  Add 25µL of bead solution to each well. 
c. Cover with plate cover and incubate 1 hour with agitation on plate shaker 
at room temperature. 
d. Wash plate 2 times with 200µL/well of Wash Buffer, removing Wash 
Buffer by aspiration between each wash.  To avoid washing/aspiration 
related bead loss, allow approximately 60 seconds between dispensing of 
Wash Buffer and subsequent aspiration.   
e. Add 25µL per well of diluted Anti-Human κ and λ light chain, PE. 
f. Cover with plate cover and incubate 1 hour with agitation on a plate 
shaker at room temperature. 
g. Gently remove fluid aspiration (Note: do not invert plate). To avoid 
aspiration related bead loss, allow the plate to soak on the magnet of the 
plate washer for 60 seconds prior to aspiration. 
h. Resuspend in 150µL/well of Sheath Fluid. 
i. Proceed to reading results on an appropriate Luminex instrument. 
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APPENDIX P 
MODIFIED ZIEHL-NEELSEN STAIN - FECAL SAMPLES 
 
STANDARD OPERATING PROCEDURE 
 
No.: 
 
Date: 
 
Prepared by: ___________________________ (name and date) 
 
Developed by: __________________________ (name and date) 
 
MATERIALS: 
 
1. Tongue depressors 
2. Wooden applicator sticks 
3. Pasteur pipets 
4. Plastic screw-top universal containers 20 mL, calibrated by 5mls. 
5. Formalin (40 % formaldehyde solution)  
6. Distilled water 
7. Microscope slides:  glass, 3 x 1 in (76 x 26 mm) 
8. Diamond pencil 
9. Paper towels 
10. 99.5% methanol 
11. Stop watch 
12. Strong carbol fuchsin 
13. Graduated cylinder, 50 mL 
14. Beaker, 500 mL 
15. HCl 
16. Malachite green crystals 
17. Compound Binocular Light Microscope with x10, x40, and x100 (oil) objective 
lenses with x10 eyepieces, and preferably with calibrated ocular micrometer. 
 
FIXING THE FECAL SAMPLES (for fresh fecal samples only): 
 
(Preliminary assumption: Solid feces has a sg. of ~ 1, liquid feces also) 
 
1. Transfer 5 gm feces to a 20 mL plastic universal container (if solid use a tongue 
depressor or wooden applicator stick) and add 5 mL 10% v/v formalin with a 
Pasteur pipet.  Invert tube to mix thoroughly. 
2. Let stand for at least one hour. 
 
PROCEDURES: 
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1. Transfer 2-3 drops of fecal suspension with a Pasteur pipet or wooden applicator 
stick to a labeled microscope slide and spread into a thin layer (up to 2 x 3 cm) 
with a wooden applicator stick. 
2. Allow smear to air dry completely. 
3. Fix the air-dried smear in 99.5% methanol for 3 minutes. 
4. Using a Pasteur pipet, apply adequate strong carbol fuchsin stain to completely 
cover the smear spot and let sit for 15 minutes. 
5. Rinse thoroughly with distilled water. 
6. Decolorize by dripping a solution of 1% v/v conc. HCl in 94% methanol on the 
slide for 15 seconds. 
7. Rinse thoroughly in distilled water. 
8. Counterstain with 0.4% (w/v) malachite green in distilled water for 30 seconds.  
9. Rinse thoroughly in distilled water. 
10. Allow to air dry completely. 
11. Scan the smear using the x10 objective lens and confirm the presence of oocysts 
under x40 objective lens and/or x100 oil immersion lens. 
 
 
